(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 25 May 2001 (25.05.2001)

PCT

(10) International Publication Number WO 01/35726 A1

(51) International Patent Classification?: 5/00, C12N 5/14, 15/82

A01H 1/00.

(21) International Application Number: PCT/US00/31418

.

(22) International Filing Date: 14 November 2000 (14.11.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/166,228 17 November 1999 (17.11.1999) US 60/197,899 17 April 2000 (17.04.2000) US 60/227,439 22 August 2000 (22.08.2000) US

(71) Applicant (for all designated States except US): MENDEL BIOTECHNOLOGY, INC. [US/US]; 21375 Cabot Boulevard, Hayward, CA 94541 (US).

(71) Applicants and

(72) Inventors: HEARD, Jacqueline [US/US]; 810 Guildford Avenue, San Mateo, CA 94402 (US). RATCLIFFE, Oliver [GB/US]; 814 East 21st Street, Oakland, CA 94606 (US). CREELMAN, Robert [US/US]; 2801 Jennifer Drive, Castro Valley, CA 94546 (US). JIANG, Cai-Zhong [CN/US]; 34495 Heathrow Terrace, Fremont, CA 94555 (US). PINEDA, Omaira [CO/US]; 19563 Helen Place, Castro Valley, CA 94546 (US). REUBER, Lynne [US/US]; 2000 Walnut Avenue, Fremont, CA 94538 (US). ADAM, Luc [CA/US]; 25800 Industrial Boulevard, L403, Hayward, CA 94545 (US).

- (74) Agent: GUERRERO, Karen; Mendel Biotechnology, Inc., 21375 Cabot Boulevard, Hayward, CA 94545 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PATHOGEN TOLERANCE GENES

RELATED APPLICATION INFORMATION

The present invention claims the benefit from US Provisional Patent Application Serial Nos. 60/166,228 filed November 17, 1999 and 60/197,899 filed April 17, 2000 and "Plant Trait Modification III" filed August 22, 2000.

5

10

15

20

25

30

35

FIELD OF THE INVENTION

This invention relates to the field of plant biology. More particularly, the present invention pertains to compositions and methods for phenotypically modifying a plant.

BACKGROUND OF THE INVENTION

Transcription factors can modulate gene expression, either increasing or decreasing (inducing or repressing) the rate of transcription. This modulation results in differential levels of gene expression at various developmental stages, in different tissues and cell types, and in response to different exogenous (e.g., environmental) and endogenous stimuli throughout the life cycle of the organism.

Because transcription factors are key controlling elements of biological pathways, altering the expression levels of one or more transcription factors can change entire biological pathways in an organism. For example, manipulation of the levels of selected transcription factors may result in increased expression of economically useful proteins or metabolic chemicals in plants or to improve other agriculturally relevant characteristics. Conversely, blocked or reduced expression of a transcription factor may reduce biosynthesis of unwanted compounds or remove an undesirable trait. Therefore, manipulating transcription factor levels in a plant offers tremendous potential in agricultural biotechnology for modifying a plant's traits.

The present invention provides novel transcription factors useful for modifying a plant's phenotype in desirable ways, such as modifying a plant's pathogen tolerance.

SUMMARY OF THE INVENTION

In a first aspect, the invention relates to a recombinant polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence encoding a polypeptide comprising a sequence selected from SEQ ID Nos. 2N, where N=1-29, or a complementary nucleotide sequence thereof; (b) a nucleotide sequence encoding a polypeptide comprising a conservatively substituted variant of a polypeptide of (a); (c) a nucleotide sequence comprising a sequence selected from those of SEQ ID Nos. 2N-1, where N=1-29, or a complementary nucleotide sequence thereof; (d) a nucleotide sequence

comprising silent substitutions in a nucleotide sequence of (c); (e) a nucleotide sequence which hybridizes under stringent conditions over substantially the entire length of a nucleotide sequence of one or more of: (a), (b), (c), or (d); (f) a nucleotide sequence comprising at least 15 consecutive nucleotides of a sequence of any of (a)-(e); (g) a nucleotide sequence comprising a subsequence or fragment of any of (a)-(f), which subsequence or fragment encodes a polypeptide having a biological activity that modifies a plant's pathogen tolerance; (h) a nucleotide sequence having at least 31% sequence identity to a nucleotide sequence of any of (a)-(g); (i) a nucleotide sequence having at least 60% identity sequence identity to a nucleotide sequence of any of (a)-(g); (j) a nucleotide sequence which encodes a polypeptide having at least 31% identity sequence identity to a polypeptide of SEQ ID Nos. 2N, where N=1-29; (k) a nucleotide sequence which encodes a polypeptide having at least 60% identity sequence identity to a polypeptide of SEQ ID Nos. 2N, where N=1-29; and (I) a nucleotide sequence which encodes a conserved domain of a polypeptide having at least 65% sequence identity to a conserved domain of a polypeptide of SEQ ID Nos. 2N, where N=1-29. The recombinant polynucleotide may further comprise a constitutive, inducible, or tissue-active promoter operably linked to the nucleotide sequence. The invention also relates to compositions comprising at least two of the above described polynucleotides.

5

10

15

25

30

35

In a second aspect, the invention is an isolated or recombinant polypeptide comprising a subsequence of at least about 15 contiguous amino acids encoded by the recombinant or isolated polynucleotide described above.

In another aspect, the invention is a transgenic plant comprising one or more of the above described recombinant polynucleotides. In yet another aspect, the invention is a plant with altered expression levels of a polynucleotide described above or a plant with altered expression or activity levels of an above described polypeptide. Further, the invention may be a plant lacking a nucleotide sequence encoding a polypeptide comprising a sequence selected from SEQ ID Nos. 2N, where N=1-29.

The plant may be a soybean, wheat, corn, potato, cotton, rice, oilseed rape, sunflower, alfalfa, sugarcane, turf, banana, blackberry, blueberry, strawberry, raspberry, cantaloupe, carrot, cauliflower, coffee, cucumber, eggplant, grapes, honeydew, lettuce, mango, melon, onion, papaya, peas, peppers, pineapple, spinach, squash, sweet corn, tobacco, tomato, watermelon, rosaceous fruits, or vegetable brassicas plant.

In a further aspect, the invention relates to a cloning or expression vector comprising the isolated or recombinant polynucleotide described above or cells comprising the cloning or expression vector.

In yet a further aspect, the invention relates to a composition produced by incubating a polynucleotide of the invention with a nuclease, a restriction enzyme, a polymerase; a polymerase and a primer; a cloning vector, or with a cell.

Furthermore, the invention relates to a method for producing a plant having improved pathogen tolerance. The method comprises altering the expression of an isolated or recombinant polynucleotide of the invention or altering the expression or activity of a polypeptide of the invention in a plant to produce a modified plant, and selecting the modified plant for modified pathogen tolerance.

5

10

15

20

25

30

35

In another aspect, the invention relates to a method of identifying a factor that is modulated by or interacts with a polypeptide encoded by a polynucleotide of the invention. The method comprises expressing a polypeptide encoded by the polynucleotide in a plant; and identifying at least one factor that is modulated by or interacts with the polypeptide. In one embodiment the method for identifying modulating or interacting factors is by detecting binding by the polypeptide to a promoter sequence, or by detecting interactions between an additional protein and the polypeptide in a yeast two hybrid system, or by detecting expression of a factor by hybridization to a microarray, subtractive hybridization or differential display.

In yet another aspect, the invention is a method of identifying a molecule that modulates activity or expression of a polynucleotide or polypeptide of interest. The method comprises placing the molecule in contact with a plant comprising the polynucleotide or polypeptide encoded by the polynucleotide of the invention and monitoring one or more of the expression level of the polynucleotide in the plant, the expression level of the polypeptide in the plant, and modulation of an activity of the polypeptide in the plant.

In yet another aspect, the invention relates to an integrated system, computer or computer readable medium comprising one or more character strings corresponding to a polynucleotide of the invention, or to a polypeptide encoded by the polynucleotide. The integrated system, computer or computer readable medium may comprise a link between one or more sequence strings to a modified plant pathogen tolerance phenotype.

In yet another aspect, the invention is a method for identifying a sequence similar or homologous to one or more polynucleotides of the invention, or one or more polypeptides encoded by the polynucleotides. The method comprises providing a sequence database; and, querying the sequence database with one or more target sequences corresponding to the one or more polynucleotides or to the one or more polypeptides to identify one or more sequence members of the database that display sequence similarity or homology to one or more of the one or more target sequences.

The method may further comprise of linking the one or more of the polynucleotides of the invention, or encoded polypeptides, to a modified plant pathogen tolerance phenotype.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 provides a table of exemplary polynucleotide and polypeptide sequences of the invention. The table includes from left to right for each sequence: the SEQ ID No., the internal code reference number (GID), whether the sequence is a polynucleotide or polypeptide sequence, and identification of any conserved domains for the polypeptide sequences.

Figure 2 provides a table of exemplary sequences that are homologous to other sequences provided in the Sequence Listing and that are derived from *Arabidopsis thaliana*. The table includes from left to right: the SEQ ID No., the internal code reference number (GID), identification of the homologous sequence, whether the sequence is a polynucleotide or polypeptide sequence, and identification of any conserved domains for the polypeptide sequences.

Figure 3 provides a table of exemplary sequences that are homologous to the sequences provided in Figures 1 and 2 and that are derived from plants other than *Arabidopsis thaliana*. The table includes from left to right: the SEQ ID No., the internal code reference number (GID), the unique GenBank sequence ID No. (NID), the probability that the comparison was generated by chance (P-value), and the species from which the homologous gene was identified.

20

25

30

35

10

15

DETAILED DESCRIPTION

The present invention relates to polynucleotides and polypeptides, e.g. for modifying phenotypes of plants.

In particular, the polynucleotides or polypeptides are useful for modifying traits associated with a plant's pathogen tolerance when the expression levels of the polynucleotides or expression levels or activity levels of the polypeptides are altered. Specifically, the polynucleotides and polypeptides are useful for modifying traits associated with a plant's pathogen tolerance, such as alterations in cell wall composition, trichome number or structure, callose induction, phytoalexin induction, alterations in the cell death response, or the like. Transgenic plants employing the polynucleotides or polypeptides of the invention are more tolerant to biotrophic or necrotrophic pathogens such as fungi, bacteria, mollicutes, viruses, nematodes, parasitic higher plants or the like.

The polynucleotides of the invention encode plant transcription factors. The plant transcription factors are derived, e.g., from *Arabidopsis thaliana* and can belong, e.g., to one or more of the following transcription factor families: the AP2 (APETALA2) domain transcription factor family (Riechmann and Meyerowitz (1998) <u>J. Biol. Chem.</u> 379:633-646); the MYB transcription factor family (Martin and Paz-Ares (1997) <u>Trends Genet.</u> 13:67-73); the MADS domain transcription factor family (Riechmann and Meyerowitz (1997) <u>J. Biol.</u>

Chem. 378:1079-1101); the WRKY protein family (Ishiguro and Nakamura (1994) Mol. Gen. Genet. 244:563-571); the ankyrin-repeat protein family (Zhang et al. (1992) Plant Cell 4:1575-1588); the miscellaneous protein (MISC) family (Kim et al. (1997) Plant J. 11:1237-1251); the zinc finger protein (Z) family (Klug and Schwabe (1995) FASEB J. 9: 597-604); the homeobox (HB) protein family (Duboule (1994) Guidebook to the Homeobox Genes. Oxford University Press); the CAAT-element binding proteins (Forsburg and Guarente (1989) Genes Dev. 3:1166-1178); the squamosa promoter binding proteins (SPB) (Klein et al. (1996) Mol. Gen. Genet. 1996 250:7-16); the NAM protein family; the IAA/AUX proteins (Rouse et al. (1998) Science 279:1371-1373); the HLH/MYC protein family (Littlewood et al. (1994) Prot. Profile 1:639-709); the DNA-binding protein (DBP) family (Tucker et al. (1994) EMBO J. 13:2994-3002); the bZIP family of transcription factors (Foster et al. (1994) FASEB J. 8:192-200); the BPF-1 protein (Box P-binding factor) family (da Costa e Silva et al. (1993) Plant J. 4:125-135); and the golden protein (GLD) family (Hall et al. (1998) Plant Cell 10:925-936).

In addition to methods for modifying a plant phenotype by employing one or more polynucleotides and polypeptides of the invention described herein, the polynucleotides and polypeptides of the invention have a variety of additional uses. These uses include their use in the recombinant production (i.e, expression) of proteins; as regulators of plant gene expression, as diagnostic probes for the presence of complementary or partially complementary nucleic acids (including for detection of natural coding nucleic acids); as substrates for further reactions, e.g., mutation reactions, PCR reactions, or the like, of as substrates for cloning e.g., including digestion or ligation reactions, and for identifying exogenous or endogenous modulators of the transcription factors.

DEFINITIONS

10

15

20

25

30

35

A "polynucleotide" is a nucleic acid sequence comprising a plurality of polymerized nucleotide residues, e.g., at least about 15 consecutive polymerized nucleotide residues, optionally at least about 30 consecutive nucleotides, at least about 50 consecutive nucleotides. In many instances, a polynucleotide comprises a nucleotide sequence encoding a polypeptide (or protein) or a domain or fragment thereof. Additionally, the polynucleotide may comprise a promoter, an intron, an enhancer region, a polyadenylation site, a translation initiation site, 5' or 3' untranslated regions, a reporter gene, a selectable marker, or the like. The polynucleotide can be single stranded or double stranded DNA or RNA. The polynucleotide optionally comprises modified bases or a modified backbone. The polynucleotide can be, e.g., genomic DNA or RNA, a transcript (such as an mRNA), a cDNA, a PCR product, a cloned DNA, a synthetic DNA or RNA, or the like. The polynucleotide can comprise a sequence in either sense or antisense orientations.

A "recombinant polynucleotide" is a polynucleotide that is not in its native state, e.g., the polynucleotide comprises a nucleotide sequence not found in nature, or the polynucleotide is in a context other than that in which it is naturally found, e.g., separated from nucleotide sequences with which it typically is in proximity in nature, or adjacent (or contiguous with) nucleotide sequences with which it typically is not in proximity. For example, the sequence at issue can be cloned into a vector, or otherwise recombined with one or more additional nucleic acid.

5

10

15

20

25

30

35

An "isolated polynucleotide" is a polynucleotide whether naturally occurring or recombinant, that is present outside the cell in which it is typically found in nature, whether purified or not. Optionally, an isolated polynucleotide is subject to one or more enrichment or purification procedures, e.g., cell lysis, extraction, centrifugation, precipitation, or the like.

A "recombinant polypeptide" is a polypeptide produced by translation of a recombinant polynucleotide. An "isolated polypeptide," whether a naturally occurring or a recombinant polypeptide, is more enriched in (or out of) a cell than the polypeptide in its natural state in a wild type cell, e.g., more than about 5% enriched, more than about 10% enriched, or more than about 20%, or more than about 50%, or more, enriched, i.e., alternatively denoted: 105%, 110%, 120%, 150% or more, enriched relative to wild type standardized at 100%. Such an enrichment is not the result of a natural response of a wild type plant. Alternatively, or additionally, the isolated polypeptide is separated from other cellular components with which it is typically associated, e.g., by any of the various protein purification methods herein.

The term "transgenic plant" refers to a plant that contains genetic material, not found in a wild type plant of the same species, variety or cultivar. The genetic material may include a transgene, an insertional mutagenesis event (such as by transposon or T-DNA insertional mutagenesis), an activation tagging sequence, a mutated sequence, a homologous recombination event or a sequence modified by chimeraplasty. Typically, the foreign genetic material has been introduced into the plant by human manipulation.

A transgenic plant may contain an expression vector or cassette. The expression cassette typically comprises a polypeptide-encoding sequence operably linked (i.e., under regulatory control of) to appropriate inducible or constitutive regulatory sequences that allow for the expression of polypeptide. The expression cassette can be introduced into a plant by transformation or by breeding after transformation of a parent plant. A plant refers to a whole plant as well as to a plant part, such as seed, fruit, leaf, or root, plant tissue, plant cells or any other plant material, e.g., a plant explant, as well as to progeny thereof, and to *in vitro* systems that mimic biochemical or cellular components or processes in a cell.

The phrase "ectopically expression or altered expression" in reference to a polynucleotide indicates that the pattern of expression in, e.g., a transgenic plant or plant

tissue, is different from the expression pattern in a wild type plant or a reference plant of the same species. For example, the polynucleotide or polypeptide is expressed in a cell or tissue type other than a cell or tissue type in which the sequence is expressed in the wild type plant, or by expression at a time other than at the time the sequence is expressed in the wild type plant, or by a response to different inducible agents, such as hormones or environmental signals, or at different expression levels (either higher or lower) compared with those found in a wild type plant. The term also refers to altered expression patterns that are produced by lowering the levels of expression to below the detection level or completely abolishing expression. The resulting expression pattern can be transient or stable, constitutive or inducible. In reference to a polypeptide, the term "ectopic expression or altered expression" further may relate to altered activity levels resulting from the interactions of the polypeptides with exogenous or endogenous modulators or from interactions with factors or as a result of the chemical modification of the polypeptides.

10

15

20

25

30

35

The term "fragment" or "domain," with respect to a polypeptide, refers to a subsequence of the polypeptide. In some cases, the fragment or domain, is a subsequence of the polypeptide which performs at least one biological function of the intact polypeptide in substantially the same manner, or to a similar extent, as does the intact polypeptide. For example, a polypeptide fragment can comprise a recognizable structural motif or functional domain such as a DNA binding domain that binds to a DNA promoter region, an activation domain or a domain for protein-protein interactions. Fragments can vary in size from as few as 6 amino acids to the full length of the intact polypeptide, but are preferably at least about 30 amino acids in length and more preferably at least about 60 amino acids in length. In reference to a nucleotide sequence, "a fragment" refers to any subsequence of a polynucleotide, typically, of at least consecutive about 15 nucleotides, preferably at least about 30 nucleotides, more preferably at least about 50, of any of the sequences provided herein.

The term "trait" refers to a physiological, morphological, biochemical or physical characteristic of a plant or particular plant material or cell. In some instances, this characteristic is visible to the human eye, such as seed or plant size, or can be measured by available biochemical techniques, such as the protein, starch or oil content of seed or leaves or by the observation of the expression level of genes, e.g., by employing Northern analysis, RT-PCR, microarray gene expression assays or reporter gene expression systems, or by agricultural observations such as stress tolerance, yield or pathogen tolerance.

"Trait modification" refers to a detectable difference in a characteristic in a plant ectopically expressing a polynucleotide or polypeptide of the present invention relative to a plant not doing so, such as a wild type plant. In some cases, the trait modification can be evaluated quantitatively. For example, the trait modification can entail at least about a 2%

increase or decrease in an observed trait (difference), at least a 5% difference, at least about a 10% difference, at least about a 20% difference, at least about a 30%, at least about a 50%, at least about a 70%, or at least about a 100%, or an even greater difference. It is known that there can be a natural variation in the modified trait. Therefore, the trait modification observed entails a change of the normal distribution of the trait in the plants compared with the distribution observed in wild type plant.

5

10

15

20

25

35

Trait modifications of particular interest include those to seed (such as embryo or endosperm), fruit, root, flower, leaf, stem, shoot, seedling or the like, including: enhanced tolerance to environmental conditions including freezing, chilling, heat, drought, water saturation, radiation and ozone; improved tolerance to microbial, fungal or viral diseases; improved tolerance to pest infestations, including nematodes, mollicutes, parasitic higher plants or the like; decreased herbicide sensitivity; improved tolerance of heavy metals or enhanced ability to take up heavy metals; improved growth under poor photoconditions (e.g., low light and/or short day length), or changes in expression levels of genes of interest. Other phenotype that can be modified relate to the production of plant metabolites, such as variations in the production of taxol, tocopherol, tocotrienol, sterols, phytosterols, vitamins, wax monomers, anti-oxidants, amino acids, lignins, cellulose, tannins, prenyllipids (such as chlorophylls and carotenoids), glucosinolates, and terpenoids, enhanced or compositionally altered protein or oil production (especially in seeds), or modified sugar (insoluble or soluble) and/or starch composition. Physical plant characteristics that can be modified include cell development (such as the number of trichomes), fruit and seed size and number, yields of plant parts such as stems, leaves and roots, the stability of the seeds during storage, characteristics of the seed pod (e.g., susceptibility to shattering), root hair length and quantity, internode distances, or the quality of seed coat. Plant growth characteristics that can be modified include growth rate, germination rate of seeds, vigor of plants and seedlings, leaf and flower senescence, male sterility, apomixis, flowering time, flower abscission, rate of nitrogen uptake, biomass or transpiration characteristics, as well as plant architecture characteristics such as apical dominance, branching patterns, number of organs, organ identity, organ shape or size.

30 POLYPEPTIDES AND POLYNUCLEOTIDES OF THE INVENTION

The present invention provides, among other things, transcription factors (TFs), and transcription factor homologue polypeptides, and isolated or recombinant polynucleotides encoding the polypeptides. These polypeptides and polynucleotides may be employed to modify a plant's pathogen tolerance.

Exemplary polynucleotides encoding the polypeptides of the invention were identified in the *Arabidopsis thaliana* GenBank database using publicly available sequence

analysis programs and parameters. Sequences initially identified were then further characterized to identify sequences comprising specified sequence strings corresponding to sequence motifs present in families of known transcription factors. Polynucleotide sequences meeting such criteria were confirmed as transcription factors.

Additional polynucleotides of the invention were identified by screening Arabidopsis thaliana and/or other plant cDNA libraries with probes corresponding to known transcription factors under low stringency hybridization conditions. Additional sequences, including full length coding sequences were subsequently recovered by the rapid amplification of cDNA ends (RACE) procedure, using a commercially available kit according to the manufacturer's instructions. Where necessary, multiple rounds of RACE are performed to isolate 5' and 3' ends. The full length cDNA was then recovered by a routine end-to-end polymerase chain reaction (PCR) using primers specific to the isolated 5' and 3' ends. Exemplary sequences are provided in the Sequence Listing.

The polynucleotides of the invention were ectopically expressed in overexpressor or knockout plants and changes in the pathogen tolerance of the plants was observed. Therefore, the polynucleotides and polypeptides can be employed to improve the pathogen resistance of plants.

Making polynucleotides

5

10

15

20

25

30

35

The polynucleotides of the invention include sequences that encode transcription factors and transcription factor homologue polypeptides and sequences complementary thereto, as well as unique fragments of coding sequence, or sequence complementary thereto. Such polynucleotides can be, e.g., DNA or RNA, e.g., mRNA, cRNA, synthetic RNA, genomic DNA, cDNA synthetic DNA, oligonucleotides, etc. The polynucleotides are either double-stranded or single-stranded, and include either, or both sense (i.e., coding) sequences and antisense (i.e., non-coding, complementary) sequences. The polynucleotides include the coding sequence of a transcription factor, or transcription factor homologue polypeptide, in isolation, in combination with additional coding sequences (e.g., a purification tag, a localization signal, as a fusion-protein, as a pre-protein, or the like), in combination with non-coding sequences (e.g., introns or inteins, regulatory elements such as promoters, enhancers, terminators, and the like), and/or in a vector or host environment in which the polynucleotide encoding a transcription factor or transcription factor homologue polypeptide is an endogenous or exogenous gene.

A variety of methods exist for producing the polynucleotides of the invention. Procedures for identifying and isolating DNA clones are well known to those of skill in the art, and are described in, e.g., Berger and Kimmel, <u>Guide to Molecular Cloning Techniques</u>. Methods in Enzymology volume 152 Academic Press, Inc., San Diego, CA ("Berger");

Sambrook et al., <u>Molecular Cloning - A Laboratory Manual</u> (2nd Ed.), Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989 ("Sambrook") and <u>Current Protocols in Molecular Biology</u>, F.M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (supplemented through 2000) ("Ausubel").

Alternatively, polynucleotides of the invention, can be produced by a variety of in vitro amplification methods adapted to the present invention by appropriate selection of specific or degenerate primers. Examples of protocols sufficient to direct persons of skill through in vitro amplification methods, including the polymerase chain reaction (PCR) the ligase chain reaction (LCR), Qbeta-replicase amplification and other RNA polymerase mediated techniques (e.g., NASBA), e.g., for the production of the homologous nucleic acids of the invention are found in Berger, Sambrook, and Ausubel, as well as Mullis et al., (1987) PCR Protocols A Guide to Methods and Applications (Innis et al. eds) Academic Press Inc. San Diego, CA (1990) (Innis). Improved methods for cloning in vitro amplified nucleic acids are described in Wallace et al., U.S. Pat. No. 5,426,039. Improved methods for amplifying large nucleic acids by PCR are summarized in Cheng et al. (1994) Nature 369: 684-685 and the references cited therein, in which PCR amplicons of up to 40kb are generated. One of skill will appreciate that essentially any RNA can be converted into a double stranded DNA suitable for restriction digestion, PCR expansion and sequencing using reverse transcriptase and a polymerase. See, e.g., Ausubel, Sambrook and Berger, all supra.

Alternatively, polynucleotides and oligonucleotides of the invention can be assembled from fragments produced by solid-phase synthesis methods. Typically, fragments of up to approximately 100 bases are individually synthesized and then enzymatically or chemically ligated to produce a desired sequence, e.g., a polynucleotide encoding all or part of a transcription factor. For example, chemical synthesis using the phosphoramidite method is described, e.g., by Beaucage et al. (1981) Tetrahedron Letters 22:1859-69; and Matthes et al. (1984) EMBO J. 3:801-5. According to such methods, oligonucleotides are synthesized, purified, annealed to their complementary strand, ligated and then optionally cloned into suitable vectors. And if so desired, the polynucleotides and polypeptides of the invention can be custom ordered from any of a number of commercial suppliers.

HOMOLOGOUS SEQUENCES

5

15

25

30

35

Sequences homologous, i.e., that share significant sequence identity or similarity, to those provided in the Sequence Listing, derived from Arabidopsis thaliana or from other plants of choice are also an aspect of the invention. Homologous sequences can be derived from any plant including monocots and dicots and in particular agriculturally important plant species, including but not limited to, crops such as soybean, wheat, com,

potato, cotton, rice, oilseed rape (including canola), sunflower, alfalfa, sugarcane and turf; or fruits and vegetables, such as banana, blackberry, blueberry, strawberry, and raspberry, cantaloupe, carrot, cauliflower, coffee, cucumber, eggplant, grapes, honeydew, lettuce, mango, melon, onion, papaya, peas, peppers, pineapple, spinach, squash, sweet corn, tobacco, tomato, watermelon, rosaceous fruits (such as apple, peach, pear, cherry and plum) and vegetable brassicas (such as broccoli, cabbage, cauliflower, brussel sprouts and kohlrabi). Other crops, fruits and vegetables whose phenotype can be changed include barley, rye, millet, sorghum, currant, avocado, citrus fruits such as oranges, lemons, grapefruit and tangerines, artichoke, cherries, nuts such as the walnut and peanut, endive, leek, roots, such as arrowroot, beet, cassava, turnip, radish, yam, and sweet potato, and beans. The homologous sequences may also be derived from woody species, such pine, poplar and eucalyptus.

10

15

20

25

30

35

Transcription factors that are homologous to the listed sequences will typically share at least about 31% amino acid sequence identity. More closely related transcription factors can share at least about 50%, about 60%, about 65%, about 70%, about 75% or about 80% or about 90% or about 95% or about 98% or more sequence identity with the listed sequences. Factors that are most closely related to the listed sequences share, e.g., at least about 85%, about 90% or about 95% or more % sequence identity to the listed sequences. At the nucleotide level, the sequences will typically share at least about 40% nucleotide sequence identity, preferably at least about 50%, about 60%, about 70% or about 80% sequence identity, and more preferably about 85%, about 90%, about 95% or about 97% or more sequence identity to one or more of the listed sequences. The degeneracy of the genetic code enables major variations in the nucleotide sequence of a polynucleotide while maintaining the amino acid sequence of the encoded protein. Conserved domains within a transcription factor family may exhibit a higher degree of sequence homology, such as at least 65% sequence identity including conservative substitutions, and preferably at least 80% sequence identity.

Identifying Nucleic Acids by Hybridization

Polynucleotides homologous to the sequences illustrated in the Sequence Listing can be identified, e.g., by hybridization to each other under stringent or under highly stringent conditions. Single stranded polynucleotides hybridize when they associate based on a variety of well characterized physico-chemical forces, such as hydrogen bonding, solvent exclusion, base stacking and the like. The stringency of a hybridization reflects the degree of sequence identity of the nucleic acids involved, such that the higher the stringency, the more similar are the two polynucleotide strands. Stringency is influenced by a variety of factors, including temperature, salt concentration and composition, organic and non-organic additives, solvents, etc. present in both the hybridization and wash solutions and incubations (and number), as described in more detail in the references cited above.

An example of stringent hybridization conditions for hybridization of complementary nucleic acids which have more than 100 complementary residues on a filter in a Southern or northern blot is about 5°C to 20°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Nucleic acid molecules that hybridize under stringent conditions will typically hybridize to a probe based on either the entire cDNA or selected portions, e.g., to a unique subsequence, of the cDNA under wash conditions of 0.2x SSC to 2.0 x SSC, 0.1% SDS at 50-65° C, for example 0.2 x SSC, 0.1% SDS at 65° C. For identification of less closely related homologues washes can be performed at a lower temperature, e.g., 50° C. In general, stringency is increased by raising the wash temperature and/or decreasing the concentration of SSC.

As another example, stringent conditions can be selected such that an oligonucleotide that is perfectly complementary to the coding oligonucleotide hybridizes to the coding oligonucleotide with at least about a 5-10x higher signal to noise ratio than the ratio for hybridization of the perfectly complementary oligonucleotide to a nucleic acid encoding a transcription factor known as of the filing date of the application. Conditions can be selected such that a higher signal to noise ratio is observed in the particular assay which is used, e.g., about 15x, 25x, 35x, 50x or more. Accordingly, the subject nucleic acid hybridizes to the unique coding oligonucleotide with at least a 2x higher signal to noise ratio as compared to hybridization of the coding oligonucleotide to a nucleic acid encoding known polypeptide. Again, higher signal to noise ratios can be selected, e.g., about 5x, 10x, 25x, 35x, 50x or more. The particular signal will depend on the label used in the relevant assay, e.g., a fluorescent label, a colorimetric label, a radio active label, or the like.

Alternatively, transcription factor homologue polypeptides can be obtained by screening an expression library using antibodies specific for one or more transcription factors. With the provision herein of the disclosed transcription factor, and transcription factor homologue nucleic acid sequences, the encoded polypeptide(s) can be expressed and purified in a heterologous expression system (e.g., E. coli) and used to raise antibodies (monoclonal or polyclonal) specific for the polypeptide(s) in question. Antibodies can also be raised against synthetic peptides derived from transcription factor, or transcription factor homologue, amino acid sequences. Methods of raising antibodies are well known in the art and are described in Harlow and Lane (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York. Such antibodies can then be used to screen an expression library produced from the plant from which it is desired to clone additional transcription

factor homologues, using the methods described above. The selected cDNAs can be confirmed by sequencing and enzymatic activity.

SEQUENCE VARIATIONS

5

10

It will readily be appreciated by those of skill in the art, that any of a variety of polynucleotide sequences are capable of encoding the transcription factors and transcription factor homologue polypeptides of the invention. Due to the degeneracy of the genetic code, many different polynucleotides can encode identical and/or substantially similar polypeptides in addition to those sequences illustrated in the Sequence Listing.

For example, Table 1 illustrates, e.g., that the codons AGC, AGT, TCA, TCC, TCG, and TCT all encode the same amino acid: serine. Accordingly, at each position in the sequence where there is a codon encoding serine, any of the above trinucleotide sequences can be used without altering the encoded polypeptide.

Table 1

Amino acids			Codon	·····	-	•		
Alanine	Ala	Α	GCA	GCC	GCG	GCU	·	
Cysteine	Cys	С	TGC	TGT				
Aspartic acid	Asp	D	GAC	GAT				
Glutamic acid	Glu	E	GAA	GAG			•	
Phenylalanine	Phe	F	TTC	TTT				
Glycine	Gly	G	GGA	GGC	GGG	GGT		
Histidine	His	H	CAC	CAT				
Isoleucine	Ile	I	ATA	ATC	ATT			
Lysine	Lys	K	AAA ·	AAG	•			
Leucine	Leu	L	TTA	TTG	CTA	CTC	CTG	CTT
Methionine	Met	M	ATG					
Asparagine	Asn	N	AAC	AAT			•	
Proline	Pro	P	CCA	CCC	CCG	CCT		
Glutamine	Gln	Q	CAA	CAG				
Arginine	Arg	R	AGA	AGG	CGA	CGC	CGG	CGT
Serine	Ser	S	AGC	AGT	TCA	TCC	TCG	TCT
Threonine	Thr	T	ACA	ACC	ACG	ACT		
Valine	Val	V	GTA	GTC	GTG	GTT		
Tryptophan	Trp	W	TGG					
Tyrosine	Tyr	Y	TAC	TAT				

15

20

Sequence alterations that do not change the amino acid sequence encoded by the polynucleotide are termed "silent" variations. With the exception of the codons ATG and TGG, encoding methionine and tryptophan, respectively, any of the possible codons for the same amino acid can be substituted by a variety of techniques, e.g., site-directed mutagenesis, available in the art. Accordingly, any and all such variations of a sequence selected from the above table are a feature of the invention.

In addition to silent variations, other conservative variations that alter one, or a few amino acids in the encoded polypeptide, can be made without altering the function of the polypeptide, these conservative variants are, likewise, a feature of the invention.

For example, substitutions, deletions and insertions introduced into the sequences provided in the Sequence Listing are also envisioned by the invention. Such sequence modifications can be engineered into a sequence by site-directed mutagenesis (Wu (ed.) Meth. Enzymol. (1993) vol. 217, Academic Press) or the other methods noted below. Amino acid substitutions are typically of single residues; insertions usually will be on the order of about from 1 to 10 amino acid residues; and deletions will range about from 1 to 30 residues. In preferred embodiments, deletions or insertions are made in adjacent pairs, e.g., a deletion of two residues or insertion of two residues. Substitutions, deletions, insertions or any combination thereof can be combined to arrive at a sequence. The mutations that are made in the polynucleotide encoding the transcription factor should not place the sequence out of reading frame and should not create complementary regions that could produce secondary mRNA structure. Preferably, the polypeptide encoded by the DNA performs the desired function.

Conservative substitutions are those in which at least one residue in the amino acid sequence has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the Table 2 when it is desired to maintain the activity of the protein. Table 2 shows amino acids which can be substituted for an amino acid in a protein and which are typically regarded as conservative substitutions.

25

5

10

15

20

30

35

Table 2

Residue	Conservative Substitutions
Ala	Ser
Arg	Lys
Asn	Gln; His
Asp	Glu
Gln	Asn
Cys	Ser
Glu	Asp
Gly	Pro
His	Asn; Gln
Ile	Leu, Val
Leu	Ile; Val
Lys	Arg; Gln
Met	Leu; Ile
Phe	Met; Leu; Tyr
Ser	Thr; Gly
Thr	Ser;Val
Trp	Tyr
Тут	Trp; Phe
Val	Ile; Leu

Substitutions that are less conservative than those in Table 2 can be selected by picking residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in protein properties will be those in which (a) a hydrophilic residue, e.g., seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g., leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g., glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine.

5

10

FURTHER MODIFYING SEQUENCES OF THE INVENTION—MUTATION/ FORCED EVOLUTION

In addition to generating silent or conservative substitutions as noted, above, the present invention optionally includes methods of modifying the sequences of the Sequence Listing. In the methods, nucleic acid or protein modification methods are used to alter the given sequences to produce new sequences and/or to chemically or enzymatically modify given sequences to change the properties of the nucleic acids or proteins.

Thus, in one embodiment, given nucleic acid sequences are modified, e.g., according to standard mutagenesis or artificial evolution methods to produce modified sequences. For example, Ausubel, *supra*, provides additional details on mutagenesis methods. Artificial forced evolution methods are described, e.g., by Stemmer (1994) Nature 370:389-391, and Stemmer (1994) Proc. Natl. Acad. Sci. USA 91:10747-10751. Many other mutation and evolution methods are also available and expected to be within the skill of the practitioner.

10

15

20

30

35

Similarly, chemical or enzymatic alteration of expressed nucleic acids and polypeptides can be performed by standard methods. For example, sequence can be modified by addition of lipids, sugars, peptides, organic or inorganic compounds, by the inclusion of modified nucleotides or amino acids, or the like. For example, protein modification techniques are illustrated in Ausubel, *supra*. Further details on chemical and enzymatic modifications can be found herein. These modification methods can be used to modify any given sequence, or to modify any sequence produced by the various mutation and artificial evolution modification methods noted herein.

Accordingly, the invention provides for modification of any given nucleic acid by mutation, evolution, chemical or enzymatic modification, or other available methods, as well as for the products produced by practicing such methods, e.g., using the sequences herein as a starting substrate for the various modification approaches.

For example, optimized coding sequence containing codons preferred by a particular prokaryotic or eukaryotic host can be used e.g., to increase the rate of translation or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, as compared with transcripts produced using a non-optimized sequence. Translation stop codons can also be modified to reflect host preference. For example, preferred stop codons for S. cerevisiae and mammals are TAA and TGA, respectively. The preferred stop codon for monocotyledonous plants is TGA, whereas insects and E. coli prefer to use TAA as the stop codon.

The polynucleotide sequences of the present invention can also be engineered in order to alter a coding sequence for a variety of reasons, including but not limited to, alterations which modify the sequence to facilitate cloning, processing and/or expression of

the gene product. For example, alterations are optionally introduced using techniques which are well known in the art, e.g., site-directed mutagenesis, to insert new restriction sites, to alter glycosylation patterns, to change codon preference, to introduce splice sites, etc.

Furthermore, a fragment or domain derived from any of the polypeptides of the invention can be combined with domains derived from other transcription factors or synthetic domains to modify the biological activity of a transcription factor. For instance, a DNA binding domain derived from a transcription factor of the invention can be combined with the activation domain of another transcription factor or with a synthetic activation domain. A transcription activation domain assists in initiating transcription from a DNA binding site. Examples include the transcription activation region of VP16 or GAL4 (Moore et al. (1998) Proc. Natl. Acad. Sci. USA 95: 376-381; and Aoyama et al. (1995) Plant Cell 7:1773-1785), peptides derived from bacterial sequences (Ma and Ptashne (1987) Cell 51; 113-119) and synthetic peptides (Giniger and Ptashne, (1987) Nature 330:670-672).

EXPRESSION AND MODIFICATION OF POLYPEPTIDES

15

20

25

5

10

Typically, polynucleotide sequences of the invention are incorporated into recombinant DNA (or RNA) molecules that direct expression of polypeptides of the invention in appropriate host cells, transgenic plants, in vitro translation systems, or the like. Due to the inherent degeneracy of the genetic code, nucleic acid sequences which encode substantially the same or a functionally equivalent amino acid sequence can be substituted for any listed sequence to provide for cloning and expressing the relevant homologue.

Vectors, Promoters and Expression Systems

The present invention includes recombinant constructs comprising one or more of the nucleic acid sequences herein. The constructs typically comprise a vector, such as a plasmid, a cosmid, a phage, a virus (e.g., a plant virus), a bacterial artificial chromosome (BAC), a yeast artificial chromosome (YAC), or the like, into which a nucleic acid sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available.

30

35

General texts which describe molecular biological techniques useful herein, including the use and production of vectors, promoters and many other relevant topics, include Berger, Sambrook and Ausubel, *supra*. Any of the identified sequences can be incorporated into a cassette or vector, e.g., for expression in plants. A number of expression vectors suitable for stable transformation of plant cells or for the establishment of transgenic plants have been described including those described in Weissbach and Weissbach, (1989) Methods for Plant Molecular Biology, Academic Press, and Gelvin et al., (1990) Plant

Molecular Biology Manual, Kluwer Academic Publishers. Specific examples include those derived from a Ti plasmid of *Agrobacterium tumefaciens*, as well as those disclosed by Herrera-Estrella et al. (1983) Nature 303: 209, Bevan (1984) Nucl Acid Res. 12: 8711-8721, Klee (1985) Bio/Technology 3: 637-642, for dicotyledonous plants.

5

Alternatively, non-Ti vectors can be used to transfer the DNA into monocotyledonous plants and cells by using free DNA delivery techniques. Such methods can involve, for example, the use of liposomes, electroporation, microprojectile bombardment, silicon carbide whiskers, and viruses. By using these methods transgenic plants such as wheat, rice (Christou (1991) Bio/Technology 9: 957-962) and corn (Gordon-Kamm (1990) Plant Cell 2: 603-618) can be produced. An immature embryo can also be a good target tissue for monocots for direct DNA delivery techniques by using the particle gun (Weeks et al. (1993) Plant Physiol 102: 1077-1084; Vasil (1993) Bio/Technology 10: 667-674; Wan and Lemeaux (1994) Plant Physiol 104: 37-48, and for Agrobacterium-mediated DNA transfer (Ishida et al. (1996) Nature Biotech 14: 745-750).

15

20

25

30

35

10

Typically, plant transformation vectors include one or more cloned plant coding sequence (genomic or cDNA) under the transcriptional control of 5' and 3' regulatory sequences and a dominant selectable marker. Such plant transformation vectors typically also contain a promoter (e.g., a regulatory region controlling inducible or constitutive, environmentally-or developmentally-regulated, or cell- or tissue-specific expression), a transcription initiation start site, an RNA processing signal (such as intron splice sites), a transcription termination site, and/or a polyadenylation signal.

Examples of constitutive plant promoters which can be useful for expressing the TF sequence include: the cauliflower mosaic virus (CaMV) 35S promoter, which confers constitutive, high-level expression in most plant tissues (see, e.g., Odel et al. (1985) Nature 313:810); the nopaline synthase promoter (An et al. (1988) Plant Physiol 88:547); and the octopine synthase promoter (Fromm et al. (1989) Plant Cell 1: 977).

A variety of plant gene promoters that regulate gene expression in response to environmental, hormonal, chemical, developmental signals, and in a tissue-active manner can be used for expression of a TF sequence in plants. Choice of a promoter is based largely on the phenotype of interest and is determined by such factors as tissue (e.g., seed, fruit, root, pollen, vascular tissue, flower, carpel, etc.), inducibility (e.g., in response to wounding, heat, cold, drought, light, pathogens, etc.), timing, developmental stage, and the like. Numerous known promoters have been characterized and can favorable be employed to promote expression of a polynucleotide of the invention in a transgenic plant or cell of interest. For example, tissue specific promoters include: seed-specific promoters (such as the napin, phaseolin or DC3 promoter described in US Pat. No. 5,773,697), fruit-specific promoters that are active during fruit ripening (such as the dru 1 promoter (US Pat. No. 5,783,393), or the

2A11 promoter (US Pat. No. 4,943,674) and the tomato polygalacturonase promoter (Bird et al. (1988) Plant Mol Biol 11:651), root-specific promoters, such as those disclosed in US Patent Nos. 5,618,988, 5,837,848 and 5,905,186, pollen-active promoters such as PTA29, PTA26 and PTA13 (US Pat. No. 5,792,929), promoters active in vascular tissue (Ringli and Keller (1998) Plant Mol Biol 37:977-988), flower-specific (Kaiser et al. (1995) Plant Mol Biol 28:231-243), pollen (Baerson et al. (1994) Plant Mol Biol 26:1947-1959), carpels (Ohl et al. (1990) Plant Cell 2:837-848), pollen and ovules (Baerson et al. (1993) Plant Mol Biol 22:255-267), auxin-inducible promoters (such as that described in van der Kop et al. (1999) Plant Mol Biol 39:979-990 or Baumann et al. (1999) Plant Cell 11:323-334), cytokinininducible promoter (Guevara-Garcia (1998) Plant Mol Biol 38:743-753), promoters responsive to gibberellin (Shi et al. (1998) Plant Mol Biol 38:1053-1060, Willmott et al. (1998) 38:817-825) and the like. Additional promoters are those that elicit expression in response to heat (Ainley et al. (1993) Plant Mol Biol 22: 13-23), light (e.g., the pea rbcS-3A promoter, Kuhlemeier et al. (1989) Plant Cell 1:471, and the maize rbcS promoter, Schaffner and Sheen (1991) Plant Cell 3: 997); wounding (e.g., wunI, Siebertz et al. (1989) Plant Cell 1: 961); pathogens (such as the PR-1 promoter described in Buchel et al. (1999) Plant Mol. Biol. 40:387-396, and the PDF1.2 promoter described in Manners et al. (1998) Plant Mol. Biol. 38:1071-80), and chemicals such as methyl jasmonate or salicylic acid (Gatz et al. (1997) Plant Mol Biol 48: 89-108). In addition, the timing of the expression can be controlled by using promoters such as those acting at senescence (An and Amazon (1995) Science 270: 1986-1988); or late seed development (Odell et al. (1994) Plant Physiol 106:447-458).

10

15

20

25

30

Plant expression vectors can also include RNA processing signals that can be positioned within, upstream or downstream of the coding sequence. In addition, the expression vectors can include additional regulatory sequences from the 3'-untranslated region of plant genes, e.g., a 3' terminator region to increase mRNA stability of the mRNA, such as the PI-II terminator region of potato or the octopine or nopaline synthase 3' terminator regions.

Additional Expression Elements

Specific initiation signals can aid in efficient translation of coding sequences. These signals can include, e.g., the ATG initiation codon and adjacent sequences. In cases where a coding sequence, its initiation codon and upstream sequences are inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only coding sequence (e.g., a mature protein coding sequence), or a portion thereof, is inserted, exogenous transcriptional control signals including the ATG initiation codon can be separately provided. The initiation codon is provided in the correct reading frame to facilitate transcription. Exogenous transcriptional elements and initiation

codons can be of various origins, both natural and synthetic. The efficiency of expression can be enhanced by the inclusion of enhancers appropriate to the cell system in use.

Expression Hosts

5

10

15

20

25

30

35

The present invention also relates to host cells which are transduced with vectors of the invention, and the production of polypeptides of the invention (including fragments thereof) by recombinant techniques. Host cells are genetically engineered (i.e, nucleic acids are introduced, e.g., transduced, transformed or transfected) with the vectors of this invention, which may be, for example, a cloning vector or an expression vector comprising the relevant nucleic acids herein. The vector is optionally a plasmid, a viral particle, a phage, a naked nucleic acids, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants, or amplifying the relevant gene. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to those skilled in the art and in the references cited herein, including, Sambrook and Ausubel.

The host cell can be a eukaryotic cell, such as a yeast cell, or a plant cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Plant protoplasts are also suitable for some applications. For example, the DNA fragments are introduced into plant tissues, cultured plant cells or plant protoplasts by standard methods including electroporation (Fromm et al., (1985) Proc. Natl. Acad. Sci. USA 82, 5824, infection by viral vectors such as cauliflower mosaic virus (CaMV) (Hohn et al., (1982) Molecular Biology of Plant Tumors, (Academic Press, New York) pp. 549-560; US 4,407,956), high velocity ballistic penetration by small particles with the nucleic acid either within the matrix of small beads or particles, or on the surface (Klein et al., (1987) Nature 327, 70-73), use of pollen as vector (WO 85/01856), or use of Agrobacterium tumefaciens or A. rhizogenes carrying a T-DNA plasmid in which DNA fragments are cloned. The T-DNA plasmid is transmitted to plant cells upon infection by Agrobacterium tumefaciens, and a portion is stably integrated into the plant genome (Horsch et al. (1984) Science 233:496-498; Fraley et al. (1983) Proc. Natl. Acad. Sci. USA 80, 4803).

The cell can include a nucleic acid of the invention which encodes a polypeptide, wherein the cells expresses a polypeptide of the invention. The cell can also include vector sequences, or the like. Furthermore, cells and transgenic plants which include any polypeptide or nucleic acid above or throughout this specification, e.g., produced by transduction of a vector of the invention, are an additional feature of the invention.

For long-term, high-yield production of recombinant proteins, stable expression can be used. Host cells transformed with a nucleotide sequence encoding a polypeptide of the invention are optionally cultured under conditions suitable for the

expression and recovery of the encoded protein from cell culture. The protein or fragment thereof produced by a recombinant cell may be secreted, membrane-bound, or contained intracellularly, depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides encoding mature proteins of the invention can be designed with signal sequences which direct secretion of the mature polypeptides through a prokaryotic or eukaryotic cell membrane.

Modified Amino Acids

10

15

25

30

35

Polypeptides of the invention may contain one or more modified amino acids. The presence of modified amino acids may be advantageous in, for example, increasing polypeptide half-life, reducing polypeptide antigenicity or toxicity, increasing polypeptide storage stability, or the like. Amino acid(s) are modified, for example, co-translationally or post-translationally during recombinant production or modified by synthetic or chemical means.

Non-limiting examples of a modified amino acid include incorporation or other use of acetylated amino acids, glycosylated amino acids, sulfated amino acids, prenylated (e.g., farnesylated, geranylgeranylated) amino acids, PEG modified (e.g., "PEGylated") amino acids, biotinylated amino acids, carboxylated amino acids, phosphorylated amino acids, etc. References adequate to guide one of skill in the modification of amino acids are replete throughout the literature.

20 <u>IDENTIFICATION OF ADDITIONAL FACTORS</u>

A transcription factor provided by the present invention can also be used to identify additional endogenous or exogenous molecules that can affect a phentoype or trait of interest. On the one hand, such molecules include organic (small or large molecules) and/or inorganic compounds that affect expression of (i.e., regulate) a particular transcription factor. Alternatively, such molecules include endogenous molecules that are acted upon either at a transcriptional level by a transcription factor of the invention to modify a phenotype as desired. For example, the transcription factors can be employed to identify one or more downstream gene with which is subject to a regulatory effect of the transcription factor. In one approach, a transcription factor or transcription factor homologue of the invention is expressed in a host cell, e.g, a transgenic plant cell, tissue or explant, and expression products, either RNA or protein, of likely or random targets are monitored, e.g., by hybridization to a microarray of nucleic acid probes corresponding to genes expressed in a tissue or cell type of interest, by two-dimensional gel electrophoresis of protein products, or by any other method known in the art for assessing expression of gene products at the level of RNA or protein. Alternatively, a transcription factor of the invention can be used to identify promoter sequences (i.e., binding sites) involved in the regulation of a downstream target. After

identifying a promoter sequence, interactions between the transcription factor and the promoter sequence can be modified by changing specific nucleotides in the promoter sequence or specific amino acids in the transcription factor that interact with the promoter sequence to alter a plant trait. Typically, transcription factor DNA binding sites are identified by gel shift assays. After identifying the promoter regions, the promoter region sequences can be employed in double-stranded DNA arrays to identify molecules that affect the interactions of the transcription factors with their promoters (Bulyk et al. (1999) Nature Biotechnology 17:573-577).

The identified transcription factors are also useful to identify proteins that modify the activity of the transcription factor. Such modification can occur by covalent modification, such as by phosphorylation, or by protein-protein (homo or-heteropolymer) interactions. Any method suitable for detecting protein-protein interactions can be employed. Among the methods that can be employed are co-immunoprecipitation, cross-linking and co-purification through gradients or chromatographic columns, and the two-hybrid yeast system.

The two-hybrid system detects protein interactions in vivo and is described in Chien, et al., (1991), Proc. Natl. Acad. Sci. USA 88, 9578-9582 and is commercially available from Clontech (Palo Alto, Calif.). In such a system, plasmids are constructed that encode two hybrid proteins: one consists of the DNA-binding domain of a transcription activator protein fused to the TF polypeptide and the other consists of the transcription activator protein's activation domain fused to an unknown protein that is encoded by a cDNA that has been recombined into the plasmid as part of a cDNA library. The DNA-binding domain fusion plasmid and the cDNA library are transformed into a strain of the yeast Saccharomyces cerevisiae that contains a reporter gene (e.g., lacZ) whose regulatory region contains the transcription activator's binding site. Either hybrid protein alone cannot activate transcription of the reporter gene. Interaction of the two hybrid proteins reconstitutes the functional activator protein and results in expression of the reporter gene, which is detected by an assay for the reporter gene product. Then, the library plasmids responsible for reporter gene expression are isolated and sequenced to identify the proteins encoded by the library plasmids. After identifying proteins that interact with the transcription factors, assays for compounds that interfere with the TF protein-protein interactions can be preformed.

IDENTIFICATION OF MODULATORS

10

15

20

25

30

35

In addition to the intracellular molecules described above, extracellular molecules that alter activity or expression of a transcription factor, either directly or indirectly, can be identified. For example, the methods can entail first placing a candidate molecule in contact with a plant or plant cell. The molecule can be introduced by topical administration, such as spraying or soaking of a plant, and then the molecule's effect on the

expression or activity of the TF polypeptide or the expression of the polynucleotide monitored. Changes in the expression of the TF polypeptide can be monitored by use of polyclonal or monoclonal antibodies, gel electrophoresis or the like. Changes in the expression of the corresponding polynucleotide sequence can be detected by use of microarrays, Northerns, quantitative PCR, or any other technique for monitoring changes in mRNA expression. These techniques are exemplified in Ausubel et al. (eds) <u>Current Protocols in Molecular Biology</u>, John Wiley & Sons (1998). Such changes in the expression levels can be correlated with modified plant traits and thus identified molecules can be useful for soaking or spraying on fruit, vegetable and grain crops to modify traits in plants.

Essentially any available composition can be tested for modulatory activity of expression or activity of any nucleic acid or polypeptide herein. Thus, available libraries of compounds such as chemicals, polypeptides, nucleic acids and the like can be tested for modulatory activity. Often, potential modulator compounds can be dissolved in aqueous or organic (e.g., DMSO-based) solutions for easy delivery to the cell or plant of interest in which the activity of the modulator is to be tested. Optionally, the assays are designed to screen large modulator composition libraries by automating the assay steps and providing compounds from any convenient source to assays, which are typically run in parallel (e.g., in microtiter formats on microtiter plates in robotic assays).

10

15

20

25

30

35

In one embodiment, high throughput screening methods involve providing a combinatorial library containing a large number of potential compounds (potential modulator compounds). Such "combinatorial chemical libraries" are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as target compounds.

A combinatorial chemical library can be, e.g., a collection of diverse chemical compounds generated by chemical synthesis or biological synthesis. For example, a combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks (e.g., in one example, amino acids) in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound of a set length). Exemplary libraries include peptide libraries, nucleic acid libraries, antibody libraries (see, e.g., Vaughn et al. (1996) Nature Biotechnology, 14(3):309-314 and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al. Science (1996) 274:1520-1522 and U.S. Patent 5,593,853), peptide nucleic acid libraries (see, e.g., U.S. Patent 5,539,083), and small organic molecule libraries (see, e.g., benzodiazepines, Baum C&EN Jan 18, page 33 (1993); isoprenoids, U.S. Patent 5,569,588; thiazolidinones and metathiazanones, U.S. Patent 5,549,974; pyrrolidines, U.S. Patents 5,525,735 and 5,519,134; morpholino compounds, U.S. Patent 5,506,337) and the like.

Preparation and screening of combinatorial or other libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Patent 5,010,175, Furka, Int. J. Pept. Prot. Res. 37:487-493 (1991) and Houghton et al. Nature 354:84-88 (1991)). Other chemistries for generating chemical diversity libraries can also be used.

5

10

15

20

25

30

35

In addition, as noted, compound screening equipment for high-throughput screening is generally available, e.g., using any of a number of well known robotic systems that have also been developed for solution phase chemistries useful in assay systems. These systems include automated workstations including an automated synthesis apparatus and robotic systems utilizing robotic arms. Any of the above devices are suitable for use with the present invention, e.g., for high-throughput screening of potential modulators. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art.

Indeed, entire high throughput screening systems are commercially available. These systems typically automate entire procedures including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. Similarly, microfluidic implementations of screening are also commercially available.

The manufacturers of such systems provide detailed protocols the various high throughput. Thus, for example, Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like. The integrated systems herein, in addition to providing for sequence alignment and, optionally, synthesis of relevant nucleic acids, can include such screening apparatus to identify modulators that have an effect on one or more polynucleotides or polypeptides according to the present invention.

In some assays it is desirable to have positive controls to ensure that the components of the assays are working properly. At least two types of positive controls are appropriate. That is, known transcriptional activators or inhibitors can be incubated with cells/plants/ etc. in one sample of the assay, and the resulting increase/decrease in transcription can be detected by measuring the resulting increase in RNA/ protein expression, etc., according to the methods herein. It will be appreciated that modulators can also be combined with transcriptional activators or inhibitors to find modulators which inhibit transcriptional activation or transcriptional repression. Either expression of the nucleic acids and proteins herein or any additional nucleic acids or proteins activated by the nucleic acids or proteins herein, or both, can be monitored.

In an embodiment, the invention provides a method for identifying compositions that modulate the activity or expression of a polynucleotide or polypeptide of the invention. For example, a test compound, whether a small or large molecule, is placed in contact with a cell, plant (or plant tissue or explant), or composition comprising the polynucleotide or polypeptide of interest and a resulting effect on the cell, plant, (or tissue or explant) or composition is evaluated by monitoring, either directly or indirectly, one or more of: expression level of the polynucleotide or polypeptide, activity (or modulation of the activity) of the polynucleotide or polypeptide. In some cases, an alteration in a plant phenotype can be detected following contact of a plant (or plant cell, or tissue or explant) with the putative modulator, e.g., by modulation of expression or activity of a polynucleotide or polypeptide of the invention.

SUBSEQUENCES

10

15

20

25

30

35

Also contemplated are uses of polynucleotides, also referred to herein as oligonucleotides, typically having at least 12 bases, preferably at least 15, more preferably at least 20, 30, or 50 bases, which hybridize under at least highly stringent (or ultra-high stringent or ultra-ultra- high stringent conditions) conditions to a polynucleotide sequence described above. The polynucleotides may be used as probes, primers, sense and antisense agents, and the like, according to methods as noted *supra*.

Subsequences of the polynucleotides of the invention, including polynucleotide fragments and oligonucleotides are useful as nucleic acid probes and primers. An oligonucleotide suitable for use as a probe or primer is at least about 15 nucleotides in length, more often at least about 18 nucleotides, often at least about 21 nucleotides, frequently at least about 30 nucleotides, or about 40 nucleotides, or more in length. A nucleic acid probe is useful in hybridization protocols, e.g., to identify additional polypeptide homologues of the invention, including protocols for microarray experiments. Primers can be annealed to a complementary target DNA strand by nucleic acid hybridization to form a hybrid between the primer and the target DNA strand, and then extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR) or other nucleic-acid amplification methods. See Sambrook and Ausubel, supra.

In addition, the invention includes an isolated or recombinant polypeptide including a subsequence of at least about 15 contiguous amino acids encoded by the recombinant or isolated polynucleotides of the invention. For example, such polypeptides, or domains or fragments thereof, can be used as immunogens, e.g., to produce antibodies specific for the polypeptide sequence, or as probes for detecting a sequence of interest. A

subsequence can range in size from about 15 amino acids in length up to and including the full length of the polypeptide.

PRODUCTION OF TRANSGENIC PLANTS

5

10

15

20

25

30

35

Modification of Traits

The polynucleotides of the invention are favorably employed to produce transgenic plants with various traits, or characteristics, that have been modified in a desirable manner, e.g., to improve the pathogen resistance of a plant. For example, alteration of expression levels or patterns (e.g., spatial or temporal expression patterns) of one or more of the transcription factors (or transcription factor homologues) of the invention, as compared with the levels of the same protein found in a wild type plant, can be used to modify a plant's traits. An illustrative example of trait modification, improved pathogen tolerance, by altering expression levels of a particular transcription factor is described further in the Examples and the Sequence Listing.

Antisense and Cosuppression Approaches

In addition to expression of the nucleic acids of the invention as gene replacement or plant phenotype modification nucleic acids, the nucleic acids are also useful for sense and anti-sense suppression of expression, e.g., to down-regulate expression of a nucleic acid of the invention, e.g., as a further mechanism for modulating plant phenotype. That is, the nucleic acids of the invention, or subsequences or anti-sense sequences thereof, can be used to block expression of naturally occurring homologous nucleic acids. A variety of sense and anti-sense technologies are known in the art, e.g., as set forth in Lichtenstein and Nellen (1997) Antisense Technology: A Practical Approach IRL Press at Oxford University, Oxford, England. In general, sense or anti-sense sequences are introduced into a cell, where they are optionally amplified, e.g., by transcription. Such sequences include both simple oligonucleotide sequences and catalytic sequences such as ribozymes.

For example, a reduction or elimination of expression (i.e., a "knock-out") of a transcription factor or transcription factor homologue polypeptide in a transgenic plant, e.g., to modify a plant trait, can be obtained by introducing an antisense construct corresponding to the polypeptide of interest as a cDNA. For antisense suppression, the transcription factor or homologue cDNA is arranged in reverse orientation (with respect to the coding sequence) relative to the promoter sequence in the expression vector. The introduced sequence need not be the full length cDNA or gene, and need not be identical to the cDNA or gene found in the plant type to be transformed. Typically, the antisense sequence need only be capable of hybridizing to the target gene or RNA of interest. Thus, where the introduced sequence is of shorter length, a higher degree of homology to the endogenous transcription factor sequence will be needed for effective antisense suppression. While antisense sequences of various

lengths can be utilized, preferably, the introduced antisense sequence in the vector will be at least 30 nucleotides in length, and improved antisense suppression will typically be observed as the length of the antisense sequence increases. Preferably, the length of the antisense sequence in the vector will be greater than 100 nucleotides. Transcription of an antisense construct as described results in the production of RNA molecules that are the reverse complement of mRNA molecules transcribed from the endogenous transcription factor gene in the plant cell.

5

10

15

20

25

30

35

Suppression of endogenous transcription factor gene expression can also be achieved using a ribozyme. Ribozymes are RNA molecules that possess highly specific endoribonuclease activity. The production and use of ribozymes are disclosed in U.S. Patent No. 4,987,071 and U.S. Patent No. 5,543,508. Synthetic ribozyme sequences including antisense RNAs can be used to confer RNA cleaving activity on the antisense RNA, such that endogenous mRNA molecules that hybridize to the antisense RNA are cleaved, which in turn leads to an enhanced antisense inhibition of endogenous gene expression.

Vectors in which RNA encoded by a transcription factor or transcription factor homologue cDNA is over-expressed can also be used to obtain co-suppression of a corresponding endogenous gene, e.g., in the manner described in U.S. Patent No. 5,231,020 to Jorgensen. Such co-suppression (also termed sense suppression) does not require that the entire transcription factor cDNA be introduced into the plant cells, nor does it require that the introduced sequence be exactly identical to the endogenous transcription factor gene of interest. However, as with antisense suppression, the suppressive efficiency will be enhanced as specificity of hybridization is increased, e.g., as the introduced sequence is lengthened, and/or as the sequence similarity between the introduced sequence and the endogenous transcription factor gene is increased.

Vectors expressing an untranslatable form of the transcription factor mRNA, e.g., sequences comprising one or more stop codon, or nonsense mutation) can also be used to suppress expression of an endogenous transcription factor, thereby reducing or eliminating it's activity and modifying one or more traits. Methods for producing such constructs are described in U.S. Patent No. 5,583,021. Preferably, such constructs are made by introducing a premature stop codon into the transcription factor gene. Alternatively, a plant trait can be modified by gene silencing using double-strand RNA (Sharp (1999) Genes and Development 13: 139-141).

Another method for abolishing the expression of a gene is by insertion mutagenesis using the T-DNA of Agrobacterium tumefaciens. After generating the insertion mutants, the mutants can be screened to identify those containing the insertion in a transcription factor or transcription factor homologue gene. Plants containing a single

transgene insertion event at the desired gene can be crossed to generate homozygous plants for the mutation (Koncz et al. (1992) Methods in Arabidopsis Research, World Scientific).

Alternatively, a plant phenotype can be altered by eliminating an endogenous gene, such as a transcription factor or transcription factor homologue, e.g., by homologous recombination (Kempin et al. (1997) Nature 389:802).

5

10

15

20

25

30

35

A plant trait can also be modified by using the cre-lox system (for example, as described in US Paent No. 5,658,772). A plant genome can be modified to include first and second lox sites that are then contacted with a Cre recombinase. If the lox sites are in the same orientation, the intervening DNA sequence between the two sites is excised. If the lox sites are in the opposite orientation, the intervening sequence is inverted.

The polynucleotides and polypeptides of this invention can also be expressed in a plant in the absence of an expression cassette by manipulating the activity or expression level of the endogenous gene by other means. For example, by ectopically expressing a gene by T-DNA activation tagging (Ichikawa et al. (1997) Nature 390 698-701; Kakimoto et al. (1996) Science 274: 982-985). This method entails transforming a plant with a gene tag containing multiple transcriptional enhancers and once the tag has inserted into the genome, expression of a flanking gene coding sequence becomes deregulated. In another example, the transcriptional machinery in a plant can be modified so as to increase transcription levels of a polynucleotide of the invention (See, e.g., PCT Publications WO 96/06166 and WO 98/53057 which describe the modification of the DNA binding specificity of zinc finger proteins by changing particular amino acids in the DNA binding motif).

The transgenic plant can also include the machinery necessary for expressing or altering the activity of a polypeptide encoded by an endogenous gene, for example by altering the phosphorylation state of the polypeptide to maintain it in an activated state.

Transgenic plants (or plant cells, or plant explants, or plant tissues) incorporating the polynucleotides of the invention and/or expressing the polypeptides of the invention can be produced by a variety of well established techniques as described above. Following construction of a vector, most typically an expression cassette, including a polynucleotide, e.g., encoding a transcription factor or transcription factor homologue, of the invention, standard techniques can be used to introduce the polynucleotide into a plant, a plant cell, a plant explant or a plant tissue of interest. Optionally, the plant cell, explant or tissue can be regenerated to produce a transgenic plant.

The plant can be any higher plant, including gymnosperms, monocotyledonous and dicotyledenous plants. Suitable protocols are available for Leguminosae (alfalfa, soybean, clover, etc.), Umbelliferae (carrot, celery, parsnip), Cruciferae (cabbage, radish, rapeseed, broccoli, etc.), Curcurbitaceae (melons and cucumber), Gramineae (wheat, corn, rice, barley, millet, etc.), Solanaceae (potato, tomato, tobacco,

peppers, etc.), and various other crops. See protocols described in Ammirato et al. (1984) Handbook of Plant Cell Culture —Crop Species. Macmillan Publ. Co. Shimamoto et al. (1989) Nature 338:274-276; Fromm et al. (1990) Bio/Technology 8:833-839; and Vasil et al. (1990) Bio/Technology 8:429-434.

5

10

15

20

25

30

35

Transformation and regeneration of both monocotyledonous and dicotyledonous plant cells is now routine, and the selection of the most appropriate transformation technique will be determined by the practitioner. The choice of method will vary with the type of plant to be transformed; those skilled in the art will recognize the suitability of particular methods for given plant types. Suitable methods can include, but are not limited to: electroporation of plant protoplasts; liposome-mediated transformation; polyethylene glycol (PEG) mediated transformation; transformation using viruses; microinjection of plant cells; micro-projectile bombardment of plant cells; vacuum infiltration; and Agrobacterium tumeficiens mediated transformation. Transformation means introducing a nucleotide sequence in a plant in a manner to cause stable or transient expression of the sequence.

Successful examples of the modification of plant characteristics by transformation with cloned sequences which serve to illustrate the current knowledge in this field of technology, and which are herein incorporated by reference, include: U.S. Patent Nos. 5,571,706; 5,677,175; 5,510,471; 5,750,386; 5,597,945; 5,589,615; 5,750,871; 5,268,526; 5,780,708; 5,538,880; 5,773,269; 5,736,369 and 5,610,042.

Following transformation, plants are preferably selected using a dominant selectable marker incorporated into the transformation vector. Typically, such a marker will confer antibiotic or herbicide resistance on the transformed plants, and selection of transformants can be accomplished by exposing the plants to appropriate concentrations of the antibiotic or herbicide.

After transformed plants are selected and grown to maturity, those plants showing a modified trait are identified. The modified trait can be any of those traits described above. Additionally, to confirm that the modified trait is due to changes in expression levels or activity of the polypeptide or polynucleotide of the invention can be determined by analyzing mRNA expression using Northern blots, RT-PCR or microarrays, or protein expression using immunoblots or Western blots or gel shift assays.

INTEGRATED SYSTEMS—SEQUENCE IDENTITY

Additionally, the present invention may be an integrated system, computer or computer readable medium that comprises an instruction set for determining the identity of one or more sequences in a database. In addition, the instruction set can be used to generate or identify sequences that meet any specified criteria. Furthermore, the instruction set may

be used to associate or link certain functional benefits, such improved pathogen tolerance, with one or more identified sequence.

For example, the instruction set can include, e.g., a sequence comparison or other alignment program, e.g., an available program such as, for example, the Wisconsin Package Version 10.0, such as BLAST, FASTA, PILEUP, FINDPATTERNS or the like (GCG, Madision, WI). Public sequence databases such as GenBank, EMBL, Swiss-Prot and PIR or private sequence databases such as PhytoSeq (Incyte Pharmaceuticals, Palo Alto, CA) can be searched.

Alignment of sequences for comparison can be conducted by the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. U.S.A. 85: 2444, by computerized implementations of these algorithms. After alignment, sequence comparisons between two (or more) polynucleotides or polypeptides are typically performed by comparing sequences of the two sequences over a comparison window to identify and compare local regions of sequence similarity. The comparison window can be a segment of at least about 20 contiguous positions, usually about 50 to about 200, more usually about 100 to about 150 contiguous positions. A description of the method is provided in Ausubel et al., supra.

10

15

20

25

30

35

A variety of methods of determining sequence relationships can be used, including manual alignment and computer assisted sequence alignment and analysis. This later approach is a preferred approach in the present invention, due to the increased throughput afforded by computer assisted methods. As noted above, a variety of computer programs for performing sequence alignment are available, or can be produced by one of skill.

One example algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al. J. Mol. Biol 215:403-410 (1990). Software for performing BLAST analyses is publicly available, e.g., through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters

M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, a cutoff of 100, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915).

In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5787). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence (and, therefore, in this context, homologous) if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, or less than about 0.01, and or even less than about 0.001. An additional example of a useful sequence alignment algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments. The program can align, e.g., up to 300 sequences of a maximum length of 5,000 letters.

The integrated system, or computer typically includes a user input interface allowing a user to selectively view one or more sequence records corresponding to the one or more character strings, as well as an instruction set which aligns the one or more character strings with each other or with an additional character string to identify one or more region of sequence similarity. The system may include a link of one or more character strings with a particular phenotype or gene function. Typically, the system includes a user readable output element which displays an alignment produced by the alignment instruction set.

The methods of this invention can be implemented in a localized or distributed computing environment. In a distributed environment, the methods may implemented on a single computer comprising multiple processors or on a multiplicity of computers. The computers can be linked, e.g. through a common bus, but more preferably the computer(s) are nodes on a network. The network can be a generalized or a dedicated local or

wide-area network and, in certain preferred embodiments, the computers may be components of an intra-net or an internet.

Thus, the invention provides methods for identifying a sequence similar or homologous to one or more polynucleotides as noted herein, or one or more target polypeptides encoded by the polynucleotides, or otherwise noted herein and may include linking or associating a given plant phenotype or gene function with a sequence. In the methods, a sequence database is provided (locally or across an inter or intra net) and a query is made against the sequence database using the relevant sequences herein and associated plant phenotypes or gene functions.

5

10

15

25

30

35

Any sequence herein can be entered into the database, before or after querying the database. This provides for both expansion of the database and, if done before the querying step, for insertion of control sequences into the database. The control sequences can be detected by the query to ensure the general integrity of both the database and the query. As noted, the query can be performed using a web browser based interface. For example, the database can be a centralized public database such as those noted herein, and the querying can be done from a remote terminal or computer across an internet or intranet.

EXAMPLES

The following examples are intended to illustrate but not limit the present invention.

20 EXAMPLE I. FULL LENGTH GENE IDENTIFICATION AND CLONING

Putative transcription factor sequences (genomic or ESTs) related to known transcription factors were identified in the *Arabidopsis thaliana* GenBank database using the tblastn sequence analysis program using default parameters and a P-value cutoff threshold of -4 or -5 or lower, depending on the length of the query sequence. Putative transcription factor sequence hits were then screened to identify those containing particular sequence strings. If the sequence hits contained such sequence strings, the sequences were confirmed as transcription factors.

Alternatively, Arabidopsis thaliana cDNA libraries derived from different tissues or treatments, or genomic libraries were screened to identify novel members of a transcription family using a low stringency hybridization approach. Probes were synthesized using gene specific primers in a standard PCR reaction (annealing temperature 60° C) and labeled with ³²P dCTP using the High Prime DNA Labeling Kit (Boehringer Mannheim). Purified radiolabelled probes were added to filters immersed in Church hybridization medium (0.5 M NaPO₄ pH 7.0, 7% SDS, 1 % w/v bovine serum albumin) and hybridized overnight at 60 °C with shaking. Filters were washed two times for 45 to 60 minutes with 1xSCC, 1% SDS at 60° C.

To identify additional sequence 5' or 3' of a partial cDNA sequence in a cDNA library, 5' and 3' rapid amplification of cDNA ends (RACE) was performed using the MarathonTM cDNA amplification kit (Clontech, Palo Alto, CA). Generally, the method entailed first isolating poly(A) mRNA, performing first and second strand cDNA synthesis to generate double stranded cDNA, blunting cDNA ends, followed by ligation of the MarathonTM Adaptor to the cDNA to form a library of adaptor-ligated ds cDNA.

Gene-specific primers were designed to be used along with adaptor specific primers for both 5' and 3' RACE reactions. Nested primers, rather than single primers, were used to increase PCR specificity. Using 5' and 3' RACE reactions, 5' and 3' RACE fragments were obtained, sequenced and cloned. The process can be repeated until 5' and 3' ends of the full-length gene were identified. Then the full-length cDNA was generated by PCR using primers specific to 5' and 3' ends of the gene by end-to-end PCR.

EXAMPLE II. CONSTRUCTION OF EXPRESSION VECTORS

5

10

30

35

The sequence was amplified from a genomic or cDNA library using primers specific to sequences upstream and downstream of the coding region. The expression vector 15 was pMEN20 or pMEN65, which are both derived from pMON316 (Sanders et al, (1987) Nucleic Acids Research 15:1543-58) and contain the CaMV 35S promoter to express transgenes. To clone the sequence into the vector, both pMEN20 and the amplified DNA fragment were digested separately with SalI and NotI restriction enzymes at 37° C for 2 hours. The digestion products were subject to electrophoresis in a 0.8% agarose gel and visualized 20 by ethidium bromide staining. The DNA fragments containing the sequence and the linearized plasmid were excised and purified by using a Qiaquick gel extraction kit (Qiagen, CA). The fragments of interest were ligated at a ratio of 3:1 (vector to insert). Ligation reactions using T4 DNA ligase (New England Biolabs, MA) were carried out at 16° C for 16 hours. The ligated DNAs were transformed into competent cells of the E. coli strain 25 DH5alpha by using the heat shock method. The transformations were plated on LB plates containing 50 mg/l kanamycin (Sigma).

Individual colonies were grown overnight in five milliliters of LB broth containing 50 mg/l kanamycin at 37° C. Plasmid DNA was purified by using Qiaquick Mini Prep kits (Qiagen, CA).

EXAMPLE III. TRANSFORMATION OF AGROBACTERIUM WITH THE EXPRESSION VECTOR

After the plasmid vector containing the gene was constructed, the vector was used to transform Agrobacterium tumefaciens cells expressing the gene products. The stock of Agrobacterium tumefaciens cells for transformation were made as described by Nagel et al. (1990) FEMS Microbiol Letts. 67: 325-328. Agrobacterium strain ABI was grown in 250 ml

LB medium (Sigma) overnight at 28°C with shaking until an absorbance (A_{600}) of 0.5 – 1.0 was reached. Cells were harvested by centrifugation at 4,000 x g for 15 min at 4° C. Cells were then resuspended in 250 μ l chilled buffer (1 mM HEPES, pH adjusted to 7.0 with KOH). Cells were centrifuged again as described above and resuspended in 125 μ l chilled buffer. Cells were then centrifuged and resuspended two more times in the same HEPES buffer as described above at a volume of 100 μ l and 750 μ l, respectively. Resuspended cells were then distributed into 40 μ l aliquots, quickly frozen in liquid nitrogen, and stored at -80° C.

Agrobacterium cells were transformed with plasmids prepared as described above following the protocol described by Nagel et al. For each DNA construct to be transformed, 50 – 100 ng DNA (generally resuspended in 10 mM Tris-HCl, 1 mM EDTA, pH 8.0) was mixed with 40 μl of Agrobacterium cells. The DNA/cell mixture was then transferred to a chilled cuvette with a 2mm electrode gap and subject to a 2.5 kV charge dissipated at 25 μF and 200 μF using a Gene Pulser II apparatus (Bio-Rad). After electroporation, cells were immediately resuspended in 1.0 ml LB and allowed to recover without antibiotic selection for 2 – 4 hours at 28° C in a shaking incubator. After recovery, cells were plated onto selective medium of LB broth containing 100 μg/ml spectinomycin (Sigma) and incubated for 24-48 hours at 28° C. Single colonies were then picked and inoculated in fresh medium. The presence of the plasmid construct was verified by PCR amplification and sequence analysis.

10

15

20

25

30

35

EXAMPLE IV. TRANSFORMATION OF ARABIDOPSIS PLANTS WITH AGROBACTERIUM TUMEFACIENS WITH EXPRESSION VECTOR

After transformation of Agrobacterium tumefaciens with plasmid vectors containing the gene, single Agrobacterium colonies were identified, propagated, and used to transform Arabidopsis plants. Briefly, 500 ml cultures of LB medium containing 50 mg/l kanamycin were inoculated with the colonies and grown at 28° C with shaking for 2 days until an absorbance (A_{600}) of > 2.0 is reached. Cells were then harvested by centrifugation at 4,000 x g for 10 min, and resuspended in infiltration medium (1/2 X Murashige and Skoog salts (Sigma), 1 X Gamborg's B-5 vitamins (Sigma), 5.0% (w/v) sucrose (Sigma), 0.044 μ M benzylamino purine (Sigma), 200 μ l/L Silwet L-77 (Lehle Seeds) until an absorbance (A_{600}) of 0.8 was reached.

Prior to transformation, Arabidopsis thaliana seeds (ecotype Columbia) were sown at a density of ~10 plants per 4" pot onto Pro-Mix BX potting medium (Hummert International) covered with fiberglass mesh (18 mm X 16 mm). Plants were grown under continuous illumination (50-75 μ E/m²/sec) at 22-23° C with 65-70% relative humidity. After about 4 weeks, primary inflorescence stems (bolts) are cut off to encourage growth of

multiple secondary bolts. After flowering of the mature secondary bolts, plants were prepared for transformation by removal of all siliques and opened flowers.

The pots were then immersed upside down in the mixture of Agrobacterium infiltration medium as described above for 30 sec, and placed on their sides to allow draining into a 1' x 2' flat surface covered with plastic wrap. After 24 h, the plastic wrap was removed and pots are turned upright. The immersion procedure was repeated one week later, for a total of two immersions per pot. Seeds were then collected from each transformation pot and analyzed following the protocol described below.

EXAMPLE V. IDENTIFICATION OF ARABIDOPSIS PRIMARY TRANSFORMANTS

Seeds collected from the transformation pots were sterilized essentially as follows. Seeds were dispersed into in a solution containing 0.1% (v/v) Triton X-100 (Sigma) and sterile H₂O and washed by shaking the suspension for 20 min. The wash solution was then drained and replaced with fresh wash solution to wash the seeds for 20 min with shaking. After removal of the second wash solution, a solution containing 0.1% (v/v) Triton X-100 and 70% ethanol (Equistar) was added to the seeds and the suspension was shaken for 5 min. After removal of the ethanol/detergent solution, a solution containing 0.1% (v/v) Triton X-100 and 30% (v/v) bleach (Clorox) was added to the seeds, and the suspension was shaken for 10 min. After removal of the bleach/detergent solution, seeds were then washed five times in sterile distilled H2O. The seeds were stored in the last wash water at 4° C for 2 days in the dark before being plated onto antibiotic selection medium (1 X Murashige and Skoog salts (pH adjusted to 5.7 with 1M KOH), 1 X Gamborg's B-5 vitamins, 0.9% phytagar (Life Technologies), and 50 mg/l kanamycin). Seeds were germinated under continuous illumination (50-75 µE/m²/sec) at 22-23° C. After 7-10 days of growth under these conditions, kanamycin resistant primary transformants (T₁ generation) were visible and obtained. These seedlings were transferred first to fresh selection plates where the seedlings continued to grow for 3-5 more days, and then to soil (Pro-Mix BX potting medium).

Primary transformants were crossed and progeny seeds (T₂) collected; kanamycin resistant seedlings were selected and analyzed. The expression levels of the recombinant polynucleotides in the transformants varies from about a 5% expression level increase to a least a 100% expression level increase. Similar observations are made with respect to polypeptide level expression.

EXAMPLE VI. IDENTIFICATION OF ARABIDOPSIS PLANTS WITH TRANSCRIPTION FACTOR GENE KNOCKOUTS

10

15

20

25

30

The screening of insertion mutagenized *Arabidopsis* collections for null mutants in a known target gene was essentially as described in Krysan et al (1999) <u>Plant Cell</u> 11:2283-2290. Briefly, gene-specific primers, nested by 5-250 bases to each other, were designed from the 5' and 3' regions of a known target gene. Similarly, nested sets of primers were also created specific to each of the T-DNA or transposon ends (the "right" and "left" borders). All possible combinations of gene specific and T-DNA/transposon primers were used to detect by PCR an insertion event within or close to the target gene. The amplified DNA fragments were then sequenced which allows the precise determination of the T-DNA/transposon insertion point relative to the target gene. Insertion events within the coding or intervening sequence of the genes were deconvoluted from a pool comprising a plurality of insertion events to a single unique mutant plant for functional characterization. The method is described in more detail in Yu and Adam, US Application Serial No. 09/177,733 filed October 23, 1998.

15 EXAMPLE VII. IDENTIFICATION OF PATHOGEN INDUCED GENES

5

10

20

25

30

In some instances, expression patterns of the pathogen induced genes (such as defense genes) was monitored by microarray experiments. cDNAs were generated by PCR and resuspended at a final concentration of ~ 100 ng/ul in 3X SSC or 150mM Na-phosphate (Eisen and Brown (1999) *Meth. in Enzymol.* 303:179-205). The cDNAs were spotted on microscope glass slides coated with polylysine. The prepared cDNAs were aliquoted into 384 well plates and spotted on the slides using an x-y-z gantry (OmniGrid) purchased from GeneMachines (Menlo Park, CA) outfitted with quill type pins purchased from Telechem International (Sunnyvale, CA). After spotting, the arrays were cured for a minimum of one week at room temperature, rehydrated and blocked following the protocol recommended by Eisen and Brown (1999).

Sample total RNA (10 ug) samples were labeled using fluorescent Cy3 and Cy5 dyes. Labeled samples were resuspended in 4X SSC/0.03% SDS/4 ug salmon sperm DNA/2 ug tRNA/ 50mM Na-pyrophosphate, heated for 95°C for 2.5 minutes, spun down and placed on the array. The array was then covered with a glass coverslip and placed in a sealed chamber. The chamber was then kept in a water bath at 62°C overnight. The arrays were washed as described in Eisen and Brown (1999) and scanned on a General Scanning 3000 laser scanner. The resulting files are subsequently quantified using Imagene a software purchased from BioDiscovery (Los Angeles, CA).

EXAMPLE VIII. IDENTIFICATION OF PATHOGEN TOLERANCE PHENOTYPE IN OVEREXPRESSOR OR GENE KNOCKOUT PLANTS

5

10

15

20

25

30

35

Experiments were performed to identify those transformants or knockouts that exhibited an improved pathogen tolerance. For such studies, the transformants were exposed to biotropic fungal pathogens, such as Erisyphe orontii; and necrotropic fungal pathogens, such as Fusarium oxysporum. Fusarium oxysporum isolates cause vascular wilts and damping off of various annual vegetables, perennials and weeds (Mauch-Mani and Slusarenko (1994) Molecular Plant-Microbe Interactions 7: 378-383). For Fusarium oxysporum experiments, plants grown on petri dishes were sprayed with a fresh spore suspension of F. oxysporum. The spore suspension was prepared as follows: A plug of fungal hyphae from a plate culture was placed on a fresh potato dextrose agar plate and allowed to spread for one week. 5 ml sterile water was then added to the plate, swirled, and pipetted into 50 ml Armstrong Fusarium medium. Spores were grown overnight in Fusarium medium and then sprayed onto plants using a Preval paint sprayer. Plant tissue was harvested and frozen in liquid nitrogen 48 hours post infection.

Erysiphe orontii is a causal agent of powdery mildew. For Erysiphe orontii experiments, plants were grown approximately 4 weeks in a greenhouse under 12 hour light (20 C, ~30% relative humidity (rh)). Individual leaves were infected with E. orontii spores from infected plants using a camel's hair brush, and the plants were transferred to a Percival growth chamber (20 C, 80% rh.). Plant tissue was harvested and frozen in liquid nitrogen 7 days post infection.

Botrytis cinerea is a necrotrophic pathogen. Botrytis cinerea was grown on potato dextrose agar in the light. A spore culture was made by spreading 10 ml of sterile water on the fungus plate, swirling and transferring spores to 10 ml of sterile water. The spore inoculum (approx. 105 spores/ml) was used to spray 10 day-old seedlings grown under sterile conditions on MS (-sucrose) media. Symptoms were evaluated every day up to approximately 1 week.

Infection with bacterial pathogens Pseudomonas syringae pv maculicola strain 4326 and pv maculicola strain 4326 was performed by hand inoculation at two doses. Two inoculation doses allows the differentiation between plants with enhanced susceptibility and plants with enhanced resistance to the pathogen. Plants were grown for 3 weeks in the greenhouse, then transferred to the growth chamber for the remainder of their growth. Psm ES4326 was hand inoculated with 1 ml syringe on 3 fully-expanded leaves per plant (4 1/2 wk old), using at least 9 plants per overexpressing line at two inoculation doses, OD=0.005 and OD=0.0005. Disease scoring occured at day 3 post-inoculation with pictures of the plants and leaves taken in parallel.

Table 3 shows the phenotypes observed for particular overexpressor or knockout plants and provides the SEQ ID No., the internal reference code (GID), whether a knockout or overexpressor plant was analyzed and the observed phenotype.

Table 3

SEQ ID No.	GID	Knockout (KO) or overexpressor (OE)	Phenotype
1	G188	KO	Increased susceptibility to Fusarium
3	G616	OE	Increased tolerance to Erysiphe
5	G19	OE	Increased tolerance to Erysiphe
7.	G261	OE .	Increased susceptibility to Botrytis
9	G28	OE	Increased resistance to Erysiphe
11	G869	OE	Increased susceptibility to Fusarium
13	G237	OE	Increased tolerance to Erysiphe
15	G409	OE	Increased tolerance to Erysiphe
17	G418	OE	Increased tolerance to Pseudomonas
19	G591	OE	Increased tolerance to Erysiphe
21	G525	OE ·	Increased tolerance to Pseudomonas
23	G545	OE	Increased susceptibility to Pseudomonas, Erysiphe and Fusarium
25	G865	OE	Increased susceptibility to Erysiphe and Botrytis
27 ·	G881	OE	Increased susceptibility to Erysiphe and Botrytis
29	G896	KO	Increased susceptibility to Fusarium
31	G378	OE	Increased resistance to Erysiphe
33	G569	OE	Decreased expression of defense genes
35	G558	OE	Increased expression of defense genes

For a particular overexpressor that shows an increased susceptibility to a pathogen, it may be more useful to select a plant with a decreased expression of the particular transcription factor. For a particular knockout that shows an increased susceptibility to a pathogen, it may be more useful to select a plant with an increased expression of the particular transcription factor.

Other than Fusarium oxysporum, Erysyphe orontii, the transgenic plants are more tolerant to Sclerotinia spp., soil-borne oomycetes, foliar oomycetes, Botrytis spp., Rhizoctonia spp, Verticillium dahliae/albo-atrum, Alternaria spp., rusts, Mycosphaerella spp, Fusarium solani, or the like. The transgenic plants are more resistant to fungal diseases such as rusts, smuts, wilts, yellows, root rot, leaf drop, ergot, leaf blight of potato, brown spot of rice, leaf blight, late blight, powdery mildew, downy mildew, and the like; viral diseases such as sugarcane mosaic, cassava mosaic, sugar beet yellows, plum pox, barley yellow dwarf, tomato yellow leaf curl, tomato spotted wilt virus, and the like; bacterial diseases such as citrus canker, bacterial leaf blight, bacterial will, soft rot of vegetables, and the like; nematode diseases such as root knot, sugar beet cyst nematode or the like.

15

5

EXAMPLE IX. IDENTIFICATION OF HOMOLOGOUS SEQUENCES

10

15

20

25

30

35

Homologous sequences from *Arabidopsis* and plant species other than *Arabidopsis* were identified using database sequence search tools, such as the Basic Local Alignment Search Tool (BLAST) (Altschul et al. (1990) <u>J. Mol. Biol.</u> 215:403-410; and Altschul et al. (1997) <u>Nucl. Acid Res.</u> 25: 3389-3402). The tblastx sequence analysis programs were employed using the BLOSUM-62 scoring matrix (Henikoff, S. and Henikoff, J. G. (1992) <u>Proc. Natl. Acad. Sci. USA</u> 89: 10915-10919).

Identified *Arabidopsis* homologous sequences are provided in Figure 2 and included in the Sequence Listing. The percent sequence identity among these sequences is as low as 47% sequence identity. Additionally, the entire NCBI GenBank database was filtered for sequences from all plants except *Arabidopsis thaliana* by selecting all entries in the NCBI GenBank database associated with NCBI taxonomic ID 33090 (Viridiplantae; all plants) and excluding entries associated with taxonomic ID 3701 (*Arabidopsis thaliana*). These sequences were compared to sequences representing genes of SEQ IDs Nos. 1-58 on 9/26/2000 using the Washington University TBLASTX algorithm (version 2.0a19MP). For each gene of SEQ IDs Nos. 1-58, individual comparisons were ordered by probability score (P-value), where the score reflects the probability that a particular alignment occurred by chance. For example, a score of 3.6e-40 is 3.6 x 10⁻⁴⁰. For up to ten species, the gene with the lowest P-value (and therefore the most likely homolog) is listed in Figure 3.

In addition to P-values, comparisons were also scored by percentage identity. Percentage identity reflects the degree to which two segments of DNA or protein are identical over a particular length. The ranges of percent identity between the non-Arabidopsis genes shown in Figure 3 and the Arabidopsis genes in the sequence listing are: SEQ ID No. 1: 38%-76%; SEQ ID No. 3: 36%-72%; SEQ ID No. 5: 51%-75%; SEQ ID No. 7: 37%-76%; SEQ ID No. 9: 48%-75%; SEQ ID No. 11: 31%-68%; SEQ ID No. 13: 59%-81%; SEQ ID No. 15: 49%-81%; SEQ ID No. 17: 53%-87%; SEQ ID No. 19: 48%-84%; SEQ ID No. 21: 73%-89%; SEQ ID No. 23: 52%-64%; SEQ ID No. 25: 48%-83%; SEQ ID No. 27: 35%-92%; SEQ ID No. 29: 56%-89%; SEQ ID No. 31: 50%-90%; SEQ ID No. 33: 50%-93%; SEQ ID No. 35: 52%-81%; SEQ ID No. 37: 75%-81%; SEQ ID No. 39: 35%-72%; SEQ ID No. 41: 55%-89%; SEQ ID No. 43: 56%-77%; SEQ ID No. 45: 34%-72%; SEQ ID No. 47: 51%-86%; SEQ ID No. 49: 46%-86%; SEQ ID No. 51: 58%-80%; SEQ ID No. 53: 46%-55%; SEQ ID No. 55: 84%-89%; and SEQ ID No. 57: 43%-71%.

The polynucleotides and polypeptides in the Sequence Listing and the identified homologous sequences may be stored in a computer system and have associated or linked with the sequences a function, such as that the polynucleotides and polypeptides are useful for modifying the pathogen tolerance of a plant.

All references, publications, patents and other documents herein are incorporated by reference in their entirety for all purposes. Although the invention has been described with reference to the embodiments and examples above, it should be understood that various modifications can be made without departing from the spirit of the invention.

What is claimed is:

5

15

20

1. A transgenic plant with modified pathogen tolerance, which plant comprises a recombinant polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence encoding a polypeptide comprising a sequence selected from SEQ ID Nos. 2N, where N=1-29, or a complementary nucleotide sequence thereof;
 - (b) a nucleotide sequence encoding a polypeptide comprising a conservatively substituted variant of a polypeptide of (a);
- (c) a nucleotide sequence comprising a sequence selected from those of SEQ ID Nos.
 2N-1, where N=1-29, or a complementary nucleotide sequence thereof;
 - (d) a nucleotide sequence comprising silent substitutions in a nucleotide sequence of (c);
 - (e) a nucleotide sequence which hybridizes under stringent conditions to a nucleotide sequence of one or more of: (a), (b), (c), or (d);
 - (f) a nucleotide sequence comprising at least 15 consecutive nucleotides of a sequence of any of (a)-(e);
 - (g) a nucleotide sequence comprising a subsequence or fragment of any of (a)-(f), which subsequence or fragment encodes a polypeptide that modifies a plant's pathogen tolerance;
 - (h) a nucleotide sequence having at least 31% sequence identity to a nucleotide sequence of any of (a)-(g);
 - (i) a nucleotide sequence having at least 60% identity sequence identity to a nucleotide sequence of any of (a)-(g);
- 25 (j) a nucleotide sequence which encodes a polypeptide having at least 31% identity sequence identity to a polypeptide of SEQ ID Nos. 2N, where N=1-29;
 - (k) a nucleotide sequence which encodes a polypeptide having at least 60% identity sequence identity to a polypeptide of SEQ ID Nos. 2N, where N=1-29; and
- (l) a nucleotide sequence which encodes a polypeptide having at least 65% sequence identity to a conserved domain of a polypeptide of SEQ ID Nos. 2N, where N=1-29.
 - 2. The transgenic plant of claim 1, further comprising a constitutive, inducible, or tissueactive promoter operably linked to said nucleotide sequence.
- 35 3. The transgenic plant of claim 1, wherein the plant is selected from the group consisting of: soybean, wheat, corn, potato, cotton, rice, oilseed rape, sunflower, alfalfa, sugarcane, turf, banana, blackberry, blueberry, strawberry, raspberry, cantaloupe, carrot,

cauliflower, coffee, cucumber, eggplant, grapes, honeydew, lettuce, mango, melon, onion, papaya, peas, peppers, pineapple, spinach, squash, sweet corn, tobacco, tomato, watermelon, rosaceous fruits, and vegetable brassicas.

- 5 4. An isolated or recombinant polynucleotide comprising a nucleotide sequence selected from the group consisting of:
 - (a) a nucleotide sequence encoding a polypeptide comprising a sequence selected from SEQ ID Nos. 2N, where N=1-29, or a complementary nucleotide sequence thereof:
- (b) a nucleotide sequence encoding a polypeptide comprising a conservatively substituted variant of a polypeptide of (a);

15

- (c) a nucleotide sequence comprising a sequence selected from those of SEQ ID Nos. 2N-1, where N=1-29, or a complementary nucleotide sequence thereof;
- (d) a nucleotide sequence comprising silent substitutions in a nucleotide sequence of (c);
- (e) a nucleotide sequence which hybridizes under stringent conditions to a nucleotide sequence of one or more of: (a), (b), (c), or (d);
- (f) a nucleotide sequence comprising at least 15 consecutive nucleotides of a sequence of any of (a)-(e);
- 20 (g) a nucleotide sequence comprising a subsequence or fragment of any of (a)-(f), which subsequence or fragment encodes a polypeptide having a biological activity that modifies a plant's pathogen tolerance;
 - (h) a nucleotide sequence having at least 31% sequence identity to a nucleotide sequence of any of (a)-(g);
- 25 (i) a nucleotide sequence having at least 60% identity sequence identity to a nucleotide sequence of any of (a)-(g);
 - (j) a nucleotide sequence which encodes a polypeptide having at least 31% identity sequence identity to a polypeptide of SEQ ID Nos. 2N, where N=1-29;
 - (k) a nucleotide sequence which encodes a polypeptide having at least 60% identity sequence identity to a polypeptide of SEQ ID Nos. 2N, where N=1-29; and
 - (1) a nucleotide sequence which encodes a conserved domain of a polypeptide having at least 65% sequence identity to a conserved domain of a polypeptide of SEQ ID Nos. 2N, where N=1-29.
- 35 5. The isolated or recombinant polynucleotide of claim 4, further comprising a constitutive, inducible, or tissue-active promoter operably linked to the nucleotide sequence.

6. A cloning or expression vector comprising the isolated or recombinant polynucleotide of claim 4.

- 7. A cell comprising the cloning or expression vector of claim 6.
- 8. A transgenic plant comprising the isolated or recombinant polynucleotide of claim 4.
- 9. A composition produced by one or more of:
 - (a) incubating one or more polynucleotide of claim 4 with a nuclease;
- 10 (b) incubating one or more polynucleotide of claim 4 with a restriction enzyme;
 - (c) incubating one or more polynucleotide of claim 4 with a polymerase;
 - (d) incubating one or more polynucleotide of claim 4 with a polymerase and a primer;
 - (e) incubating one or more polynucleotide of claim 4 with a cloning vector, or
 - (f) incubating one or more polynucleotide of claim 4 with a cell.

15

5

- 10. A composition comprising two or more different polynucleotides of claim 4.
- 11. An isolated or recombinant polypeptide comprising a subsequence of at least about 15 contiguous amino acids encoded by the recombinant or isolated polynucleotide of claim 4.

20

25

- 12. A plant comprising an isolated polypeptide of claim 11.
- 13. A method for producing a plant having a modified pathogen tolerance, the method comprising altering the expression of the isolated or recombinant polynucleotide of claim 4 or the expression levels or activity of a polypeptide of claim 11 in a plant, thereby producing a modified plant, and selecting the modified plant for improved pathogen tolerance thereby providing the modified plant with a modified pathogen tolerance.
 - 14. The method of claim 13, wherein the polynucleotide is a polynucleotide of claim 4.

- 15. A method of identifying a factor that is modulated by or interacts with a polypeptide encoded by a polynucleotide of claim 4, the method comprising:
 - (a) expressing a polypeptide encoded by the polynucleotide in a plant; and
- (b) identifying at least one factor that is modulated by or interacts with the polypeptide.

16. The method of claim 15, wherein the identifying is performed by detecting binding by the polypeptide to a promoter sequence, or detecting interactions between an additional protein and the polypeptide in a yeast two hybrid system.

- 5 17. The method of claim 15, wherein the identifying is performed by detecting expression of a factor by hybridization to a microarray, subtractive hybridization or differential display.
 - 18. A method of identifying a molecule that modulates activity or expression of a polynucleotide or polypeptide of interest, the method comprising:
- (a) placing the molecule in contact with a plant comprising the polynucleotide or polypeptide encoded by the polynucleotide of claim 4; and,
 - (b) monitoring one or more of:
 - (i) expression level of the polynucleotide in the plant;
 - (ii) expression level of the polypeptide in the plant;
 - (iii) modulation of an activity of the polypeptide in the plant; or
 - (iv) modulation of an activity of the polynucleotide in the plant.
 - 19. An integrated system, computer or computer readable medium comprising one or more character strings corresponding to a polynucleotide of claim 4, or to a polypeptide encoded by the polynucleotide.
 - 20. The integrated system, computer or computer readable medium of claim 19, further comprising a link between said one or more sequence strings to a modified plant pathogen tolerance phenotype.

25

15

- 21. A method of identifying a sequence similar or homologous to one or more polynucleotides of claim 4, or one or more polypeptides encoded by the polynucleotides, the method comprising:
 - (a) providing a sequence database; and,
- 30 (b) querying the sequence database with one or more target sequences corresponding to the one or more polynucleotides or to the one or more polypeptides to identify one or more sequence members of the database that display sequence similarity or homology to one or more of the one or more target sequences.
- 35 22. The method of claim 21, wherein the querying comprises aligning one or more of the target sequences with one or more of the one or more sequence members in the sequence database.

23. The method of claim 21, wherein the querying comprises identifying one or more of the one or more sequence members of the database that meet a user-selected identity criteria with one or more of the target sequences.

5

- 24. The method of claim 21, further comprising linking the one or more of the polynucleotides of claim 4, or encoded polypeptides, to a modified plant pathogen tolerance phenotype.
- 10 25. A plant comprising altered expression levels of an isolated or recombinant polynucleotide of claim 4.
 - 26. A plant comprising altered expression levels or the activity of an isolated or recombinant polypeptide of claim 11.

15

27. A plant lacking a nucleotide sequence encoding a polypeptide of claim 11.

Figure 1

SEQ ID No.	GID	cDNA or protein	conserved domain
1	G188	cDNA	
2	G188	protein	175-222
3	G616	cDNA	
4	G616	protein	39-95
5	G19	cDNA	
6	G19	protein	76-145
7	G261	cDNA	
8	G261	protein	16-104
9	G28	cDNA	
10	G28	protein	145-213
11	G869	cDNA	
12	G869	protein	109-177
13	G237	cDNA	
14	G237	protein	11-113
15	G409	cDNA	
16	G409	protein	64-124
17	G418	cDNA	
18	G418	protein	500-560
19	G591	cDNA	
20	G591	protein	143-240
21	G525	cDNA	
22	G525	protein	23-167
23	G545	cDNA	
24	G545	protein	82-102, 136-154
25	G865	cDNA	
26	G865	protein	36-103
27	G881	cDNA	
28	G881	protein	176-233
29	G896	cDNA	
30	G896	protein	18-39
31	G378	cDNA	
32	G378	protein	196-237
33	G569	cDNA	
34	G569	protein	90-153
35	G558	cDNA	
36	G558	protein	45-105

Figure 2

SEQ ID No.	GID	homolog	cDNA or protein	conserved domain
37	G1396	homolog of G1394	cDNA	
38	G1396	homolog of G1394	protein	entire protein
39	G265	homolog of G261	cDNA	
40	G265	homolog of G261	protein	14-105
41	G1006	homolog of G28	cDNA	·
42	G1006	homolog of G28	protein	114-182
43	G1309	homolog of G237	cDNA	
44	G1309	homolog of G237	protein	9-114
45	G2550	homolog of G418	cDNA	
46	G2550	homolog of G418	protein	348-408
47	G965	homolog of G418	cDNA	
48	G965	homolog of G418	protein	423-486
49	G793	homolog of G591	cDNA	<u> </u>
50	G793	homolog of G591	protein	151-206
51	G764	homolog of G525	cDNA	
52	G764	homolog of G525	protein	27-171 ·
53	G350	homolog of G545	cDNA	
54	G350	homolog of G545	protein	91-113,150-170
55	G986	homolog of G881	cDNA	
56	G986	homolog of G881	protein	146-203
57	G1349	homolog of G896	cDNA	
58	G1349	homolog of G896	protein	13-63

Figure 3A

SEQ ID No.	GID	Genbank NiD	P-value	Species
1	G188	7779802	5.20E-36	Lotus japonicus
1	G188	7284340	2.10E-34	Glycine max
1	G188	9361307	1.20E-27	Triticum aestivum
1	G188	7340336	1.10E-22	Oryza sativa
1	G188	6529152	3.60E-22	Lycopersicon esculentum
1	G188	8748477	7.70E-21	Medicago truncatula
1	G188	5456433	7.10Ė-14	Zea mays
1	G188	9302479	1.60E-12	Sorghum bicolor
1	G188	6696287	4.10E-12	Pinus taeda
1	G188	562242	9.00E-12	Brassica rapa
3	G616	7719440	8.30E-37	Lotus japonicus
3	G616	7692230	5.90E-33	Glycine max
3	G616	7501307	1.10E-21	Gossypium arboreum
3	G616	8071090	1.50E-21	Solanum tuberosum
3	G616	8858771	1.50E-21	Oryza sativa
3	G616	5047315	1.50E-21	Gossypium hirsutum
3	G616	6358532	5.80E-20	Antirrhinum graniticum
3	G616	2826867	7.00E-20	Antirrhinum majus
3	G616	6358535	7.40E-20	Antirrhinum majus subsp. linkianum
3	G616	6358538	7.50E-20	Antirrhinum braun-blanquetii
5	G19	8789223	2.80E-34	Citrus x paradisi
5	G19	9434234		Lycopersicon esculentum
5	G19	7478682	4.50E-34	Glycine max
5	G19	6654934	1.30E-30 1.20E-28	
5	G19			Medicago truncatula
. 5		3264766	5.50E-26	Prunus armeniaca
5	G19	7624302	8.30E-26	Gossypium arboreum
	G19	9425363	2.90E-25	Triticum aestivum
5	G19	688579	3.60E-25	Ricinus communis_
5	G19	9419304	6.00E-25	Hordeum vulgare
5	G19	7720316	8.80E-25	Lotus japonicus
7	G261	5821137	5.10E-93	Nicotiana tabacum
7	G261	7158881	8.80E-86	Medicago sativa
7	G261	886741	1.00E-73	Zea mays
7	G261	5900449	5.20E-47	Lycopersicon esculentum
7	G261	7561318	1.20E-46	Medicago truncatula
7	G261	19491	1.70E-42	Lycopersicon peruvianum
7	G261	7233914	3.50E-41	Glycine max
7	G261	4528238	9.00E-41	Citrus unshiu
7	G261	8903922	4.00E-39	Hordeum vulgare
7	G261	9251913	1.90E-36`	Solanum tuberosum
9	G28	7528275	4.20E-62	Mesembryanthemum crystallinum
9	G28	6654776	1.20E-57	Medicago truncatula
9	G28	790362	2.30E-54	Nicotiana tabacum
9	G28	8809570	8.00E-54	Nicotiana sylvestris
9	G28	3342210	8.40E-54	Lycopersicon esculentum
9	G28	6566281	8.40E-47	Glycine max
9	G28	7627061	8.40E-47	Gossypium arboreum
9	G28	7324479	2.00E-44	Lycopersicon pennellii
9	G28	6478844	1.80E-35	Matricaria chamomilla
9	G28	7273972	7.80E-29	Oryza sativa
11	G869	2213784	1.30E-19	Lycopersicon esculentum
11	G869	3065894	7.30E-19	Nicotiana tabacum

Figure 3B

SEQ ID No.	GID	Genbank NID	P-value	Species
		8570080	4.20E-18	Oryza sativa
11	G869		1.50E-17	Medicago truncatula
11	G869	7560260	5.20E-14	Sorghum bicolor
11	G869	7534890	1.10E-13	Glycine max
11	G869	6455322		Triticum aestivum
11	G869	9362061	2.70E-13	
11	G869	7788764	5.70E-13	Lotus japonicus Gossypium arboreum
11	G869	7624302	2.50E-12	Populus balsamifera subsp. trichocarpa
11	G869	3858036	2.80E-12	Glycine max
13	G237	8283916	4.70E-42	Triticum aestivum
13	G237	9361969	8.30E-41	Zea mays
13	G237	4753385	4.10E-39	
13	G237	7535969	4.10E-33	Sorghum bicolor Medicago truncatula
13	G237	7566043	9.30E-33	Lycopersicon esculentum
13	G237	7339127	2.00E-32	
13	G237	5860031	1.10E-28	Pinus taeda
13	G237	7776223	2.20E-28	Lotus japonicus
13	G237	6850206	5.10E-28	Oryza sativa
13	G237	5048991	8.50E-28	Gossypium hirsutum
15	G409	6654773	6.10E-57	Medicago truncatula
15	G409	6531235	2.00E-56	Lycopersicon esculentum
15	G409	7924152	1.10E-47	Glycine max
15	G409	. 5006854	6.50E-43.	Oryza sativa
15	G409	8098529	2.10E-41	Hordeum vulgare
15	G409	767697	1.40E-37	Daucus carota
15	G409	8328991	3.30E-37	Mesembryanthemum crystallinum
15	G409	7415613	1.40E-32	Physcomitrella patens
15	G409	7785121	2.80E-32	Lotus japonicus
15	G409	6916941	4.80E-32	Lycopersicon pennellii
17	G418	7239156	1.90E-123	Maius x domestica
17	G418	5892190	2.00E-62	Lycopersicon esculentum
17	G418	7628137	8.70E-58	Gossypium arboreum
17	G418	9205496	3.90E-51	Glycine max
17	G418	6069643	1.50E-45	Oryza sativa
17	G418	7562931	6.90E-45	Medicago truncatula
17	G418	7781695	5.50E-40	Lotus japonicus
17	G418	9298824	7.80E-34	Sorghum bicolor
17	G418	9428023	3.90E-32	Triticum aestivum
17	G418	7244366	1.30E-31	Mentha x piperita Lycopersicon esculentum
19	G591	7646333	1.90E-55	
19	G591	7924288	4.10E-53	Glycine max
19	G591	7722838	1.10E-41	Lotus japonicus
19	G591	5804781	1.40E-24	Nicotiana tabacum
19	G591	9198126	2.50E-23	Medicago truncatula Oryza sativa
19	G591	427677	9.50E-15	Gossypium arboreum
19	G591	7624745	1.80E-14	Sorghum bicolor
19	G591	7535578	8.70E-14	
19	G591	5915205	1.30E-11	Zea mays Solanum tuberosum
19	G591	9249806	2.60E-11	Lycopersicon esculentum
21	G525	4384535	5.60E-61	
21	G525	6454868	2.00E-58	Glycine max Petunia x hybrida
21	G525	6066594	9.30E-54	
21	G525	4977542	8.60E-51	Oryza sativa

Figure 3C

SEQ ID No.	GID	Genbank NID	P-value	Species
21	G525	9361647	2.50E-50	Triticum aestivum
21	G525	4218536	5.20E-50	Triticum sp.
21	G525	6732159	5.20E-50	Triticum monococcum
21	G525	5343151	2.70E-49	Zea mays
21	G525	5049217	4.20E-48	Gossypium hirsutum
21	G525	8708684	8.90E-48	Hordeum vulgare
23	G545	4666359	8.30E-55	Datisca glomerata
23	G545	7228328	3.70E-52	Medicago sativa
23	G545	1763062	1.30E-51	Glycine max
23	G545	7206360	3.10E-44	Medicago truncatula
23	G545	7626808	9.60E-40	Gossypium arboreum
23	G545	439492	3.90E-39	Petunia x hybrida
23	G545	4382658	1.70E-38	Lycopersicon esculentum
23	G545	8486215	8.70E-38	Euphorbia esula
23	G545	7322653	6.80E-37	Lycopersicon hirsutum
23	G545	7785845	1.10E-33	Lotus japonicus
25	G865	9417297	1.70E-32	Triticum aestivum
25	G865	7206394	4.90E-29	Medicago truncatula
25	G865	7796858	5.70E-27	Glycine max
25	G865	4387560	9.20E-25	Lycopersicon esculentum
25	G865	569065	1.50E-23	Oryza sativa
25	G865	7788764	4.10E-23	Lotus japonicus
25	G865	790362	8.40E-22	Nicotiana tabacum
25	G865	7528275	5.90E-21	Mesembryanthemum crystallinum
25	G865	3264766	8.80E-20	Prunus armeniaca
25	G865	8098026	2.00E-19	Hordeum vulgare
27	G881	5820418	9.80E-29	Glycine max
27	G881	8440065	1.00E-27	Gossypium hirsutum
. 27	G881	4380578	1.50E-27	Lycopersicon esculentum
27	G881	9199620	2.70E-27	Medicago truncatula
27	G881	6472584	2.20E-24	Nicotiana tabacum
27	G881	9250698	3.20E-24	Solanum tuberosum
27	G881	8205146	5.20E-21	Oryza sativa
27	G881	1159878	8.20E-17	Avena fatua
27	G881	9299778	2.70E-16	Sorghum bicolor
27	G881	9444636	1.10E-14	Triticum aestivum
29	G896	9410462	1.90E-101	Hordeum vulgare
29	G896	7628908	3.60E-82	Gossypium arboreum
29	G896	7244408	1.80E-79	Mentha x piperita
29	G896	5046180	2.10E-73	Gossypium hirşutum
29	G896	7678652	1.10E-63	Lotus japonicus
29	G896	8286031	1.40E-60	Glycine max
29	G896	5888938	4.50E-58	Lycopersicon esculentum
29	G896	9298238	9.20E-54	Sorghum bicolor
29	G896	7566414	8.00E-52	Medicago truncatula
29	G896	8845076	1.00E-46	Triticum aestivum
31	G378	5270028	5.10E-73	Lycopersicon esculentum
31	G378	5048335	4.10E-58	Gossypium hirsutum
31	G378	7239521	5.90E-42	Oryza sativa
31	G378	5606120	6.80E-36	Glycine max
31	G378	3853800	3.20E-30	Populus tremula x Populus tremuloides
31	G378	7659983	1.70E-23	Sorghum bicolor

Figure 3D

SEQ ID No.	GID	Genbank NID	P-value	Species
31	G378	6626305	1.10E-21	Zea mays
31	G378	9412941	9.40E-19	Triticum aestivum
31	G378	3242033	4.30E-17	Mesembryanthemum crystallinum
31	G378	7626259	7.70E-13	Gossypium arboreum
33	G229	7337390	6.60E-51	Lycopersicon esculentum
33	G229	9823237	3.60E-50	Hordeum vulgare
33	G229	7244424	4.90E-50	Mentha x piperita
33	G229	7776053	1.70E-49	Lotus japonicus
33	G229	2921335	5.80E-48	Gossypium hirsutum
33	G229	1491932	4.50E-47	Zea mays
33	G229	6455590	2.80E-44	Glycine max
33	G229	6020191	2.00E-41	Pinus taeda
33	G229	10697236	4.20E-41	Oryza sativa
33	G229	7765706	5.10E-41	Medicago truncatula
35	G663	7673087	5.10E-43	Petunia integrifolia
35	G663	9508051	3.00E-41	Lycopersicon esculentum
35	G663	7673091	3.30E-41	Petunia x hybrida
35	G663	7673097	2.40E-36	Petunia axillaris
35	G663	5048991	1.20E-33	Gossypium hirsutum
35	G663	6455590	2.50E-31	Glycine max
35	G663	7560175	1.90E-27	Medicago truncatula
35	G663	7244424	4.10E-26	Mentha x piperita
35	G663	9954117	3.40E-25	Solanum tuberosum
35	G663	6020191	3.60E-25	Pinus taeda
37	G1396	498704	5.20E-22	Spinacia oleracea
37	G1396	7502400	1.20E-21	Gossypium arboreum
37	G1396	3857536	3.40E-21	Populus balsamifera subsp. trichocarpa
37	G1396	4385300	1.20E-20	Lycopersicon esculentum
37	G1396	6917249	1.50E-20	Lycopersicon pennellii
37	G1396	6915979	1.70E-20	Glycine max
37	G1396	7674530	2.70E-20	Medicago truncatula
37	G1396	8090319	3.40E-20	Sorghum bicolor
	G1396	3592182	9.10E-20	Oryza sativa
37	G1396	6654124	1.10E-19	Zea mays
37	G265	5821137	6.50E-83	Nicotiana tabacum
39 39	G265	7158881	3.80E-79	Medicago sativa
39	G265	886741	1.60E-70	Zea mays
39	G265	5900449	5.60E-43	Lycopersicon esculentum
39	G265	8903922	8.20E-43	Hordeum vulgare
39	G265	7561318	2.10E-41	Medicago truncatula
39	G265	9204445	5.30E-36	Glycine max
. 39	G265	4528238	5.40E-36	Citrus unshiu
39	G265	19489	2.10E-35	Lycopersicon peruvianum
39	G265	9251913	2.00E-32	Solanum tuberosum
41	G1006	7528275	2.70E-51	Mesembryanthemum crystallinum
41	G1006	3342210	4.90E-49	Lycopersicon esculentum
41	G1006	6654776	1.90E-48	Medicago truncatula
41	G1006	790362	2.30E-47	Nicotiana tabacum
41	G1006	8809570	2.00E-46	Nicotiana sylvestris
41	G1006	7627061	6.40E-41	Gossypium arboreum
41	G1006	7324479	1.20E-35	Lycopersicon pennellii
	G1006	6478844	1.80E-35	Matricaria chamomilla
41	G 1000	1 07/0077	1.000	,

Figure 3E

SEQ ID No.	GID	Genbank NID	P-value	Species
41	G1006	6566281	1.30E-34	Glycine max
41	G1006	4716624	3.80E-28	Oryza sativa
43	G1309	9361969	2.40E-45	Triticum aestivum
43	G1309	7566043	9.60E-35	Medicago truncatula
43	G1309	5891104	2.20E-31	Lycopersicon esculentum
43	G1309	5860031	2.10E-30	Pinus taeda
43	G1309	5049507	6.20E-30	Gossypium hirsutum
43	G1309	5139805	1.30E-29	Glycine max
43	G1309	6850206	2.50E-29	Oryza sativa
43	G1309	7721017	3.40E-29	Lotus japonicus
43	G1309	8368245	5.20E-28	Zea mays
43	G1309	20560	9.50E-27	Petunia x hybrida
45	G2550	4380729	2.80E-51	Lycopersicon esculentum
45	G2550	5667196	2.20E-49	Oryza sativa
45	G2550	8669454	1.40E-48	Glycine max
45	G2550	9298824	1.50E-48	Sorghum bicolor
45	G2550	7239156	9.90E-46	Malus x domestica
45	G2550	7570704	5.70E-45	Medicago truncatula
45	G2550	7628137	3.30E-42	Gossypium arboreum
. 45	G2550	7244366	6.00E-41	Mentha x piperita
45	G2550	9428023	4.70E-40	Triticum aestivum
45	G2550	9250642	3.50E-39	Solanum tuberosum
47	G965	7239156	3.10E-126	Malus x domestica
47	G965	5892190	2.00E-62	Lycopersicon esculentum
47	G965	7628137	1.60E-56	Gossypium arboreum
47	G965	9205496	2.60E-49	Glycine max
47	G965	6069643	1.70E-45	Oryza sativa
47	G965	7562931	2.50E-44	Medicago truncatula
47	G965	7781695	1.60E-41	Lotus japonicus
47	G965	9298824	6.30E-33	Sorghum bicolor
47	G965	9428023	1.50E-31	Triticum aestivum
47	G965	7244366	1.20E-29	Mentha x piperita
49	G793	6976712	3.60E-43	Lycopersicon esculentum
49	G793	7924288	2.00E-41	Glycine max
49	G793	7614163	3.90E-34	Lotus japonicus
49	G793	9198126	5.70E-23	Medicago truncatula
49	G793	5804781	1.10E-22	Nicotiana tabacum
49	G793	7535578	1.60E-14	Sorghum bicolor
49	G793	427677	6.10E-14	Oryza sativa
49	G793	5915205	2.90E-10	Zea mays
49	G793	9249806	4.20E-10	Solanum tuberosum
49	G793 .	7624745	1.30E-09	Gossypium arboreum
51	G764	4384535	7.00E-70	Lycopersicon esculentum
51	G764	5049217	1.80E-65	Gossypium hirsutum
51	G764	6454868	1.90E-64	Glycine max
51	G764	6066594	5.20E-59	Petunia x hybrida
51	G764	4218536	2.30E-52	Triticum sp.
51	G764	6732159	2.30E-52	Triticum monococcum
51	G764	9361647	7.50E-52	Triticum aestivum
51	G764	4977542	4.10E-49	Oryza sativa
51	G764	6799764	4.40E-49	Medicago truncatula
51	G764	9296257	1.00E-48	Sorghum bicolor

Figure 3F

SEQ ID No.	GID	Genbank NID	P-value	Species
53	G350	439492	5.20E-53	Petunia x hybrida
53	G350	7228328	8.90E-51	Medicago sativa
53	G350	4666359	3.10E-48	Datisca glomerata
53	G350	1763062	8.30E-48	Glycine max
53	G350	7626808	9.10E-44	Gossypium arboreum
53	G350	7206360	2.20E-43	Medicago truncatula
53	G350	2981168	2.10E-38	Nicotiana tabacum
53	G350	7322653	2.00E-37	Lycopersicon hirsutum
53	G350	5276755	2.40E-37	Lycopersicon esculentum
53	G350	2058503	1.10E-31	Brassica rapa
55	G986	6472584	1.00E-34	Nicotiana tabacum
55	G986	8440065	8.80E-33	Gossypium hirsutum
55	G986	4385167	1.50E-32	Lycopersicon esculentum
55	G986	8205146	5.50E-30	Oryza sativa
55	G986	5820418	8.80E-26	Glycine max
55	G986	1159878	2.30E-23	Avena fatua
55	G986	9250698	4.60E-22	Solanum tuberosum
55	G986	9413507	7.90E-21	Triticum aestivum
55	G986	7748539	2.30E-20	Lotus japonicus
55	G986	9199620	1.30E-16	Medicago truncatula
57	G1349	8904043	1.50E-47	Hordeum vulgare
57	G1349	7244408	2.40E-47	Mentha x piperita
57	G1349	8286031	3.60E-46	Glycine max
57	G1349	9298238	9.10E-36	Sorghum bicolor
. 57	G1349	7628908	4.70E-34	Gossypium arboreum
57	G1349	5046180	1.50E-33	Gossypium hirsutum
57	G1349	5888938	1.30E-30	Lycopersicon esculentum
57	G1349	5043924	6.20E-30	Pinus taeda
57	G1349	8845076	4.40E-29	Triticum aestivum
57	G1349	7678652	4.20E-27	Lotus japonicus

MBI15 Sequence Listing.ST25 SEQUENCE LISTING

:	Heard, Keddie Yu, Guo Ratclii Creelma Jiang, Pineda Reuber Adam,	, Jame o-Liar ffe, C an, Ro Cai-2 , Omai , Lynr	es ng Dliver obert chong											:
<120>	Patho	gen Re	esistan	ce Ge	enes	1								
<130>	MBI-0	015				·								
<150> <151>	60/16 1999-					٠		•			٠.			•
<150> <151>	Plant 2000-		: Modif	icati	ion	III								
<150> <151>	60/19 2000-									-				
<160>	58									,				
<170>	Paten	tIn ve	ersion	3.0										
	1 1187 DNA Arabi	dopsi	s thali	iana										
	CDS (50). G188	. (1096	5)											
<400> ctctca	l accaa c	ataato	caaa ga	agct	ttcc	: tca	ıcgaa	ittc	aaga	itege	c at Me 1	g to	c tcc er Ser	58
ctctca	1 accaa c at tgg ap Trp	gat ci	te tte	acc (atc	qtc	aqa	agc	tgc	agc	Me 1 tct	tct	er Ser gtt	58 106
gag ga Glu As 5	nccaa c	gat ci Asp Lo	tc ttc eu Phe	gcc q Ala 1	gtc Val	gtc Val cat	aga Arg qaa	agc Ser	tgc Cys 15	agc Ser	tct Ser	tct Ser	gtt Val	
gag ga Glu As 5 tcc ac Ser Th 20	at tgg	gat ci Asp Le aat to Asn Se	tc ttc eu Phe et tgt er Cys 25 at cct sp Pro	gcc (Ala (10) gct (Ala (10) cct (10) gct (10) act (10) ac	gtc Val ggt Gly	gtc Val cat His	aga Arg gaa Glu	agc Ser gac Asp 30	tgc Cys 15 gac Asp	agc Ser ata Ile	tct Ser gga Gly	tct Ser aac Asn	gtt Val tgt Cys 35	106
gag ga Glu As 5 tcc ac Ser Th 20 aaa ca Lys Gl	at tgg ap Trp cc acc nr Thr aa caa in Gln gc aac	gat chasp Least to Asn Secan gan A	tc ttc eu Phe et tgt er Cys 25 at ect sp Pro	gcc Ala 10 gct Ala cct Pro	gtc Val ggt Gly cct Pro	gtc Val cat His cct Pro	aga Arg gaa Glu cct Pro 45	agc Ser gac Asp 30 ctg Leu	tgc Cys 15 gac Asp ttt Phe	agc Ser ata Ile caa Gln	tct Ser gga Gly gct Ala	tct Ser aac Asn tct Ser 50	gtt Val tgt Cys 35 tct Ser	106
gag ga Glu As 5 tcc ac Ser Th 20 aaa ca Lys Gl tct tg Ser Cy	at tgg ap Trp cc acc nr Thr aa caa in Gln gc aac	gat class Local Garage Caa Garage Caa Garage Caa Garage Caa Garage Caa Garage Caa Caa Caa Caa Caa Caa Caa Caa Caa Ca	tc ttc eu Phe et tgt er Cys 25 at cct sp Pro 0	gcc Ala 10 gct Ala cct pro gat Asp tgg Trp	gtc Val ggt Gly cct Pro	gtc Val cat His cct Pro tgc Cys 60	aga Arg gaa Glu cct Pro 45 aaa Lys	agc Ser gac Asp 30 ctg Leu cca Pro	tgc Cys 15 gac Asp ttt Phe ttt	agc Ser ata Ile caa Gln tta Leu	gga Gly gct Ala ccc Pro 65	tct Ser aac Asn tct Ser 50 gtt Val	gtt Val tgt Cys 35 tct Ser act Thr	106 154 202
gag ga Glu As 5 tcc ac Ser Th 20 aaa ca Lys Gl tct tg Ser Cy act ac	at tgg ap Trp as acc ar Thr as cas an Gln ac asc r Thr ac acc acc	gat class Load San	tc ttc eu Phe et tgt er Cys 25 et cct sp Pro 0 ta caa eu Gln et act hr Thr	gcc Ala 10 gct Ala cct Pro gat Asp	gtc Val ggt Gly cct Pro tct Ser tct Ser 75	gtc Val cat His cct Pro tgc Cys 60 cct Pro	aga Arg gaa Glu cct Pro 45 aaa Lys	agc Ser gac Asp 30 ctg Leu cca Pro	tgc Cys 15 gac Asp ttt Phe ttt Phe	agc Ser ata Ile caa Gln tta Leu ctt Leu 80	tct Ser gga Gly gct Ala ccc Pro 65 cct Pro	tct Ser aac Asn tct Ser 50 gtt Val cct Pro	gtt Val tgt Cys 35 tct Ser act Thr	106 154 202 250
gag gag gag gag gag gag s 5 tcc ac ser Th 20 aaa ca Lys Gl tct tg ser Cy act ac Thr Th	at tgg ap Trp as acc ar Thr as cas an Gln ac asc r Thr ac acc acc	gat character and the case gag the case gag the case gag the case the case the case the case the case the case case the case the case case the	tc ttc eu Phe et tgt er Cys 25 et cct sp Pro 0 ta caa eu Gln et act hr Thr ca tct ro Ser	gcc Ala 10 gct Ala cct pro gat Asp tgg Trp ccc pro 90 caa	gtc Val ggt Gly cct Pro tct Ser tct Ser aat	gtc Val cat His cct Pro tgc Cys 60 cct Pro	aga Arg gaa Glu cct Pro 45 aaa Lys cct Pro	agc Ser gac Asp 30 ctg Leu cca Pro cct Pro cta Leu ctt	tgc Cys 15 gac Asp ttt Phe ttt Phe cta Leu aaa Lys 95	agc Ser ata Ile caa Gln tta Leu ctt Leu 80 caa Gln	Med 1 tct Ser gga Gly gct Ala ccc Pro 65 cct Pro	tct Ser aac Asn tct Ser 50 gtt Val cct Pro	gtt Val tgt Cys 35 tct Ser act Thr	106 154 202 250

Page 1

	120		uence Listin	g.ST25 130	
cag ctt ctt caa Gln Leu Leu Gln 135	caa caa tcc Gln Gln Ser	caa cct cc Gln Pro Pr 140	cc ctt cga to ro Leu Arg Se	ct aga aaa aga er Arg Lys Arg 145	490
aag aat cag caa Lys Asn Gln Gln 150	aaa aga acc Lys Arg Thr	ata tgt ca Ile Cys H: 155	18 val lint G	aa gag aat ctt ln Glu Asn Leu 50	538
tct tct gat ttg Ser Ser Asp Leu 165	tgg gct tgg Trp Ala Trp 170	cgt aaa t Arg Lys T	ac ggt caa a yr Gly Gln L 175	aa ccc atc aaa ys Pro Ile Lys	-586
ggc tct cct tat Gly Ser Pro Tyr 180	cca agg aat Pro Arg Asn 185	tat tac a Tyr Tyr A	ga tgt agt a rg Cys Ser S 190	gc tca aaa gga er Ser Lys Gly 195	634
tgt tta gca cga Cys Leu Ala Arg	aaa caa gtt Lys Gln Val 200	GIU AIG 3	gt aat tta g er Asn Leu A :05	at cct aat atc sp Pro Asn Ile 210	682
ttc atc gtt act Phe Ile Val Thr 215	Tyr Thr Gly	gaa cac a Glu His T 220	ct cat cca c Thr His Pro A	gt cct act cac rg Pro Thr His 225	730
cgg aac tct ctc Arg Asn Ser Leu 230	gcc gga agt Ala Gly Ser	act cgt a Thr Arg A 235	ABIL DAS DET C	ag ccc gtt aac lln Pro Val Asn 140	778
ccg gtt cct aaa Pro Val Pro Lys 245	ccg gac aca Pro Asp Thr 250	Ser Pro r	tta tcg gat a Leu Ser Asp 1 255	ica gta aaa gaa Thr Val Lys Glu	826
gag att cat ctt Glu Ile His Lev 260	tet eeg acg Ser Pro Thr 265	aca ccg t Thr Pro I	ttg aaa gga a Leu Lys Gly 1 270	ac gat gac gtt Asn Asp Asp Val 275	874
caa gaa acg aat Gln Glu Thr Ası	gga gat gaa Gly Asp Glu 280	1 Wab wer	gtt ggt caa g Val Gly Gln (285	gaa gtc aac atg 3lu Val Asn Met 290	922
Glu Glu Glu Glu 29	i gin gin gir 5	300		gat gaa gaa gaa Asp Glu Glu Glu 305	970
Glu Asp Asp Asp 310	p Asp val As	315	DCG 110 110 .	aat tta gcg gtg Asn Leu Ala Val 320	1018
Arg Asp Arg As 325	p Asp Leu Pn 33	e Phe Ala	335	cca tct tgg tcc Pro Ser Trp Ser	1066
gcc gga tcc gc Ala Gly Ser Al 340	a GIY ASP GI 345	A GIA GIA			1116
atttacaatt tac	aaaaaga aaaa	agtcag ttt	ttaatta ttat	ttttgt ttgttaaaac	: 1176
ttgacattta t					1187
<210> 2 <211> 348 <212> PRT <213> Arabido	opsis thaliar	ıa			
<400> 2					
Met Ser Ser Gl	lu Asp Trp As 5	p Leu Phe	Ala Val Val 10	Arg Ser Cys Ser 15	

Ser Ser Val Ser Thr Thr Asn Ser Cys Ala Gly His Glu Asp Asp Ile Page 2 MBI15 Sequence Listing.ST25 25 30

20

Gly Asn Cys Lys Gln Gln Gln Asp Pro Pro Pro Pro Pro Leu Phe Gln 35 40 45

Ala Ser Ser Ser Cys Asn Glu Leu Gln Asp Ser Cys Lys Pro Phe Leu 50 55 60

Pro Val Thr Thr Thr Thr Thr Thr Thr Trp Ser Pro Pro Pro Leu Leu 65 70 80

Pro Pro Pro Lys Ala Ser Ser Pro Ser Pro Asn Ile Leu Leu Lys Gln
85 90 95

Glu Gln Val Leu Leu Glu Ser Gln Asp Gln Lys Pro Pro Leu Ser Val 100 105 110

Arg Val Phe Pro Pro Ser Thr Ser Ser Ser Val Phe Val Phe Arg Gly

Gln Arg Asp Gln Leu Leu Gln Gln Gln Ser Gln Pro Pro Leu Arg Ser 130 135 140

Arg Lys Arg Lys Asn Gln Gln Lys Arg Thr Ile Cys His Val Thr Gln 145 150 150 160

Glu Asn Leu Ser Ser Asp Leu Trp Ala Trp Arg Lys Tyr Gly Gln Lys 165 170 175

Pro Ile Lys Gly Ser Pro Tyr Pro Arg Asn Tyr Tyr Arg Cys Ser Ser 180 185 190

Ser Lys Gly Cys Leu Ala Arg Lys Gln Val Glu Arg Ser Asn Leu Asp 195 200 205

Pro Asn Ile Phe Ile Val Thr Tyr Thr Gly Glu His Thr His Pro Arg 210 215 220

Pro Thr His Arg Asn Ser Leu Ala Gly Ser Thr Arg Asn Lys Ser Gln 225 230 240

Pro Val Asn Pro Val Pro Lys Pro Asp Thr Ser Pro Leu Ser Asp Thr 245 250 255

Val Lys Glu Glu Ile His Leu Ser Pro Thr Thr Pro Leu Lys Gly Asn 260 265 270

Asp Asp Val Glu Glu Thr Asn Gly Asp Glu Asp Met Val Gly Glu Glu 275 280 285

Val Asn Met Glu Glu Glu Glu Glu Glu Glu Val Glu Glu Asp Asp 290 295 300

Glu Glu Glu Glu Asp Asp Asp Asp Val Asp Asp Leu Leu Ile Pro Asn 305 310 315 320

Leu Ala Val Arg Asp Arg Asp Leu Phe Phe Ala Gly Ser Phe Pro 325

Ser Trp Ser Ala Gly Ser Ala Gly Asp Gly Gly Gly 340

<210																
<211 <212		431 NA														
<213			aqob	is t	hali	ana										
<220	_															
<221		DS														
<222		129)	(1	211)							·					
<223	> G	616													•	
<400 cttt	> 3 aaat	cc c	aaac	caac	c ct	aaag	ttt	gat	tttt	aat	tttg		ta a	ccaa	aaaaa	60
aaac	aaaa	cc c	taat	tttt	t tt	cttt	agtg	atg	agat	tat	tggt	gatg	at g	aaat	gattg	120
qaga	tcta	atg	aag	aat	aac	aac	aat	ggc	gac	gtt	gtg	gat	aac	gaa	gtg	170
, ,		Met 1	Lys	Asn	Asn	Asn 5	Asn	Gly	' Asp	Val	Val	Авр	Asn	Glu	Val	
aac	aac	cqq	tta	agc	cgg	tgg	cat	cac	aat	tct	tcc	cgg	ata	att	agg	218
Asn	Asn	Arg	Leu	Ser	Arg	Trp	His	His	Asn	ser	Ser	Arg	Ile	Ile	Arg 30	
15					20					25				•	30	
gtt	tca	cga	gct	tcc	ggt	ggt	aaa	gat	cga	cac	agc	aaa	gtc	ttg	act	266
Val	Ser	Arg	Ala	Ser 35	Gly	Gly	ьуs	Asp	Arg	HIS	ser	гуѕ	vai	45	THE	
																224
tct	aaa	gga	cca	cgt	gac Asp	cgt	cgt	gtc	cgg	tta	tca	gtc Val	Ser	acc Thr	gct Ala	314
Ser	Lys	GIA	Pro 50	Arg	Asp	Arg	Arg	55	ALG	neu	SEI	Vai	60	****	****	
			-									ant	633	cct	200	362
ctt	caa	ttc	tat	gat	ctt Leu	Caa	gat	cgg	Leu	Glv	Tyr	Asp	Gln	Pro	Ser	302
Den	GIII	65	171	мор	200		70			,	•	75				
					tta	atc	222	act	act	gaa	gat	tca	atc	tct.	gag	410
Lvs	Ala	Val	Glu	Trp	Leu	Ile	Lув	Ala	Ala	Glu	Asp	Ser	Ile	Ser	Glu	
-3 -	80			-		85					90					
ctt	cct	tca	ctc	aac	aac	act	cat	ttt	ccq	acc	gat	gac	gag	aat	cac	458
Leu	Pro	Ser	Leu	Asn	Asn	Thr	His	Phe	Pro	Thr	Āsp	Āsp	Ğlü	Asn	HIS	
95					100					105					110	
caq	aat	caq	aca	tta	aca	aca	gtt	gct	gct	aat	tcc	ttg	tct	aaa	tct	506
Gln	Asn	Gln	Thr	Leu	Thr	Thr	Val	Ala	Ala	Asn	Ser	Leu	Ser	Lys 125	Ser	
				115					120							
gct	tgt	agt	agc	aat	tca	gac	acg	agc	aag	aac	tct	tct	ggt	ttg	tct	554
Ala	Cys	Ser	Ser	Asn	Ser	Asp	Thr	ser 135	гЛа	Asn	ser	ser	140	Leu	Ser	
															•	600
tta	tca	aga	tcg	gag	ctt Leu	aga	gat	aaa	gct	aga	gag	agg	gct	aga	gag Glu	602
Leu	ser	Arg 145	ser	GIU	Leu	Arg	150	Буз	ΛIα	Arg	014	155	,,,,,,	5		
																650
aga	aca	gct	aaa	gag	acc Thr	aag	gaa	aga	gat	His	Asn	His	Thr	Ser	Phe	030
мгg	160		m y B	GIU		165		3			170					
						~~+	+00	ast.	ccc	att	220	tca	aac	caa	caa	698
acg Thr	gat	Leu	Leu	Asn	tcc Ser	Gly	Ser	Asp	Pro	Val	Asn	Ser	Asn	Arg	GIN	
175					180			-		185					190	
taa	ato	act	tca	act	cct	tct	tca	tct	cca	atg	gag	tat	ttc	agt	tcg	746
Trp	Met	Ala	Ser	Ala	Pro	Ser	Ser	Ser	Pro	met	Ğlu	Tyr	Phe	Ser	Ser	
				195					200					205		

Page 4

MBI15 Sequence Listing.ST25

7.5113 0.	equence broading.org
ggt tta att ctc ggg tcg ggt caa caa Gly Leu Ile Leu Gly Ser Gly Gln Gln 210 215	acc cat ttc cct att tca aca Thr His Phe Pro Ile Ser Thr 220
aat tct cat cct ttc tca tca atc tcc Asn Ser His Pro Phe Ser Ser Ile Ser 225 230	gat cat cat cat cat cct 842 Asp His His His His Pro 235
cat cat cag cat caa gag ttt tca ttc His His Gln His Gln Glu Phe Ser Phe 240 245	gtt ccc gac cat ttg ata tca 890 Val Pro Asp His Leu Ile Ser ~250
ccg gca gaa tcc aac ggc gga gca ttc Pro Ala Glu Ser Asn Gly Gly Ala Phe 255 260	aat ctt gat ttt aat atg tca 938 Asn Leu Asp Phe Asn Met Ser 265 270
aca ccc tcc ggc gcc gga gct gcc gtc Thr Pro Ser Gly Ala Gly Ala Ala Val 275	tcc gcc gca tca ggt ggt ggc 986 Ser Ala Ala Ser Gly Gly Gly 280 285
ttc agt ggt ttc aac agg ggg acc ctt Phe Ser Gly Phe Asn Arg Gly Thr Leu 290 295	cag tcc aat tca aca aat cag Gln Ser Asn Ser Thr Asn Gln 300
cat cag tca ttc ctc gct aat cta cag His Gln Ser Phe Leu Ala Asn Leu Gln 305	agg ttt cca aca tca gaa agt 1082 Arg Phe Pro Thr Ser Glu Ser 315
gga gga ggt cca cag ttc tta ttc ggt Gly Gly Gly Pro Gln Phe Leu Phe Gly 320 325	gca ctg cct gca gag aat cac 1130 Ala Leu Pro Ala Glu Asn His 330
cac cac aat cac cag ttt cag ctt tac His His Asn His Gln Phe Gln Leu Tyr 335 340	tat gaa aat gga tgc aga aac 1178 Tyr Glu Asn Gly Cys Arg Asn 350
tca tca gaa cat aag ggt aaa ggc aag Ser Ser Glu His Lys Gly Lys Gly Lys 355	
ttggttttgt tcaaatgctc attttgtatg tt	tatctttg gtttatttca aaacaaatgt 1291
taatetettt egitgtetga tgigtgttag ggl	tttgttt tatgtattga gggtctttgg 1351
aaatettttt geattgtget tgtaatgttg tal	ttgtgat aatagcattt tgtttgtgag 1411
ttaaaaaaa aaaaaaaaaa	1431

<210> 4

<211> 360

<212> PRT <213> Arabidopsis thaliana

<400> 4

Met Lys Asn Asn Asn Gly Asp Val Val Asp Asn Glu Val Asn Asn 1 5 10 15

Arg Ala Ser Gly Gly Lys Asp Arg His Ser Lys Val Leu Thr Ser Lys $_{35}$

Gly Pro Arg Asp Arg Arg Val Arg Leu Ser Val Ser Thr Ala Leu Gln 50 60

Phe Tyr Asp Leu Gln Asp Arg Leu Gly Tyr Asp Gln Pro Ser Lys Ala 65 70 75 80

Page 5

MBI15 Sequence Listing.ST25

Val Glu Trp Leu Ile Lys Ala Ala Glu Asp Ser Ile Ser Glu Leu Pro 85 90 95

Ser Leu Asn Asn Thr His Phe Pro Thr Asp Asp Glu Asn His Gln Asn 100 105 110

Gln Thr Leu Thr Thr Val Ala Ala Asn Ser Leu Ser Lys Ser Ala Cys 115 120 125

Ser Ser Asn Ser Asp Thr Ser Lys Asn Ser Ser Gly Leu Ser Leu Ser 130 135 • 140

Arg Ser Glu Leu Arg Asp Lys Ala Arg Glu Arg Ala Arg Glu Arg Thr 145 150 155 160

Ala Lys Glu Thr Lys Glu Arg Asp His Asn His Thr Ser Phe Thr Asp 165 170 175

Leu Leu Asn Ser Gly Ser Asp Pro Val Asn Ser Asn Arg Gln Trp Met 180 185 190

Ala Ser Ala Pro Ser Ser Ser Pro Met Glu Tyr Phe Ser Ser Gly Leu 195 200 205

Ile Leu Gly Ser Gly Gln Gln Thr His Phe Pro Ile Ser Thr Asn Ser 210 215 220

His Pro Phe Ser Ser Ile Ser Asp His His His His Pro His His 225 230 235 240

Gln His Gln Glu Phe Ser Phe Val Pro Asp His Leu Ile Ser Pro Ala 245 250 255

Glu Ser Asn Gly Gly Ala Phe Asn Leu Asp Phe Asn Met Ser Thr Pro 260 265 270

Ser Gly Ala Gly Ala Ala Val Ser Ala Ala Ser Gly Gly Phe Ser 275 280 285

Gly Phe Asn Arg Gly Thr Leu Gln Ser Asn Ser Thr Asn Gln His Gln 290 295 300

Ser Phe Leu Ala Asn Leu Gln Arg Phe Pro Thr Ser Glu Ser Gly Gly 305 310 315 320

Gly Pro Gln Phe Leu Phe Gly Ala Leu Pro Ala Glu Asn His His His 325 330 335

Asn His Gln Phe Gln Leu Tyr Tyr Glu Asn Gly Cys Arg Asn Ser Ser 340 345 350

Glu His Lys Gly Lys Gly Lys Asn 355 360

<210> 5

MBI15 Sequence Listing.ST25

<211> 1055 <212> DNA <213> Arabidopsis thaliana	
<220> <221> CDS <222> (70)(816) <223> G19	
<400> 5 ataaaggcat ttcagctcca ccgtaggaaa ctttctcttg aaagaaaccc acagcaacaa	60
acagagaaa atg tgt ggc ggt gct att att tcc gat tat gcc cct ctc gtc Met Cys Gly Gly Ala Ile Ile Ser Asp Tyr Ala Pro Leu Val 1 5 10	111
acc aag gcc aag ggc cgt aaa ctc acg gct gag gaa ctc tgg tca gag Thr Lys Ala Lys Gly Arg Lys Leu Thr Ala Glu Glu Leu Trp Ser Glu 15 20 25 30	159
ctc gat gct tcc gcc gcc gac gac ttc tgg ggt ttc tat tcc acc tcc Leu Asp Ala Ser Ala Ala Asp Asp Phe Trp Gly Phe Tyr Ser Thr Ser 35 40 45	207
aaa ctc cat ccc acc aac caa gtt aac gtg aaa gag gag gca gtg aag Lys Leu His Pro Thr Asn Gln Val Asn Val Lys Glu Glu Ala Val Lys 50 55 60	255
aag gag cag gca aca gag ccg ggg aaa cgg agg a	303
tat aga ggg ata cgt aag cgt cca tgg gga aaa tgg gcg gct gag att Tyr Arg Gly Ile Arg Lys Arg Pro Trp Gly Lys Trp Ala Ala Glu Ile 80 85 90	351
cga gat cca cga aaa ggt gtt aga gtt tgg ctt ggt acg ttc aac acg Arg Asp Pro Arg Lys Gly Val Arg Val Trp Leu Gly Thr Phe Asn Thr 95 100 105 110	399
gcg gag gaa gct gcc atg gct tat gat gtt gcg gcc aag cag atc cgt Ala Glu Glu Ala Ala Met Ala Tyr Asp Val Ala Ala Lys Gln Ile Arg 115 120 125	447
ggt gat aaa gcc aag ctc aac ttc cca gat ctg cac cat cct cct cct Gly Asp Lys Ala Lys Leu Asn Phe Pro Asp Leu His His Pro Pro Pro 130 135 140	495
cct aat tat act cct ccg ccg tca tcg cca cga tca acc gat cag cct Pro Asn Tyr Thr Pro Pro Pro Ser Ser Pro Arg Ser Thr Asp Gln Pro 145 150 155	543
ccg gcg aag aag gtc tgc gtt gtc tct cag agt gag agc gag tta agt Pro Ala Lys Lys Val Cys Val Val Ser Gln Ser Glu Ser Glu Leu Ser 160 165 170	591
cag ccg agt ttc ccg gtg gag tgt ata gga ttt gga aat ggg gac gag Gln Pro Ser Phe Pro Val Glu Cys Ile Gly Phe Gly Asn Gly Asp Glu 175 180 185 190	639
ttt cag aac ctg agt tac gga ttt gag ccg gat tat gat ctg aaa cag Phe Gln Asn Leu Ser Tyr Gly Phe Glu Pro Asp Tyr Asp Leu Lys Gln 195 200 205	687
cag ata tcg agc ttg gaa tcg ttc ctt gag ctg gac ggt aac acg gcg Gln Ile Ser Ser Leu Glu Ser Phe Leu Glu Leu Asp Gly Asn Thr Ala 210 215 220	735
gag caa ccg agt cag ctt gat gag tcc gtt tcc gag gtg gat atg tgg Glu Gln Pro Ser Gln Leu Asp Glu Ser Val Ser Glu Val Asp Met Trp 225 230 235	783
atg ctt gat gat gtc att gcg tcg tat gag taa aagaaaaaaa ataagtttaa Met Leu Asp Asp Val Ile Ala Ser Tyr Glu	836
Page 7	

Page 7

PCT/US00/31418 WO 01/35726

896

956 1016

1055

MBI15	Sequence	Listing.ST25

245 aaaaagttaa ataaagtctg taatatatat gtaaccgccg ttacttttaa aaggttttta ccgtcgcatt ggactgctga tgatgtctgt tgtgtaatgt gtagaatgtg accaaatgga cgttatatta cggtttgtgg tattattagt ttcttagatg gaaaaactta catgtgtaaa taagatttgt aatgtaagac gaagtactta taacttctt <210> 248 <211> PRT <212> <213> Arabidopsis thaliana <400> 6 Met Cys Gly Gly Ala Ile Ile Ser Asp Tyr Ala Pro Leu Val Thr Lys Ala Lys Gly Arg Lys Leu Thr Ala Glu Glu Leu Trp Ser Glu Leu Asp 20 25 30 Ala Ser Ala Ala Asp Asp Phe Trp Gly Phe Tyr Ser Thr Ser Lys Leu 35 40 45 His Pro Thr Asn Gln Val Asn Val Lys Glu Glu Ala Val Lys Lys Glu 50 55 60 Gln Ala Thr Glu Pro Gly Lys Arg Lys Arg Lys Asn Val Tyr Arg 65 70 75 80 Gly Ile Arg Lys Arg Pro Trp Gly Lys Trp Ala Ala Glu Ile Arg Asp 85 90 95 Pro Arg Lys Gly Val Arg Val Trp Leu Gly Thr Phe Asn Thr Ala Glu 100 105 110 Glu Ala Ala Met Ala Tyr Asp Val Ala Ala Lys Gln Ile Arg Gly Asp 115 120 125 Lys Ala Lys Leu Asn Phe Pro Asp Leu His His Pro Pro Pro Pro Asn 130 135 140 Tyr Thr Pro Pro Pro Ser Ser Pro Arg Ser Thr Asp Gln Pro Pro Ala 145 150 155 160 Lys Lys Val Cys Val Val Ser Gln Ser Glu Ser Glu Leu Ser Gln Pro 165 170 175 Ser Phe Pro Val Glu Cys Ile Gly Phe Gly Asn Gly Asp Glu Phe Gln 180 185 190 Asn Leu Ser Tyr Gly Phe Glu Pro Asp Tyr Asp Leu Lys Gln Gln Ile 195 200 205 Ser Ser Leu Glu Ser Phe Leu Glu Leu Asp Gly Asn Thr Ala Glu Gln 210 215

Pro Ser Gln Leu Asp Glu Ser Val Ser Glu Val Asp Met Trp Met Leu

MBI15 Sequence Listing.ST25

225 230 235 240

Asp Asp Val Ile Ala Ser Tyr Glu 245

<210> <211> 1857 <212> DNA Arabidopsis thaliana <221> CDS <222> (458) .. (1663) G261 <400> 7 gtttaggttc gagaagcaga gagggttcga gaagctaata agggtttctt ctttttgatt 60 120 ttaatgetaa aagggtteta gattegttga attttacaag ggttttaggg gttettagaa gettttgett gattgtettt tatttagaaa eagtggtgag tttttagtet tteaetttgt 180 tcaagttcga agctttttt ggagggaatt ttgggcttct gattttgatc gaaacttact 240 gatagtaagt tetttgagte eteettaaet gtagtttetg tgtactgaag ttattgaatt 300 360 gaaagttttt atcttttttg gttattgaaa ctttcatagt ttgatcaaaa gagtctcttg ctctgttttt ggctctgttt ttgtgagtgt gattgtaagc tttgttgtga gtagattgaa 420 tcaaggagtg tgagagttgt taaaagtgtt ttcagag atg gat gag aat aat cat Met Asp Glu Asn Asn His 475 gga gtt tca tca agc tca ctt cca cct ttc ctc acc aaa aca tat gag Gly Val Ser Ser Ser Leu Pro Pro Phe Leu Thr Lys Thr Tyr Glu 523 atg gtt gat gat tct tca tcc gat tct atc gtc tct tgg agt cag agc Met Val Asp Asp Ser Ser Ser Asp Ser Ile Val Ser Trp Ser Gln Ser 571 aat aag agt ttc atc gtt tgg aat ccg ccg gag ttt tct aga gat ctt Asn Lys Ser Phe Ile Val Trp Asn Pro Pro Glu Phe Ser Arg Asp Leu 619 ctt ccg aga ttc ttc aag cac aat aac ttc tct agc ttt atc cgc cag 667 Leu Pro Arg Phe Phe Lys His Asn Asn Phe Ser Ser Phe Ile Arg Gln ctt aac aca tat ggt ttt aga aaa gct gat cct gag caa tgg gaa ttt Leu Asn Thr Tyr Gly Phe Arg Lys Ala Asp Pro Glu Gln Trp Glu Phe 715 gcg aat gat gat ttt gtg aga ggt caa cct cat ctt atg aag aac att Ala Asn Asp Asp Phe Val Arg Gly Gln Pro His Leu Met Lys Asn Ile 763 cat aga cgc aaa cca gtt cat agc cac tct tta ccg aat ctt caa gct His Arg Arg Lys Pro Val His Ser His Ser Leu Pro Asn Leu Gln Ala 811 cag tta aac ccg ttg acg gat tca gaa cga gtg aga atg aat aat cag Gln Leu Asn Pro Leu Thr Asp Ser Glu Arg Val Arg Met Asn Asn Gln 859 att gag aga ttg aca aaa gag aaa gaa gga ttg ctt gaa gag tta cat Ile Glu Arg Leu Thr Lys Glu Lys Glu Gly Leu Leu Glu Glu Leu His 907 aaa caa gac gag gaa cga gaa gtg ttt gag atg caa gtg aaa gaa ctt Lys Gln Asp Glu Glu Arg Glu Val Phe Glu Met Gln Val Lys Glu Leu 955

Page 9

			·	155			MBI1		quen 160	ice I	ist	ing.	ST25	165		
aaa Lys	gaa Glu	cga Arg	tta Leu 170	caa Gln	cac His	atg Met	GIu	aag Lys 175	cgt Arg	cag Gln	aaa Lys	aca Thr	atg Met 180	gtt Val	tcg Ser	1003
ttt Phe	gtt Val	tct Ser 185	caa Gln	gta Val	ttg Leu	gaa Glu	aag Lys 190	cca Pro	999 Gly	ctt Leu	gct Ala	ttg Leu 195	aac Asn	cta Leu	tcg Ser	1051
ccg Pro	tgt Cys 200	gtt Val	ccc Pro	gaa Glu	aca Thr	aac Asn 205	gag Glu	agg Arg	aaa Lys	aga Arg	agg Arg 210	ttc Phe	cct Pro	agg Arg	atc Ile	1099
gag Glu 215	Phe	ttt Phe	ccc Pro	gat Asp	gaa Glu 220	ccg Pro	atg Met	ttg Leu	gaa Glu	gag Glu 225	aac Asn	aaa Lys	act Thr	tgt Cys	gtt Val 230	1147
gtt Val	gtg Val	aga Arg	gag Glu	gaa Glu 235	ggt Gly	tct Ser	aca Thr	agc Ser	cct Pro 240	tct Ser	tca Ser	cac His	aca Thr	aga Arg 245	gag Glu	1195
cat His	caa Gln	gtg Val	gaa Glu 250	cag Gln	tta Leu	gag Glu	tca Ser	tcg Ser 255	ata Ile	gcg Ala	att Ile	tgg Trp	gag Glu 260	aat Asn	ctt Leu	1243
Val	Ser	Asp 265	Ser	Сув	GIu	ser	270	ren	GIII	261	Arg	agt Ser 275	MCC	1100	••••	1291
Leu	Asp 280	Val	Asp	Glu	Ser	ser 285	Thr	Pne	Pro	GIU	290		PIO	nea	Jer	1339
Cys 295	Ile	Gln	Leu	Ser	Val 300	Asp	ser	Arg	ьеи	305	261	PIC	PIO	Der	cca Pro 310	1387
Arg	ılle	Ile	Asp	315	Asn	Cys	GIu	Pro	320	GIY	261	. Lys	. 610	325		1435
Thi	. Val	Ala	Ala 330	Pro	Pro	Pro	Pro	335	vai	Ald	GI	ATO	340)	ggc Gly	1483
Phe	e Trp	345	Glr	. Phe	Phe	Ser	350	ASI	Pro) G1}	, 261	359	5	. 011	cgg Arg	1531
Glu	1 Val	Glr	ı Lei	ı Glu	Arg	365	Asp	ASP	, па	, waf	370	0	. 01)	, , ,	cgt Arg	1579
Th:	r Glu 5	ı Lys	Cys	3 Trį	380))	ı ser	ALC	, Abi	385	5				a gaa c Glu 390	1627
Gl	n Lev	ı Gly	/ His	39!	i Thi	: Sei	r Sei	GIV	400)	•	a ta				1673
															ttgtttt	1733
															ttcccag	
tt	catt	gtag	cag	actt	caa I	tgg t :	aatga	at.aa	agcta	agag	c tt	atgg	atag	tat	tcataaa	
aa	aa															1857

<210> 8 <211> 401 <212> PRT <213> Arabidopsis thaliana

MBI15 Sequence Listing.ST25

<400>

Met Asp Glu Asn Asn His Gly Val Ser Ser Ser Ser Leu Pro Pro Phe 1 . 5 10 15

Leu Thr Lys Thr Tyr Glu Met Val Asp Asp Ser Ser Ser Asp Ser Ile 20 25 30

Val Ser Trp Ser Gln Ser Asn Lys Ser Phe Ile Val Trp Asn Pro Pro 35 40 45

Glu Phe Ser Arg Asp Leu Leu Pro Arg Phe Phe Lys His Asn Asn Phe 50 55 60

Ser Ser Phe Ile Arg Gln Leu Asn Thr Tyr Gly Phe Arg Lys Ala Asp 65 70 75 80

Pro Glu Gln Trp Glu Phe Ala Asn Asp Asp Phe Val Arg Gly Gln Pro

His Leu Met Lys Asn Ile His Arg Arg Lys Pro Val His Ser His Ser 100 105 · 110

Leu Pro Asn Leu Gln Ala Gln Leu Asn Pro Leu Thr Asp Ser Glu Arg 115 120 125

Val Arg Met Asn Asn Gln Ile Glu Arg Leu Thr Lys Glu Lys Glu Gly 130 135 140

Leu Leu Glu Glu Leu His Lys Gln Asp Glu Glu Arg Glu Val Phe Glu 145 150 155 160

Met Gln Val Lys Glu Leu Lys Glu Arg Leu Gln His Met Glu Lys Arg 165 170 175

Gln Lys Thr Met Val Ser Phe Val Ser Gln Val Leu Glu Lys Pro Gly 180 185 190

Leu Ala Leu Asn Leu Ser Pro Cys Val Pro Glu Thr Asn Glu Arg Lys 195 200 205

Arg Arg Phe Pro Arg Ile Glu Phe Phe Pro Asp Glu Pro Met Leu Glu 210 215 220

Glu Asn Lys Thr Cys Val Val Val Arg Glu Glu Gly Ser Thr Ser Pro 225 230 235 235

Ser Ser His Thr Arg Glu His Gln Val Glu Gln Leu Glu Ser Ser Ile 245 250 255

Ala Ile Trp Glu Asn Leu Val Ser Asp Ser Cys Glu Ser Met Leu Gln 260 265 270

Ser Arg Ser Met Met Thr Leu Asp Val Asp Glu Ser Ser Thr Phe Pro 275 280 285

Glu	Ser	Pro	Pro	Leu	Ser	Cys	MBII Ile	l5 Se Gln	quei Leu	nce I Ser	Jisti Val	ing.S Asp	ST25 Ser	Arg	Leu			
	290					295					300							
Lys 305	Ser	Pro	Pro	Ser	Pro 310	Arg	Ile	Ile	Asp	Met 315	Asn	Cys	Glu	Pro	Asp 320	•		
Gly	Ser	Lys	Glu	Gln 325	Asn	Thr	Val	Ala	Ala 330	Pro	Pro	Pro	Pro	Pro 335	Val			
Ala	Gly	Ala	Asn 340	Asp	Gly	Phe	Trp	Gln 345	Gln	Phe	Phe	Ser	Glu 350	Asn	Pro			
Gly	Ser	Thr 355	Glu	Gĺn	Arg	Glu	Val 360	Gln	Leu	Glu	Arg	Lys 365	Asp	Asp	Lys			
Asp	Lys 370		Gly	Val	Arg	Thr 375	Glu	Lys	Cys	Trp	Trp 380	Asn	Ser	Arg	Asn			
Val 385	Asn	Ala	Ile	Thr	Glu 390	Gln	Leu	Gly	His	Leu 395	Thr	Ser	Ser	Glu	Arg 400			
Ser																		
<21 <21 <21 <21	1> 2>	9 964 DNA Arab	idop	sis	thal	iana												
<22 <22 <22 <22	1> 2>	CDS (63) G28	(8	69)														
<40 gaa	0> atct	9 :caa	caag	aacc	aa a	ccaa	acaa	c aa	aaaa	acat	tct	taat	aat	tato	ttt	ctg		60
tt	atg Met 1	tcg Ser	atg Met	Thr	gcg Ala 5	gat Asp	tct Ser	caa Gln	tct Ser	gat Asp 10	tat Tyr	gct Ala	ttt Phe	ctt Leu	gag Glu 15		1	.07
t co Sei	ata Ile	a cga e Arg	a cga g Arg	cac His	tta Leu	cta Leu	gga Gly	gaa Glu	Ser 25	g gag Glu	ccg Pro	ata Ile	cto Lev	agt Ser 30	gaq Gl	i I	1	155
t co Sei	aca Thi	a gcg	g agt a Ser 35	tcg Ser	gtt Val	act Thr	caa Glr	tct Ser 40	tgt Cys	gta Val	acc Thr	ggt Gly	Caq Glr 45	g age	at Il	t e	2	203
aaa Lys	a cc	g gte o Va 50	g tac	gga Gly	cga Arg	aac Asn	cct Pro	ago Ser	ttt Phe	ago e Sei	aaa Lys	tet Let 60	tai Ty	r Pr	t tg o Cy	С В	2	251
Ph	e Th:	r Gl	g ago u Ser	r Trp	o Gly	70) Let	ı Pro) Lei	ı PA:	75	i Asi	ı AS	y se	. 01	.	-	299
ga As 80	р Ме	g tt t Le	a gti u Vai	t tac l Tyr	ggt Gly 85	ato Ile	cte Le	c aac u Asr	gae n Asj	p Ala	ttt a Phe	cae Hi	5 99 8 Gl	gg y Gl	t tg y Tr 95	P	;	347
ga Gl	g cc u Pr	g tc o Se	t tc r Se	t tcg r Sei 10	r Sei	tco Sei	ga As	c gaa p Glu	a ga a As 10	p Ar	t age g Se:	c tc r Se	t tt r Ph	c cc e Pr 11	0 50	t		395
gt	t aa	g at	c ga	g ac	t ccg	g gag	g ag	t tte	c gc	g gc		g ga	t tc	t gt	t cc	g		443

Val	Lys	Ile	Glu	Thr	Pro	Glu		15 S Phe							Pro	
			115					120					125			
gtc Val	aag Lys	aag Lys 130	gag Glu	aag Lys	acg Thr	agt Ser	Pro 135	gtt Val	tcg Ser	gcg Ala	gcg Ala	gtg Val 140	acg Thr	gcg Ala	gcg Ala	491
	gga Gly 145															539
	gcg Ala															587
	acg Thr															635
	ttc Phe															683
	aat Asn															731
	ttt Phe 225															779
	gcc Ala															827
	gtt Val												taa			.869
ttt	tgati	tt (cttt	gtt	gg at	gatt	atat	gat	tctt	caa	aaaa	agaag	gaa d	gtta	ataaa	929
aaa	atte	gtt (tatta	ıttaa	aa aa	aaaa	aaaa	a aaa	aa							964
<21: <21: <21: <21:	l > 2 2 > 1	10 268 PRT Arab:	idops	sis t	hali	iana										
<40) > 1	L O														
Met 1	Ser	Met	Thr	Ala 5	Asp	Ser	Gln	Ser	Asp 10	Tyr	Ala	Phe	Leu	Glu 15	Ser	
Ile	Arg	Arg	His 20	Leu	Leu	Gly	Glu	Ser 25	Glu	Pro	Ile	Leu	Ser 30	Glu	Ser	
Thr	Ala	Ser 35	Ser	Val	Thr	Gln	Ser 40	Cys	Val	Thr	Gly	Gln 45	Ser	Ile	Lys	
Pro	Val. 50	Tyr	Gly	Arg	Asn	Pro 55	Ser	Phe	Ser	Lys	Leu 60	Tyr	Pro	Суз	Phe	
Thr 65	Glu	Ser	Trp	Gly	Asp 70	Leu	Pro	Leu	Lys	Glu 75	Asn	Asp	Ser	Glų	Asp 80	

Met Leu Val Tyr Gly Ile Leu Asn Asp Ala Phe His Gly Gly Trp Glu 85 90 95

							MBI:	15 Se	eque	nce 1	List:	ing.	ST25	C	u-1	
Pro	Ser	Ser	Ser 100	Ser	Ser	Asp	Glu	105	Arg	Ser	Ser	Pne	110	ser	vai	
Lys	Ile	Glu 115	Thr	Pro	Glu	Ser	Phe 120	Ala	Ala	Val	Asp	Ser 125	Val	Pro	Val	
Lys	Lys 130	Glu	Lys	Thr	Ser	Pro 135	Val	Ser	Ala	Ala	Val 140	Thr	Ala	Ala	Lys	
Gly 145	Lys	His	Tyr	Arg	Gly 150	Val	Arg	Gln	Arg	Pro 155	Trp	Gly	Lys	Phe	Ala 160	
Ala	Glu	Ile	Arg	Asp 165	Pro	Ala	Lys	Asn	Gly 170	Ala	Arg	Val	Trp	Leu 175	Gly	
Thr	Phe	Glu	Thr 180	Ala	Glu	Asp	Ala	Ala 185	Leu	Ala	Tyr	Asp	Arg 190	Ala	Ala	
Phe	Arg	Met 195		Gly	Ser	Arg	Ala 200	Leu	Leu	Asn	Phe	Pro 205	Leu	Arg	Val	
Asn	Ser 210		Glu	Pro	Авр	Pro 215	Val	Arg	Ile	Lys	Ser 220	Lys	Arg	Ser	Ser	
Phe 225		Ser	Ser	Asn	Glu 230	Asn	Gly	Ala	Pro	Lys 235	Lув	Arg	Arg	Thr	Val 240	
Ala	Ala	Gly	Gly	Gly 245		Авр	Lys	Gly	Leu 250	Thr	Val	Lys	Cys	Glu 255	Val	
Val	Glu	Val	Ala 260		Gly	Asp	Arg	Leu 265	Leu	Val	Leu					
<21 <21 <21 <21	.1> .2>	11 1571 DNA Arab		sis	thal	iana										
<22 <22 <22 <22	!1> !2>	CDS (428 G869) (1402	:)											
<40 agg	00> gaaca	11 agtg	aaag	gtto	gg t	ttt	tggg	jt tt	.cgat	:ctga	ı taa	tcaa	ıcaa	gaaa	aaaggg	60
ttt	gati	tat	gtcg	gcts	gg t	ttga	atco	ga ct	gtga	tttt	gto	tttg	gatt	cata	tctctt	120
cto	cgai	ttc	atca	tcat	ct t	ccc	atca	at co	tcgt	ctt	gaa	atct	tgt	ctto	tcaacg	180
cto	ette	actt	ctg	tgta	aat a	agca	gagg	gc tt	gtto	tgga	a gad	tcct	tct	cttt	ccatgc	240
															taaagc	
age	caaa	agtt	ttct	tttl	tc a	tagt	tcg	ct ga	agagt	ttt	g agt	ttt	gata	ccaa	aaaagt	360
tt	tgac	cttt	taga	igtga	att (ttt	gttc	tt to	etgti	ttc	999	gtati	ttt	gag	gagtggg	420
tt	taac	a ato Me	g gti t Vai	gcg L Ala	g att	aga Arg	a aag	g gaa s Gl	a cag ı Glı	tc:	t ttg r Leu 10	g agt	t gg r Gl	y Val	t agt l Ser	469
ag	c ga	g at	t aag	g aag	g aga	a gci	t aa	g ag		c ac Page		a to	g to	c ct	t cct	51

Ser	Glu	Tle	Lvs	Lvs	Ara	Ala		15 S Arg						T.en	Pro	
15			_	_	20		_			25					30	
								gtc Val								565
								gat Asp 55								613
								gtt Val								661
								gag Glu								709
								tca Ser								757
								agg Arg								805
								act Thr 135								853
								gct Ala								901
								gtg Val								949
								tct Ser								997
								tca Ser								1045
cct Pro	gat Asp	gac Asp	gtc Val 210	tcg Ser	acc Thr	gtt Val	gct Ala	cca Pro 215	act Thr	gct Ala	cca Pro	act Thr	cca Pro 220	aat Asn	gtt Val	1093
cct Pro	gct Ala	ggt Gly 225	gga Gly	aac Asn	aag Lys	gaa Glu	acg Thr 230	ttg Leu	ttc Phe	gat Asp	ttc Phe	gac Asp 235	ttt Phe	act Thr	aat Asn	1141
cta Leu	cag Gln 240	atc Ile	cct Pro	gat Asp	ttt Phe	ggt Gly 245	ttc Phe	ttg Leu	gca Ala	gag Glu	gag Glu 250	caa Gln	caa Gln	gac Asp	cta Leu	1189
								gat Asp								1237
								gat Asp								1285
								gat Asp 295								1333
								cct Pro								1381

MBI15 Sequence Listing.ST25 aaa agt ttt gca gct tca tag gatcttgctt agtaatgtta agtgagaa	aga 1432
Lys Ser Phe Ala Ala Ser 320	
gtgttttgtt ttttcgttta tgctttagta atttaagaca tacaaaagtg tg	tgttccgg 1492
attgtagtaa gatcttaaga cataaagccg ggttttgcaa ttaggaatcg ag	ttttaatg 1552
aagttttagt ttatgtttg	1571
<210> 12 <211> 324 <212> PRT <213> Arabidopsis thaliana	
<400> 12	
Met Val Ala Ile Arg Lys Glu Gln Ser Leu Ser Gly Val Ser S 1 5 10	er Glu 5
Ile Lys Lys Arg Ala Lys Arg Asn Thr Leu Ser Ser Leu Pro G 20 25 30	iln Glu
Thr Gln Pro Leu Arg Lys Val Arg Ile Ile Val Asn Asp Pro T 35 40 45	yr Ala
Thr Asp Asp Ser Ser Ser Asp Glu Glu Glu Leu Lys Val Pro L 50 55 60	ys Pro
Arg Lys Met Lys Arg Ile Val Arg Glu Ile Asn Phe Pro Ser M	1et Glu 80
Val Ser Glu Gln Pro Ser Glu Ser Ser Ser Gln Asp Ser Thr I	ys Thr 95
Asp Gly Lys Ile Ala Val Ser Ala Ser Pro Ala Val Pro Arg I 100 105 110	Lys Lys
Pro Val Gly Val Arg Gln Arg Lys Trp Gly Lys Trp Ala Ala C	Glu Ile
Arg Asp Pro Ile Lys Lys Thr Arg Thr Trp Leu Gly Thr Phe 1	Asp Thr
Leu Glu Glu Ala Ala Lys Ala Tyr Asp Ala Lys Lys Leu Glu I 145 150 155	Phe Asp 160
Ala Ile Val Ala Gly Asn Val Ser Thr Thr Lys Arg Asp Val	Ser Ser 175
Ser Glu Thr Ser Gln Cys Ser Arg Ser Ser Pro Val Val Pro 180 185 190	Val Glu
Gln Asp Asp Thr Ser Ala Ser Ala Leu Thr Cys Val Asn Asn 195 200 205	Pro Asp
Asp Val Ser Thr Val Ala Pro Thr Ala Pro Thr Pro Asn Val 210 215 220	Pro Ala
Gly Gly Asn Lys Glu Thr Leu Phe Asp Phe Asp Phe Thr Asn Page 16	Leu Gln

W	O 01	/357:	26													PCT/US
225					230		мві	15 S	eque	nce 1 235	List	ing.	ST25	٠	240	
Ile	Pro	Asp	Phe	Gly 245	Phe	Leu	Ala	Glu	Glu 250	Gln	Gln	Авр	Leu	Asp 255	Phe	
Asp	Сув	Phe	Leu 260	Ala	Asp	Asp	Gln	Phe 265	Asp	Asp	Phe	Gly	Leu 270	Leu	Asp	
Asp	Ile	Gln 275	Gly	Phe	Glu	Asp	Asn 280	Gly	Pro	Ser	Ala	Leu 285	Pro	Asp	Phe	
Asp	Phe 290	Ala.	Asp	Val	Glu	Asp 295	Leu	Gln	Leu	Ala	Asp 300	Ser	Ser	Phe	Gly	
Phe 305	Leu	Asp	Gln	Leu	Ala 310	Pro	Ile	Asn	Ile	Ser 315	Cys	Pro	Leu	Lys	Ser 320	
Phe .	Ala	Ala	Ser													
<210 <211 <212 <213	> 9 > I	.3 220 NA Arabi	idops	sis (thali	iana										
<220 <221 <222 <223	> (> (. (852	2)												
<400 atg Met 1	gcg	aag														48
cct Pro	gaa Glu	gaa Glu	gac Asp 20	gag Glu	aag Lys	cta Leu	agg Arg	agc Ser 25	ttc Phe	atc Ile	ctc Leu	Ser	tat Tyr 30	ggc	cat His	96
tct Ser	tgc Cys	tgg Trp 35	acc Thr	act Thr	gtt Val	ccc Pro	atc Ile 40	aaa Lys	gct Ala	999 Gly	tta Leu	caa Gln 45	agg Arg	aat Asn	999 999	144
aag Lys	agc Ser 50	tgc Cys	aga Arg	tta Leu	aga Arg	tgg Trp 55	att Ile	aat Asn	tac Tyr	cta Leu	aga Arg 60	cca Pro	Gly 999	tta Leu	aag Lys	192
agg Arg 65																240
tct Ser															gga Gly	288
aga Arg	aca Thr	gac Asp	aat Asn 100	gag Glu	ata Ile	aag Lys	aac Asn	tat Tyr 105	tgg Trp	cac His	tct Ser	cat His	ttg Leu 110	aaa Lys	aag Lys	336

384

432

aaa tgg ctc aag tct cag agc tta caa gat gca aaa tct att tcc cct Lys Trp Leu Lys Ser Gln Ser Leu Gln Asp Ala Lys Ser Ile Ser Pro 115 120 125

cct tcg tct tca tca tca tca ctt gtt gct tgt gga gaa aga aat ccg Pro Ser Ser Ser Ser Ser Leu Val Ala Cys Gly Glu Arg Asn Pro 130 135 140

gaa Glu 145	acc Thr	ttg Leu	atc Ile	tcg Ser	aat Asn 150	cac His	ata	ttc	Ser	ctc	caq	aga	ctt	cta Leu	gag Glu 160	480
aac Asn	aaa Lys	tct Ser	tca Ser	tct Ser 165	ccc Pro	tca Ser	caa Gln	gaa Glu	agc Ser 170	aac Asn	gga Gly	aat Asn	aac Asn	agc Ser 175	cat His	528
caa Gln	tgt Cys	tct Ser	tct Ser 180	gct Ala	cct Pro	gag Glu	att Ile	cca Pro 185	agg Arg	ctt Leu	ttc Phe	ttc Phe	tct Ser 190	gaa Glu	tgg Trp	576
ctt Leu	tct Ser	tct Ser 195	tca Ser	tat Tyr	ccc Pro	cac His	acc Thr 200	gat Asp	tat Tyr	tcc Ser	tct Ser	gag Glu 205	ttt Phe	acc Thr	gac Asp	624
tct Ser	aag Lys 210	cac His	agt Ser	caa Gln	gct Ala	cca Pro 215	aat Asn	gtc Val	gaa Glu	gag Glu	act Thr 220	ctc Leu	tca Ser	gct Ala	tat Tyr	672
gaa Glu 225	Glu	atg Met	ggt Gly	gat Asp	gtt Val 230	gat Asp	cag Gln	ttc Phe	cat His	tac Tyr 235	aac Asn	gaa Glu	atg Met	atg Met	atc Ile 240	720
aac Asn	aac Asn	agc Ser	aac Asn	tgg Trp 245	act Thr	ctt Leu	aac Asn	gac Asp	att Ile 250	gtg Val	ttt Phe	ggt Gly	tcc Ser	aaa Lys 255	tgt Cys	768
aag Lys	aag Lys	cag Gln	gag Glu 260	cat His	cat His	att Ile	tat Tyr	aga Arg 265	gag Glu	gct Ala	tca Ser	gat Asp	tgt Cys 270	aat Asn	tct Ser	816
tct Ser	gct Ala	gaa Glu 275	Phe	ttt Phe	tct Ser	cca Pro	cca Pro 280	Thr	acg Thr	acg Thr	taa	att	gcgt	tta		862
ttg	taat	gta	aatc	aaat	tt c	taag	gcaa	a ac	cggaa	aaaa	aaa	aaaa	aaa	aaaa	aaaa	920
<21 <21 <21 <21	l1> l2>	14 283 PRT Arab	idop	sis	thal	iana										
<21 <21	12> 12>	283 PRT	idop	sis	thal	iana										
<21 <21 <21	11> 12> 13>	283 PRT Arab	-					Arg	His 10	Arg	Lys	Gly	Leu	Trp 15	Ser	
<21 <21 <21 <40 Met 1	11> 12> 13> 00> : Ala	283 PRT Arab 14	Thr	Lys 5	туг	Gly	. Glu		10					13	Ser	
<21 <21 <21 <40 Met 1	11> 12> 13> 00> : Ala	283 PRT Arab 14 Lys	Thr Asp 20	Lys 5 Glu	Tyr Lys	Gly	Glu Arg	Ser 25	Phe	Ile	Leu	. Ser	Туг 30	· Gly		
<21 <21 <40 Met 1 Pro	11> 12> 13> 00> : Ala	283 PRT Arab 14 Lys Glu 35	Thr Asp 20	Lys 5 Glu Thr	Tyr Lys Val	Gly Leu	Glu Arg	Ser 25 Lys	Phe Ala	Ile	Leu Leu	Ser Glr 45	Tyx 30	Gly	, His	
<21 <21 <4() Met 1 Pro	1>, 12>, 13>, 100, 100, 100, 100, 100, 100, 100, 10	283 PRT Arab 14 Lys Glu Trp 35	Thr Asp 20 Thr	Lys 5 Glu Thr	Tyr Lys Val	Gly Leu Pro	Glu Arg	Ser 25 Lys Asr	Phe Ala	Ile Gly Leu	Leu Leu Arg	Glr 45	Tyr 30 Arg	Gly Asi	His	
<21 <21 <21 <40 Met 1 Pro	11> 12> 13> 00> 1 Ala 1 Cya 1 See 50	283 PRT Arab 14 Lys Glu 35 Trp 35 Cys	Asp 20 Thr	Lys 5 Glu Thr Leu	Tyr Lys Val	Gly Leu Pro	Glu Arg	Ser 25 Lys Asr	Phe Ala	Ile Gly Leu Thr 75	Leu Leu Arg 60	Glr 45 Pro	Tyr 30 Arg	Gly Ass	His Gly Lys	
<21 < 21 < 21 < 41 Met 1 Pro See Ly Ar 65 Se	1> 12> 13> 00> 12 Ala OGLU Tr Cys See 50 GAB Tr Pr	283 PRT Arab 14 Lyss 15 Trp 35 Trp 35 Cys	Asp 20 Thr Arg	Lys 5 Glu Thr Let Ser 85	Tyr Lys Val Arg	Gly Leu Pro	Glu Arg 11e 40 Ile 10 I	Ser 25 25 Lyse Lyse Asr	Phe Ala Tyr Glu 1 Glu 90	Ile Gly Leu Thr 75	Leu Arc 60	Ser Glr 45 Pro	Tyr 30 Arc	Gly Ass	His Gly Lys His 80	

Page 18

WO 01/35726

PCT/US00/31418

450

MBI15 Sequence Listing.ST25 115 Pro Ser Ser Ser Ser Ser Leu Val Ala Cys Gly Glu Arg Asn Pro Glu Thr Leu Ile Ser Asn His Val Phe Ser Leu Gln Arg Leu Leu Glu Asn Lys Ser Ser Ser Pro Ser Gln Glu Ser Asn Gly Asn Asn Ser His Gln Cys Ser Ser Ala Pro Glu Ile Pro Arg Leu Phe Phe Ser Glu Trp Leu Ser Ser Ser Tyr Pro His Thr Asp Tyr Ser Ser Glu Phe Thr Asp Ser Lys His Ser Gln Ala Pro Asn Val Glu Glu Thr Leu Ser Ala Tyr Glu Glu Met Gly Asp Val Asp Gln Phe His Tyr Asn Glu Met Met Ile 225 Asn Asn Ser Asn Trp Thr Leu Asn Asp Ile Val Phe Gly Ser Lys Cys Lys Lys Gln Glu His His Ile Tyr Arg Glu Ala Ser Asp Cys Asn Ser Ser Ala Glu Phe Phe Ser Pro Pro Thr Thr Thr <210> 15 <211> 1302 <212> DNA <213> Arabidopsis thaliana <220> <221> CDS <222> (331)..(1149) <223> G409 <400> 15 60 tgtctctctc tctggctctc tttctcttaa cgtgatcata acgtgattcg aaaattggat atagataggt ttcttgttgg atcttgatcc ctctggaaaa ggaggggaga atagcagttc 120 180 atgatgggat tttgtatctg cccgttggag tcacctgcga gattactatg gagtacaagc ttottoogco ataagatoat gatottotaa toottootao ttottoccat otttttaato 240 300 atcttctcgc tatctctgct tcctctttct ctctgtttcc tctttctcag aactcagaag tagttgttgt tttatttctg ttgatcaaaa atg gaa tcc aat tcg ttt ttc ttc Met Glu Ser Asn Ser Phe Phe Phe 354 gat cca tct gct tca cac ggc aac agc atg ttc ttc ctt ggg aat ctc Asp Pro Ser Ala Ser His Gly Asn Ser Met Phe Phe Leu Gly Asn Leu 10 15 20 402

Page 19

aat ccc gtc gtc caa gga gga gga gca aga tcg atg atg aac atg gag Asn Pro Val Val Gln Gly Gly Gly Ala Arg Ser Met Met Asn Met Glu

							MBII	15 Se	ecuer	nce I	List	ing.S	T25			
25					30				_	35					40	
gaa Glu	act Thr	tcg Ser	aag Lys	cga Arg 45	agg Arg	ccc Pro	ttc Phe	ttt Phe	agc Ser 50	tcc Ser	cct Pro	gag Glu	gat Asp	ctc Leu 55	tac Tyr	498
gac Asp	gat Asp	gac Asp	ttt Phe 60	tac Tyr	gac Asp	gac Asp	cag Gln	ttg Leu 65	cct Pro	gaa Glu	aag Lys	aag Lys	cgt Arg 70	cgc Arg	ctc Leu	546
act Thr	acc Thr	gaa Glu 75	caa Gln	gtg Val	cat His	ctg Leu	ctg Leu 80	gag Glu	aaa Lys	agc Ser	ttc Phe	gag Glu 85	aca Thr	gag Glu	aac Asn	594
aag Lys	cta Leu 90	gag Glu	cct Pro	gaa Glu	cgc Arg	aag Lys 95	act Thr	cag Gln	ctt Leu	gcc Ala	aag Lys 100	aag Lys	ctt Leu	ggt Gly	cta Leu	642
cag Gln 105	cca Pro	agg Arg	caa Gln	gtg Val	gct Ala 110	gtc Val	tgg Trp	ttt Phe	cag Gln	aat Asn 115	cgc	cga Arg	gct Ala	cgt Arg	tgg Trp 120	690
aaa Lys	aca Thr	aaa Lys	cag Gln	ctt Leu 125	gag Glu	aga Arg	gac Asp	tac Tyr	gat Asp 130	neu	ctc Leu	aag Lys	tcc Ser	act Thr 135	tac Tyr	738
gac Asp	caa Gln	ctt Leu	ctt Leu 140	tct Ser	aac Asn	tac Tyr	gac Asp	tcc Ser 145	atc Ile	gtc Val	atg Met	gac Asp	aac Asn 150	vob	aag Lys	786
ctc Leu	aga Arg	tcc Ser 155	gag Glu	gtt Val	act Thr	tcc Ser	ctg Leu 160	Thr	gaa Glu	aag Lys	Leu	cag Gln 165	GIY	aaa Lys	caa Gln	834
gag Glu	aca Thr	Ala	aat Asn	gaa Glu	cca Pro	cct Pro	GLY	caa Gln	gtg Val	Pro	gaa Glu 180	PIO	aac	caa Glm	ctt Leu	882
gat Asp 189	Pro	gtt Val	tac Tyr	att Ile	aat Asn 190	Ala	gca Ala	gca Ala	ato Ile	aaa Lys	1111	gag Glu	gac	cgg Arg	tta Leu 200	930
agt Sei	tca Ser	999 Gly	agc Ser	gtt Val 205	GLY	ago Ser	gcg	gta Val	cta Leu 210	r wei	gad Ası	gac Asp	gca Ala	cct Pro 215	caa Gln	. 978
cta Lei	cta Lev	gaq 1 Asp	ago Ser 220	Cys	gac Asp	tct Sei	tac Tyr	tto Phe	PIC	a ago Sei	ato	e gta e Val	Pro 230	, 110	caa Gln	1026
ga As _l	aac Asr	age 1 Ser 23!	. Asr	gco Ala	agt Sei	gat As	cat His	a Asi	aat Asi	gao n Asp	c cg	g ago g Ser 245	. cy	tto Pho	gcc Ala	1074
ga As	gto Val	l Pho	t gtg e Val	Pro	aco Thi	act Thi	r Sei	a ccg	g to Se:	g cad	ga 8 As 26	h vr	cac His	gg Gl	gaa Glu	1122
tc Se 26	r Lei	g gc	t tto a Phe	tgg Tr	g gg p Gl	y Tr	g cci	t tag	gaa	aacc	actc	tga	taat	aaa		1169
		ttta	ttta	aagt	tca :	agag	tcat	ct t	cttg	ttgt	t tc	catg	ttga	cga	taattgt	1229
															tgctttt	
			aaa													1302
	10-	16														
<2	10> 11> 12>	16 272 PRT														

<212> PRT <213> Arabidopsis thaliana

<400> 16

MBI15 Sequence Listing.ST25

Met Glu Ser Asn Ser Phe Phe Phe Asp Pro Ser Ala Ser His Gly Asn 1 5 10 15

Ser Met Phe Phe Leu Gly Asn Leu Asn Pro Val Val Gln Gly Gly 25 30

Ala Arg Ser Met Met Asn Met Glu Glu Thr Ser Lys Arg Arg Pro Phe 35 40 45

Phe Ser Ser Pro Glu Asp Leu Tyr Asp Asp Asp Phe Tyr Asp Asp Gln 50 55

Leu Pro Glu Lys Lys Arg Arg Leu Thr Thr Glu Gln Val His Leu Leu 65 70 75 80

Glu Lys Ser Phe Glu Thr Glu Asn Lys Leu Glu Pro Glu Arg Lys Thr 85 90 95

Gln Leu Ala Lys Lys Leu Gly Leu Gln Pro Arg Gln Val Ala Val Trp 100 105 110

Phe Gln Asn Arg Arg Ala Arg Trp Lys Thr Lys Gln Leu Glu Arg Asp 115 120 125

Tyr Asp Leu Leu Lys Ser Thr Tyr Asp Gln Leu Leu Ser Asn Tyr Asp 130 135 140

Ser Ile Val Met Asp Asn Asp Lys Leu Arg Ser Glu Val Thr Ser Leu 145 150 160

Thr Glu Lys Leu Gln Gly Lys Gln Glu Thr Ala Asn Glu Pro Pro Gly 165 170 175

Gln Val Pro Glu Pro Asn Gln Leu Asp Pro Val Tyr Ile Asn Ala Ala 180 185 190

Ala Ile Lys Thr Glu Asp Arg Leu Ser Ser Gly Ser Val Gly Ser Ala 195 200 205

Val Leu Asp Asp Asp Ala Pro Gln Leu Leu Asp Ser Cys Asp Ser Tyr 210 215 220

Phe Pro Ser Ile Val Pro Ile Gln Asp Asn Ser Asn Ala Ser Asp His 225 230 235 240

Asp Asn Asp Arg Ser Cys Phe Ala Asp Val Phe Val Pro Thr Thr Ser 245 250 255

Pro Ser His Asp His His Gly Glu Ser Leu Ala Phe Trp Gly Trp Pro 260 265 270

<210> 17

<211> 2545

<212> DNA

<213> Arabidopsis thaliana

<220>

MBI15 Sequence Listing.ST25

MBI15 Sequence Listing.ST25	
<221> CDS <222> (103)(2322) <223> G418	
<400> 17 acatatgttt taaattettt gtetgaatet tacaggatee gagagagaga getetgga	aac 60
gatattaaca tatatcatga agaaaaagat tgaagtattg at atg gga ata act Met Gly Ile Thr	114
aaa act tct cct aat act aca att ctc ttg aag act ttt cac aat aa Lys Thr Ser Pro Asn Thr Thr Ile Leu Leu Lys Thr Phe His Asn As 5 10 20	• •
tct atg tcc caa gat tat cat cat cat cat cat cat aat caa cac ca Ser Met Ser Gln Asp Tyr His His His His His Asn Gln His Gl 25 30	a 210 n
gga ggt atc ttc aac ttc tct aat gga ttc gac cga tca gat tct cc Gly Gly Ile Phe Asn Phe Ser Asn Gly Phe Asp Arg Ser Asp Ser Pr 40 45 50	c 258
aat tta aca act cag cag aag caa gag cat caa agg gta gag atg ga Asn Leu Thr Thr Gln Gln Lys Gln Glu His Gln Arg Val Glu Met As 55 60 65	e 306 p
gag gaa tot toa gto goo gga ggt agg att cog gto tac gaa toa go Glu Glu Ser Ser Val Ala Gly Gly Arg Ile Pro Val Tyr Glu Ser Al 70 75 80	c 354 .a
ggt atg tta tcc gaa atg ttt aat ttc ccc gga agc agc ggt gga gg Gly Met Leu Ser Glu Met Phe Asn Phe Pro Gly Ser Ser Gly Gly Gl 85 90 95	Y
aga gat ctc gac ctc ggc caa tct ttc cgg tca aat agg cag ttg ct Arg Asp Leu Asp Leu Gly Gln Ser Phe Arg Ser Asn Arg Gln Leu Le 105 110 115	t 450 eu
gag gag caa cat cag aat att ccg gct atg aat gct acg gat tca gc Glu Glu Gln His Gln Asn Ile Pro Ala Met Asn Ala Thr Asp Ser Al 120 125 130	ec 498 La
acc gcc acc gca gcc gcc atg cag tta ttc ttg atg aat cca ccg cc Thr Ala Thr Ala Ala Ala Met Gln Leu Phe Leu Met Asn Pro Pro Pro 135 140 145	ca 546 ro
ccg caa caa cca ccg tct ccg tca tcc aca act tcc cca agg agc ca Pro Gln Gln Pro Pro Ser Pro Ser Ser Thr Thr Ser Pro Arg Ser H: 150 155 160	ac 594 is
Cac aat tot toa act oft cac atg the oft coa agt coa too acc at His Asn Ser Ser Thr Leu His Met Leu Leu Pro Ser Pro Ser Thr As 165	ac 642 sn 80
aca act cac cat cag aac tac act aat cat atg tct atg cat cag c Thr Thr His His Gln Asn Tyr Thr Asn His Met Ser Met His Gln L 185 190 195	tt 690 eu
cca cat cag cat cac caa cag ata tcg acg tgg cag tct tct ccc g Pro His Gln His His Gln Gln Ile Ser Thr Trp Gln Ser Ser Pro A 200 205 210	at 738 sp
cat cat cat cat cac acc acc acc acc gag att ggg acc gtc c His His His His His His Asn Ser Gln Thr Glu Ile Gly Thr Val H 215 220 225	.10
gtg gaa aac agc gga gga cac gga gga caa ggc ttg tcc tta tct c Val Glu Asn Ser Gly Gly His Gly Gly Gln Gly Leu Ser Leu Ser L 230 235 240	etc 834 Jeu
tca tcg tct tta gag gct gca gca aaa gcg gaa gag tat aga aac a Ser Ser Ser Leu Glu Ala Ala Ala Lys Ala Glu Glu Tyr Arg Asn I 245 250 255 2	1tt 882 11e 260

							MBI	15 S	eque	nce	List	ing.	ST25			
						tct Ser										930
						gct Ala										978
						tct Ser										1026
Ala					Arg	aac Asn 315										1074
ttg Leu 325	ttg Leu	gaa Glu	gag Glu	ttt Phe	tgt Cys 330	agt Ser	gtt Val	gga Gly	aga Arg	gga Gly 335	ttt Phe	ttg Leu	aag Lys	aag Lys	aac Asn 340	1122
					Ser	aac Asn										1170
						gcc Ala										1218
						gag Glu										1266
						gac Asp 395										1314
						tct Ser										1362
						ttg Leu										1410
aga Arg	tgc Cys	ctt Leu	aaa Lys 440	gat Asp	gca Ala	gtt Val	gcg Ala	gct Ala 445	cag Gln	ctt Leu	aag Lys	cag Gln	agt Ser 450	tgc Cys	gaa Glu	1458
ctt Leu	ctt Leu	999 Gly 455	gac Asp	aaa Lys	gat Asp	gca Ala	gcg Ala 460	gga Gly	atc Ile	tct Ser	tct Ser	tcc Ser 465	ggg Gly	tta Leu	aca Thr	1506
aaa Lys	ggt Gly 470	gaa Glu	act Thr	ccg Pro	cgt Arg	ttg Leu 475	cgt Arg	ttg Leu	cta Leu	gag Glu	caa Gln 480	agt Ser	ttg Leu	cgt Arg	cag Gln	1554
caa Gln 485	cgt Arg	gcg Ala	ttt Phe	cat His	caa Gln 490	atg Met	ggt Gly	atg Met	atg Met	gaa Glu 495	caa Gln	gaa Glu	gct Ala	tgg Trp	cgg Arg 500	1602
cca Pro	caa Gln	cgc Arg	ggt Gly	ttg Leu 505	cct Pro	gaa Glu	ege Arg	tcc Ser	gtc Val 510	aat Asn	ata Ile	ctt Leu	aga Arg	gct Ala 515	tgg Trp	1650
						cac His										1698
cta Leu	ttg Leu	gct Ala 535	cga Arg	cag Gln	act Thr	ggt Gly	tta Leu 540	tcc Ser	aga Arg	aat Asn	cag Gln	gta Val 545	tca Ser	aat Asn	tgg Trp	1746
						cgt Arg			ГЛа		Met					1794

	550					555	MBI	15 Se	equer	ice l	List: 560	ing.	ST25			
tac Tyr 565	caa Gln	caa Gln	gaa Glu	tca Ser	aaa Lys 570	gaa Glu	aga Arg	gaa Glu	aga Arg	gaa Glu 575	gag Glu	gaa Glu	tta Leu	gaa Glu	gag Glu 580	1842
aac Asn	gaa Glu	gaa Glu	gat Asp	caa Gln 585	gaa Glu	aca Thr	aaa Lys	aac Asn	agc Ser 590	aac Asn	gac Asp	gac Asp	aag Lys	agc Ser 595	aca Thr	1890
aaa Lys	tcc Ser	aac Asn	aac Asn 600	aat Asn	gaa Glu	agc Ser	aac Asn	ttc Phe 605	act Thr	gcc Ala	gtt Val	cgg Arg	acc Thr 610	act Thr	tca Ser	1938
caa Gln	act Thr	cca Pro 615	acg Thr	aca Thr	acc Thr	gca Ala	cca Pro 620	gac Asp	gca Ala	tca Ser	gac Asp	gca Ala 625	gac Asp	gca Ala	gca Ala	1986
gta Val	gcg Ala 630	aca Thr	ggc Gly	cac His	cgt Arg	cta Leu 635	aga Arg	tcc Ser	aac Asn	att Ile	aat Asn 640	gct Ala	tac Tyr	gaa Glu	aac Asn	2034
gac Asp 645	gct Ala	tca Ser	tca Ser	ctt Leu	cta Leu 650	ctc Leu	cct Pro	tcc Ser	tct Ser	tat Tyr 655	tcc Ser	aac Asn	gcc Ala	gcc Ala	gct Ala 660	2082
cct Pro	gcc Ala	gct Ala	gtt Val	tct Ser 665	gac Asp	gac Asp	ttg Leu	aat Asn	tct Ser 670	cgt Arg	tac Tyr	ggt Gly	ggc Gly	tca Ser 675	gac Asp	2130
gcg Ala	ttt Phe	tcc Ser	gcc Ala 680	Val	gcc Ala	acg Thr	tgt Cys	caa Gln 685	caa Gln	agt Ser	gta Val	ggt Gly	999 Gly 690	ttc Phe	gat Asp	2178
gat Asp	gct Ala	gac Asp 695	atg Met	gat Asp	ggt Gly	gtt Val	aac Asn 700	Vai	ata Ile	agg Arg	ttt Phe	999 Gly 705	aca Thr	aac Asn	cct Pro	2226
act Thr	ggt Gly 710	Asp	gtg Val	tct Ser	ctc Leu	acg Thr 715	ctt Leu	ggt Gly	tta Leu	cgc Arg	cac His 720	Ala	gga Gly	aac Asn	atg Met	2274
cct Pro 725	Asp	aaa Lys	gac Asp	gct Ala	tct Ser 730	Phe	tgc Cys	gtt Val	aga Arg	gag Glu 735	rne	999 Gly	ggt Gly	ttt Phe	tag	2322
ttt	gctt	ttg	tcac	tcca	tt t	aatt	aatt	a at	tata	gttt	tcc	attc	tta	ctta	ttttaa	2382
ttg	aaaa	tct	attt	ttgt	ct c	ttaa	aagt	с са	aaca	atac	att	agtc	tag	ccct	cctctg	2442
ctt	ttt	ttt	tcta	tctc	gt g	aaga	gaag	a aa	acga	tacg	taa	atco	ctt	cgaa	aactaa	2502
tgt	acgt	tgt	acga	ctta	tt g	tttt	cata	a aa	aaaa	aaaa	aaa	ı				2545
<21 <21	.0> .1>	18 739														

<211> 739 <212> PRT <213> Arabidopsis thaliana

Met Gly Ile Thr Lys Thr Ser Pro Asn Thr Thr Ile Leu Leu Lys Thr 1 10 15

Phe His Asn Asn Ser Met Ser Gln Asp Tyr His His His His His 20 25 30

Asn Gln His Gln Gly Gly Ile Phe Asn Phe Ser Asn Gly Phe Asp Arg 35

Ser Asp Ser Pro Asn Leu Thr Thr Gln Gln Lys Gln Glu His Gln Arg Page 24

50

MBI15 Sequence Listing.ST25

Val Glu Met Asp Glu Glu Ser Ser Val Ala Gly Gly Arg Ile Pro Val 80

Tyr Glu Ser Ala Gly Met Leu Ser Glu Met Phe Asn Phe Pro Gly Ser 95

Ser Gly Gly Arg Asp Leu Asp Leu Gly Gln Ser Phe Arg Ser Asn 100 105 110

Arg Gln Leu Leu Glu Glu Gln His Gln Asn Ile Pro Ala Met Asn Ala 115 120 125

Thr Asp Ser Ala Thr Ala Thr Ala Ala Ala Met Gln Leu Phe Leu Met 130 135 140

Asn Pro Pro Pro Pro Gln Gln Pro Pro Ser Pro Ser Ser Thr Thr Ser 145 150 150 160

Pro Arg Ser His His Asn Ser Ser Thr Leu His Met Leu Leu Pro Ser 165 170 175

Pro Ser Thr Asn Thr Thr His His Gln Asn Tyr Thr Asn His Met Ser 180 185 190

Met His Gln Leu Pro His Gln His His Gln Gln Ile Ser Thr Trp Gln 195 200 205

Ser Ser Pro Asp His His His His His Asn Ser Gln Thr Glu Ile 210 215 220

Gly Thr Val His Val Glu Asn Ser Gly Gly His Gly Gly Gln Gly Leu 225 230 235 240

Ser Leu Ser Leu Ser Ser Leu Glu Ala Ala Ala Lys Ala Glu Glu 245 250 255

Tyr Arg Asn Ile Tyr Tyr Gly Ala Asn Ser Ser Asn Ala Ser Pro His 260 265 270

His Gln Tyr Asn Gln Phe Lys Thr Leu Leu Ala Asn Ser Ser Gln His 275 280 285

His His Gln Val Leu Asn Gln Phe Arg Ser Ser Pro Ala Ala Ser Ser 290 295 300

Ser Ser Met Ala Ala Val Asn Ile Leu Arg Asn Ser Arg Tyr Thr Thr 305 310 315 320

Ala Ala Gln Glu Leu Leu Glu Glu Phe Cys Ser Val Gly Arg Gly Phe 325 330 335

Leu Lys Lys Asn Lys Leu Gly Asn Ser Ser Asn Pro Asn Thr Cys Gly 340 345 350

- Gly Asp Gly Gly Gly Ser Ser Pro Ser Ser Ala Gly Ala Asn Lys Glu 355 360 365
- His Pro Pro Leu Ser Ala Ser Asp Arg Ile Glu His Gln Arg Arg Lys 370 375 380
- Val Lys Leu Leu Thr Met Leu Glu Glu Val Asp Arg Arg Tyr Asn His
- Tyr Cys Glu Gln Met Gln Met Val Val Asn Ser Phe Asp Ile Val Met
- Gly His Gly Ala Ala Leu Pro Tyr Thr Ala Leu Ala Gln Lys Ala Met
- Ser Arg His Phe Arg Cys Leu Lys Asp Ala Val Ala Ala Gln Leu Lys 435 440 445
- Gln Ser Cys Glu Leu Leu Gly Asp Lys Asp Ala Ala Gly Ile Ser Ser 450 455 460
- Ser Gly Leu Thr Lys Gly Glu Thr Pro Arg Leu Arg Leu Leu Glu Gln 465 470 475 480
- Ser Leu Arg Gln Gln Arg Ala Phe His Gln Met Gly Met Met Glu Gln 485 490 495
- Glu Ala Trp Arg Pro Gln Arg Gly Leu Pro Glu Arg Ser Val Asn Ile 500 505 510
- Leu Arg Ala Trp Leu Phe Glu His Phe Leu His Pro Tyr Pro Ser Asp 515 520 525
- Ala Asp Lys His Leu Leu Ala Arg Gln Thr Gly Leu Ser Arg Asn Gln 530 535 540
- Val Ser Asn Trp Phe Ile Asn Ala Arg Val Arg Leu Trp Lys Pro Met 545 550 560
- Val Glu Glu Met Tyr Gln Gln Glu Ser Lys Glu Arg Glu Arg Glu Glu 565 570 575
- Glu Leu Glu Glu Asn Glu Glu Asp Gln Glu Thr Lys Asn Ser Asn Asp 580 585
- Asp Lys Ser Thr Lys Ser Asn Asn Glu Ser Asn Phe Thr Ala Val
- Arg Thr Thr Ser Gln Thr Pro Thr Thr Thr Ala Pro Asp Ala Ser Asp 610 615 620
- Ala Asp Ala Ala Val Ala Thr Gly His Arg Leu Arg Ser Asn Ile Asn 625 635 640
- Ala Tyr Glu Asn Asp Ala Ser Ser Leu Leu Leu Pro Ser Ser Tyr Ser 645 650 655

MBI15 Sequence Listing.ST25

Asn Ala Ala Pro Ala Ala Val Ser Asp Asp Leu Asn Ser Arg Tyr
660 665 670

Gly Gly Ser Asp Ala Phe Ser Ala Val Ala Thr Cys Gln Gln Ser Val 675 680 685

Gly Gly Phe Asp Asp Ala Asp Met Asp Gly Val Asn Val Ile Arg Phe 690 695 700

Gly Thr Asn Pro Thr Gly Asp Val Ser Leu Thr Leu Gly Leu Arg His 705 710 715 720

Ala Gly Asn Met Pro Asp Lys Asp Ala Ser Phe Cys Val Arg Glu Phe 725 730 735

Gly Gly Phe

<210> 19 <211> 1240 <212> DNA <213> Arabidopsis thaliana <220> <221> CDS <222> (88)..(1020) <223> G591

gtaaatctct ctttgaaggt tcctaactcg ttaatcgtaa ctcacagtga ctcgttcgag tcaaagtcte tgtctttage tcaaace atg get agt aac aac eet eac gac aac Met Ala Ser Asn Asn Pro His Asp Asn ctt tot gad daa act oot tot gat gat tto tto gag daa ato oto ggo 162 Leu Ser Asp Gln Thr Pro Ser Asp Asp Phe Phe Glu Gln Ile Leu Gly ctt cct aac ttc tca gcc tct tct gcc gcc ggt tta tct gga gtt gac Leu Pro Asn Phe Ser Ala Ser Ser Ala Ala Gly Leu Ser Gly Val Asp 210 gga gga tta ggt ggt gga gca ccg cct atg atg ctg cag ttg ggt tcc Gly Gly Leu Gly Gly Ala Pro Pro Met Met Leu Gln Leu Gly Ser 258 gga gaa gaa gga agt cac atg ggt ggc tta gga gga agt gga cca act Gly Glu Glu Gly Ser His Met Gly Gly Leu Gly Gly Ser Gly Pro Thr 306 ggg ttt cac aat cag atg ttt cct ttg ggg tta agt ctt gat caa ggg 354 Gly Phe His Asn Gln Met Phe Pro Leu Gly Leu Ser Leu Asp Gln Gly aaa gga cct ggg ttt ctt aga cct gaa gga gga cat gga agt ggg aaa Lys Gly Pro Gly Phe Leu Arg Pro Glu Gly Gly His Gly Ser Gly Lys 90 95 100 105 402 aga ttc tca gat gat gtt gtt gat aat cga tgt tct tct atg aaa cct Arg Phe Ser Asp Asp Val Val Asp Asn Arg Cys Ser Ser Met Lys Pro 450 gtt ttc cac ggg cag cct atg caa cag cca cct cca tcg gcc cca cat Val Phe His Gly Gln Pro Met Gln Gln Pro Pro Pro Ser Ala Pro His 125 130 135 498

MBI15 Sequence Listing.ST25

Gly Gly Leu Gly Gly Ser Gly Pro Thr Gly Phe His Asn Gln Met Phe

Pro Leu Gly Leu Ser Leu Asp Gln Gly Lys Gly Pro Gly Phe Leu Arg

Pro Glu Gly Gly His Gly Ser Gly Lys Arg Phe Ser Asp Asp Val Val

Asp Asn Arg Cys Ser Ser Met Lys Pro Val Phe His Gly Gln Pro Met

Gln Gln Pro Pro Pro Ser Ala Pro His Gln Pro Thr Ser Ile Arg Pro

Arg Val Arg Ala Arg Gly Gln Ala Thr Asp Pro His Ser Ile Ala 145 150 150 160

Glu Arg Leu Arg Glu Arg Ile Ala Glu Arg Ile Arg Ala Leu Gln 165 170 175

Glu Leu Val Pro Thr Val Asn Lys Thr Asp Arg Ala Ala Met Ile Asp 180 185 190

Glu Ile Val Asp Tyr Val Lys Phe Leu Arg Leu Gln Val Lys Val Leu

Ser Met Asn Arg Leu Gly Gly Ala Gly Ala Val Ala Pro Leu Val Thr 210 215 220

Asp Met Pro Leu Ser Ser Ser Val Glu Asp Glu Thr Gly Glu Gly

Arg Thr Pro Gln Pro Ala Trp Glu Lys Trp Ser Asn Asp Gly Thr Glu 245 250 255

Arg Gln Val Ala Lys Leu Met Glu Glu Asn Val Gly Ala Ala Met Gln 260 265 270

Leu Leu Gln Ser Lys Ala Leu Cys Met Met Pro Ile Ser Leu Ala Met 275 280 285

Ala Ile Tyr His Ser Gln Pro Pro Asp Thr Ser Ser Val Val Lys Pro 295

Glu Asn Asn Pro Pro Gln 305

<210>

<211> 1179 <212> DNA

<213> Arabidopsis thaliana

<220>

<221> CDS

<222> (109)..(966)

G525

<400 cttc	> 2 tctc	1 tt c	tcaa	aaac	c ct	tccc	tctt	cgt	ctcc	aaa	caac	aaca	aa c	acaa	caaca	60
acaa	aaat	ct t	acaa	gaag	a tc	attt	ttag	aaa	ccct	att	agga	taaa	atg Met 1	gat Asp	tac Tyr	117
gag Glu	gca Ala 5	tca Ser	aga Arg	atc Ile	Val	gaa Glu 10	atg Met	gta Val	gaa Glu	Asp	gaa Glu 15	gaa Glu	cat His	ata Ile	gat Asp	165
cta Leu 20	cca Pro	cca Pro	gga Gly	ttc Phe	aga Arg 25	ttt Phe	cac His	cct Pro	Thr	gat Asp 30	gaa Glu	gaa Glu	ctc Leu	ata Ile	act Thr 35	213
cac His	tac Tyr	ctc Leu	aaa Lys	cca Pro 40	aag Lys	gtt Val	ttc Phe	aac Asn	act Thr 45	ttc Phe	ttc Phe	tct Ser	gct Ala	act Thr 50	gcc Ala	261
att Ile	ggt Gly	gaa Glu	gtt Val 55	gat Asp	ctc Leu	aac Asn	aag Lys	att Ile 60	gag Glu	cct Pro	tgg Trp	gac Asp	tta Leu 65	cca Pro	tgg Trp	309
aag Lys	gct Ala	aag Lys 70	atg Met	gga Gly	gaa Glu	aaa Lys	gaa Glu 75	tgg Trp	tat Tyr	ttc Phe	ttc Phe	tgt Cys 80	gtg Val	aga Arg	gac Asp	357
cgg Arg	aaa Lys 85	tac Tyr	ccg Pro	acc Thr	ggt Gly	tta Leu 90	agg Arg	aca Thr	aac Asn	cgg Arg	gcg Ala 95	aca Thr	gaa Glu	gcc Ala	ggt Gly	405
tat Tyr 100	tgg Trp	aaa Lys	gcc Ala	aca Thr	gga Gly 105	aaa Lys	gac Asp	aaa Lys	gag Glu	ata Ile 110	ttc Phe	aag Lys	gga Gly	aaa Lys	tca Ser 115	453
ctt Leu	gtg Val	ggt Gly	atg Met	aag Lys 120	aaa Lys	act Thr	ttg Leu	gtt Val	ttc Phe 125	tat Tyr	aaa Lys	gga Gly	aga Arg	gct Ala 130	cct Pro	501
aaa Lys	gga Gly	gtt Val	aaa Lys 135	Thr	aat Asn	tgg Trp	gtt Val	atg Met 140	cat His	gaa Glu	tat Tyr	cgt Arg	tta Leu 145	gaa Glu	ggc Gly	549
aaa Lys	tat Tyr	tgt Cys 150	att Ile	gaa Glu	aat Asn	ctt Leu	ccc Pro 155	GIn	aca Thr	gct Ala	aag Lys	aac Asn 160	gaa Glu	tgg Trp	gtt Val	597
Ile	Cys 165	Arg	gtt Val	Phe	Gln	Lys 170	Arg	Ala	Asp	GIY	175	гÀг	vai	PIQ	met	645
Ser 180	Met	Leu	gat Asp	Pro	His 185	Ile	Asn	Arg	Met	190	Pro	Ala	GIĀ	peu	195	693
Ser	Leu	Met	gat Asp	Cys 200	Ser	Gln	Arg	Asp	205	Pne	Int	GIŞ	per	210	Ser	741
His	Val	Thr	tgc Cys 215	Phe	Ser	Asp	Gln	220	Thr	GIu	Asp	ràa	225	Leu	val	789
His	Glu	230)	Asp	Gly	Phe	Gly 235	ser	Leu	Pne	ıyr	240	Asp	PIO	, ner	837
Ph∈	245	Glr	ı Asp	Asn	Tyr	Ser 250	Leu	Met	: гув	Leu	255	Leu	Авр	GIY	caa Gln	885
gaa Glu 260	Thr	caa Glr	tto Phe	tcc Sex	ggc Gly 265	. Lys	Pro	tto Phe	e Asp	ggt Gly 270	Arg	gat Asp	tcg Ser	Ser	ggt Gly 275	933

MBI15 Sequence Listing.ST25

aca gaa gaa ttg gat tgc gtt tgg aat ttc tga gttgtataag ttatgt Thr Glu Glu Leu Asp Cys Val Trp Asn Phe 280 285	tgta 986
gacttgtagt agtcatgtgt tcgtgtgtgt gaatgaatat tcttgttaca tttttt	tgta 1046
aaaaaggaga aaaaaatatg ctagaaagtc aattgctttt gttatgtagc attagt	gttt 1106
tttatgtact caatagactt cctaattaaa taaaaatctt aatttatttg ccaaaa	aaaa 1166
aaaaaaaaa aaa	1179

<210> 22

<211> 285

<212> PRT

<213> Arabidopsis thaliana

<400> 22

Met Asp Tyr Glu Ala Ser Arg Ile Val Glu Met Val Glu Asp Glu Glu 1 10 15

His Ile Asp Leu Pro Pro Gly Phe Arg Phe His Pro Thr Asp Glu Glu 25 30

Leu Ile Thr His Tyr Leu Lys Pro Lys Val Phe Asn Thr Phe Phe Ser 35 40 45

Ala Thr Ala Ile Gly Glu Val Asp Leu Asn Lys Ile Glu Pro Trp Asp 50 55 60

Leu Pro Trp Lys Ala Lys Met Gly Glu Lys Glu Trp Tyr Phe Phe Cys 65 70 80

Val Arg Asp Arg Lys Tyr Pro Thr Gly Leu Arg Thr Asn Arg Ala Thr 85 90 95

Glu Ala Gly Tyr Trp Lys Ala Thr Gly Lys Asp Lys Glu Ile Phe Lys 100 105 110

Gly Lys Ser Leu Val Gly Met Lys Lys Thr Leu Val Phe Tyr Lys Gly

Arg Ala Pro Lys Gly Val Lys Thr Asn Trp Val Met His Glu Tyr Arg 130 135 140

Leu Glu Gly Lys Tyr Cys Ile Glu Asn Leu Pro Gln Thr Ala Lys Asn 145 150 150 160

Glu Trp Val Ile Cys Arg Val Phe Gln Lys Arg Ala Asp Gly Thr Lys 165 170 175

Val Pro Met Ser Met Leu Asp Pro His Ile Asn Arg Met Glu Pro Ala 180 185 190

Gly Leu Pro Ser Leu Met Asp Cys Ser Gln Arg Asp Ser Phe Thr Gly 195 200 205

Ser Ser Ser His Val Thr Cys Phe Ser Asp Gln Glu Thr Glu Asp Lys 210 215 220

Arg Leu Val His 225	Glu Ser Lys 2 230		ly Ser Leu Phe Tyr 35	Ser 240
Asp Pro Leu Phe	Leu Gln Asp 2 245	Asn Tyr Ser Le 250	eu Met Lys Leu Leu 255	Leu
Asp Gly Gln Glu 260	Thr Gln Phe	Ser Gly Lys Pr 265	ro Phe Asp Gly Arg 270	Asp
Ser Ser Gly Thr 275		Asp Cys Val Ti 280	rp Asn Phe 285	
<210> 23 <211> 890 <212> DNA <213> Arabidop	sis thaliana			
<220> <221> CDS <222> (55)(7 <223> G545	38)			
<400> 23 gcaaccttca aact	aaaact cgagag	gacaa gaaatcct	ca gaatctttaa ctta	atg 57 Met 1
gcg ctc gag gct Ala Leu Glu Ala 5	ctt aca tca Leu Thr Ser	cca aga tta g Pro Arg Leu A 10	ct tct ccg att cct la Ser Pro Ile Pro 15	cct 105 Pro
ttg ttc gaa gat Leu Phe Glu Asp 20	tct tca gtc Ser Ser Val	ttc cat gga g Phe His Gly V 25	tc gag cac tgg aca al Glu His Trp Thr 30	aag 153 Lys
ggt aag cga tct Gly Lys Arg Ser 35	aag aga tca Lys Arg Ser 40	aga tcc gat t Arg Ser Asp P	tc cac cac caa aac he His His Gln Asn 45	ctc 201 Leu
act gag gaa gag Thr Glu Glu Glu 50	tat cta gct Tyr Leu Ala 55	Phe Cys Leu M	tg ctt ctc gct cgc let Leu Leu Ala Arg 0	gac 249 Asp 65
aac cgt cag cct Asn Arg Gln Pro	cct cct cct Pro Pro Pro 70	ccg gcg gtg g Pro Ala Val G 75	ag aag ttg agc tac lu Lys Leu Ser Tyr 80	aag 297 Lys
tgt agc gtc tgc Cys Ser Val Cys 85	gac aag acg Asp Lys Thr	ttc tct tct t Phe Ser Ser T 90	ac caa gct ctc ggt yr Gln Ala Leu Gly 95	ggt 345 Gly
cac aag gca ago His Lys Ala Ser 100	cac cgt aag His Arg Lys	aac tta tca c Asn Leu Ser 6 105	ag act ctc tcc ggc ln Thr Leu Ser Gly 110	gga 393 Gly
gga gat gat cat Gly Asp Asp His 115	tca acc tcg Ser Thr Ser 120	Ser Ala Thr T	ncc aca tcc gcc gtg Thr Thr Ser Ala Val 125	act 441 Thr
act gga agt ggg Thr Gly Ser Gly 130	y aaa tca cac y Lys Ser His 135	Val Cys Thr	atc tgt aac aag tct Ne Cys Asn Lys Ser 140	ttt 489 Phe 145
cct tcc ggt car Pro Ser Gly Glr	gct ctc ggc Ala Leu Gly 150	gga cac aag o Gly His Lys A 155	egg tge cac tac gaa Arg Cys His Tyr Glu 160	GIA
aac aac aac at	; aac act agt		aac tee gaa ggt geg ge 32	ggg 585

Asn	Asn	Asn	Ile 165	Asn	Thr	Ser		15 S Val 170						Ala	Gly	
														aac Asn		633
cct Pro	ccg Pro 195	atc Ile	cct Pro	gaa Glu	ttc Phe	tcg Ser 200	atg Met	gtc Val	aac Asn	gga Gly	gac Asp 205	gac Asp	gaa Glu	gtc Val	atg Met	681
														aaa Lys		729
	ctt Leu	taa	ggaa	aatti	tac 1	taga	acgat	ca ag	gatti	cgt	tg!	ata	ctgt			778
tga	gagti	tgt (gtagg	gaati	tt gl	tgad	etgta	a cat	acca	aaat	tgga	actt	tga 'd	ctgai	ttccaa	838
ttc	ttcti	tgt 1	ctti	cat	tt ta	aaaa	ttal	taa	acc	gatt	ctt	acca	aca a	aa		890
<210 <210 <210 <210	1> 2 2> 1	24 227 PRT Arab	idops	sis (thal:	iana										
<400	0 > :	24														
Met 1	Ala	Leu	Glu	Ala 5	Leu	Thr	Ser	Pro	Arg 10	Leu	Ala	Ser	Pro	Ile 15	Pro	
Pro	Leu	Phe	Glu 20	Asp	Ser	Ser	Val	Phe 25	His	Gly	Val	Glu	His 30	Trp	Thr	
Lys	Gly	Lys 35	Arg	Ser	Lys	Arg	Ser 40	Arg	Ser	Asp	Phe	His 45	His	Gln	Asn	
Leu	Thr 50	Glu	Glu	Glu	Tyr	Leu 55	Ala	Phe	Сув	Leu	Met 60	Leu	Leu	Ala	Arg	•
Авр 65	Asn	Arg	Gln	Pro	Pro 70	Pro	Pro	Pro	Ala	Val 75	Glu	Lys	Leu	Ser	Tyr 80	
Lys	Сув	Ser	Val	Cys 85	Asp	Lys	Thr	Phe	Ser 90	Ser	Tyr	Gln	Ala	Leu 95	Gly	
Gly	His	Lys	Ala 100	Ser	His	Arg	Lys	Asn 105	Leu	Ser	Gln	Thr	Leu 110	Ser	Gly .	
Gly	Gly	Asp 115	Asp	His	Ser	Thr	Ser 120	Ser	Ala	Thr	Thr	Thr 125	Ser	Ala	Val	
Thr	Thr 130	Gly	Ser	Gly	Lys	Ser 135	His	Val.	Cys	Thr	Ile 140	Сув	Asn	Lys	Ser	
Phe 145	Pro	Ser	Gly	Gln	Ala 150	Leu	Gly	Gly	His	Lys 155	Arg	Сув	His	Tyr	Glu 160	
Gly	Asn	Asn	Asn	Ile 165	Asn	Thr	Ser	Ser	Val 170	Ser	Asn	Ser	Glu	Gly 175	Ala	

MBI15 Sequence Listing.ST25 Gly Ser Thr Ser His Val Ser Ser Ser His Arg Gly Phe Asp Leu Asn 185 Ile Pro Pro Ile Pro Glu Phe Ser Met Val Asn Gly Asp Asp Glu Val Met Ser Pro Met Pro Ala Lys Lys Pro Arg Phe Asp Phe Pro Val Lys Leu Gln Leu 225 <210> 25 <211> 1126 <212> DNA <213> Arabidopsis thaliana <220> <221> CDS (282) . . (920) <222> G865 <223> <400> 25 60 atccccactt gttgttcatc accaagccaa gctccatgtc ctagtcactc cacagattcc ctatcatcat caattcgttt caaacttagt tcctttcaaa gtcttgtaca tatatacaca 120 cacacctatt attetettgg tgtgtttgtg tgttacatat acgtgtgagt acatactttg 180 ttgtaaaagt ggatcggagg tatggaaagg gaccggttcc accggaaaca tcggcggcgg 240 cggatgataa ttcgtcttgg aacgagactg atgtcaccgc c atg gtc tcc gct ctc Met Val Ser Ala Leu 296 ago ogt gto ata gag aat oog aca gao oog gto aaa caa gag ott Ser Arg Val Ile Glu Asn Pro Thr Asp Pro Pro Val Lys Gln Glu Leu 344 gat aaa tcg gat caa cat caa cca gac caa gat caa cca aga aga aga Asp Lys Ser Asp Gln His Gln Pro Asp Gln Asp Gln Pro Arg Arg Arg 392 cac tat aga ggc gta agg cag aga cca tgg ggt aaa tgg gcg gca gaa His Tyr Arg Gly Val Arg Gln Arg Pro Trp Gly Lys Trp Ala Ala Glu 440 atc cgc gat cca aag aaa gca gcc cgt gtc tgg ctc ggg act ttc gag Ile Arg Asp Pro Lys Lys Ala Ala Arg Val Trp Leu Gly Thr Phe Glu 488 acg gca gag gaa gct gct tta gcc tat gac cga gct gcc ctc aaa ttc Thr Ala Glu Glu Ala Ala Leu Ala Tyr Asp Arg Ala Ala Leu Lys Phe 536 aaa ggc acc aag gct aaa ctg aac ttc cct gaa cgg gtc caa ggc cct Lys Gly Thr Lys Ala Lys Leu Asn Phe Pro Glu Arg Val Gln Gly Pro 584 95 act acc acc aca acc att tct cat gca cca aga gga gtt agt gaa tcc Thr Thr Thr Thr Thr Ile Ser His Ala Pro Arg Gly Val Ser Glu Ser 632 110 atg aac tca cct cct cct cga cct ggt cca cct tca act act act Met Asn Ser Pro Pro Pro Arg Pro Gly Pro Pro Ser Thr Thr Thr 680

Page 34

145

728

tcg tgg cca atg act tat aac cag gac ata ctt caa tac gct cag ttg Ser Trp Pro Met Thr Tyr Asn Gln Asp Ile Leu Gln Tyr Ala Gln Leu

140

MRT15	Sequence	Ligting	CT25
MDIID	Seduence	DISCING.	. 5125

														act Thr		776
														tcc Ser 180		824
														gaa Glu		872
												cca Pro 210		gaa Glu	taa	920
tcta	atta	att a	ittgi	tggt	c ga	atca	gttt	tat	aaat	agc	tato	atag	gtt 1	catt	tttgg	980
ttt	cgta	aac d	ettt	gttgo	a to	ggaaa	atat	ga a	itgaa	ıcga	9998	cate	gtg 1	taaca	atttg	1040
ttt	gtgtt	tc g	gtaaa	atgtt	a gt	tgta	tttg	g gat	ttg	etga	agtt	tgat	tt 1	ctga	igcata	1100
aato	catt	ga d	ggto	caaaa	aa aa	aaaa	ı									1126

<210> 26

<211> 212

<212> PRT

<213> Arabidopsis thaliana

<400> 26

Met Val Ser Ala Leu Ser Arg Val Ile Glu Asn Pro Thr Asp Pro Pro 1 5 10 15

Val Lys Gln Glu Leu Asp Lys Ser Asp Gln His Gln Pro Asp Gln Asp 20 25 30

Gln Pro Arg Arg Arg His Tyr Arg Gly Val Arg Gln Arg Pro Trp Gly 35 40 45

Lys Trp Ala Ala Glu Ile Arg Asp Pro Lys Lys Ala Ala Arg Val Trp 50 55 60

Leu Gly Thr Phe Glu Thr Ala Glu Glu Ala Ala Leu Ala Tyr Asp Arg 65 70 75 80

Ala Ala Leu Lys Phe Lys Gly Thr Lys Ala Lys Leu Asn Phe Pro Glu 85 90 95

Arg Val Gln Gly Pro Thr Thr Thr Thr Thr Ile Ser His Ala Pro Arg

Gly Val Ser Glu Ser Met Asn Ser Pro Pro Pro Arg Pro Gly Pro Pro 115 120 125

Ser Thr Thr Thr Ser Trp Pro Met Thr Tyr Asn Gln Asp Ile Leu

Gln Tyr Ala Gln Leu Leu Thr Ser Asn Asn Glu Val Asp Leu Ser Tyr

Tyr Thr Ser Thr Leu Phe Ser Gln Pro Phe Ser Thr Pro Ser Ser Ser 165 170 175

Ser Ser Ser Gln Gln Thr Gln Gln Gln Gln Leu Gln Gln Gln Gln Gln 180 185 190

Gln Gln Arg Glu Glu Glu Lys Asn Tyr Gly Tyr Asn Tyr Tyr Asn 195 200 205

Tyr Pro Arg Glu 210

<210> 27 <211> 1152 <212> DNA <213> Arabidopsis thaliana <220> <221> CDS <222> (76)..(1008) <223> G881

<400> 27 gtgaccgaag aaagcaaatt gagactacgc accaactagt cctttggttt gtatcttaag 60 ataaaggttt ctttt atg gac ggt tct tcg ttt ctc gac atc tct ctc gat
Met Asp Gly Ser Ser Phe Leu Asp Ile Ser Leu Asp 111 ctc aac acc aat cct ttc tcc gca aaa ctt ccg aag aag gag gtc tca Leu Asn Thr Asn Pro Phe Ser Ala Lys Leu Pro Lys Lys Glu Val Ser 159 gtt ttg gct tct act cac tta aag agg aaa tgg ttg gag caa gac gag Val Leu Ala Ser Thr His Leu Lys Arg Lys Trp Leu Glu Gln Asp Glu 207 35 agc gca agt gag tta cga gag gag cta aac aga gtt aat tca gag aac Ser Ala Ser Glu Leu Arg Glu Glu Leu Asn Arg Val Asn Ser Glu Asn 255 303 aag aag cta aca gag atg tta gct aga gtc tgt gag agc tac aac gaa Lys Lys Leu Thr Glu Met Leu Ala Arg Val Cys Glu Ser Tyr Asn Glu 65 70 75 cta cat aat cat ttg gag aag ctt cag agt cgc cag agc cct gaa atc Leu His Asn His Leu Glu Lys Leu Gln Ser Arg Gln Ser Pro Glu Ile gag cag acc gat ata ccg ata aag aaa aga aaa caa gac ccg gat gag Glu Gln Thr Asp Ile Pro Ile Lys Lys Arg Lys Gln Asp Pro Asp Glu ttc tta ggc ttt cct att gga ctc agt agt gga aaa act gag aac agc Phe Leu Gly Phe Pro Ile Gly Leu Ser Ser Gly Lys Thr Glu Asn Ser 110 115 120 tcc agc aac gaa gat cat cat cat cat cat cag caa cat gag cag aaa Ser Ser Asn Glu Asp His His His His Gln Gln His Glu Gln Lys 495 aat cag ctt ctt tca tgt aaa aga cca gtc act gat agc ttc aac aaa Asn Gln Leu Ser Cys Lys Arg Pro Val Thr Asp Ser Phe Asn Lys 543 gca aaa gtt tcg act gtc tac gtg cct act gaa aca tcg gac aca agc Ala Lys Val Ser Thr Val Tyr Val Pro Thr Glu Thr Ser Asp Thr Ser 591 ttg aca gtt aaa gat gga ttt caa tgg agg aaa tac gga caa aag gtt Leu Thr Val Lys Asp Gly Phe Gln Trp Arg Lys Tyr Gly Gln Lys Val 175 180 185 639

aca aga gac aac ccg tca cct aga gct tac ttt aga tgc tcg ttt gca Thr Arg Asp Asn Pro Ser Pro Arg Ala Tyr Phe Arg Cys Ser Phe Ala 190 195 200	687
ccgtcttgtccagtaaaaaaggtacaacgcagcgcagaggatccaProSerCysProValLysLysLysValGlnArgSerAlaGluAspPro205210215220	735
tct tta ctt gta gcg aca tac gaa ggg acg cat aac cac ttg ggt cca Ser Leu Leu Val Ala Thr Tyr Glu Gly Thr His Asn His Leu Gly Pro 225 230 235	783
Asn Ala Ser Glu Gly Asp Ala Thr Ser Gln Gly Gly Ser Ser Thr Val 240 245 250	831
act ttg gat ctg gtt aat ggc tgt cat aga cta gcg ttg gag aaa aac Thr Leu Asp Leu Val Asn Gly Cys His Arg Leu Ala Leu Glu Lys Asn 255 260 265	879
gaa agg gat aat acg atg caa gag gtt ctg att caa caa atg gcg tca Glu Arg Asp Asn Thr Met Gln Glu Val Leu Ile Gln Gln Met Ala Ser 270 275 280	927
tcg tta aca aaa gat tcg aaa ttt aca gct gct ctt gct gct gct ata Ser Leu Thr Lys Asp Ser Lys Phe Thr Ala Ala Leu Ala Ala Ala Ile 285 290 295 300	975
tct ggg agg tta atg gag caa tct aga aca tga acgtttttag tgaatgtatt Ser Gly Arg Leu Met Glu Gln Ser Arg Thr 305 310	1028
gtttttgttt gtttagaatg attcttcgtt ttcgaattgt gtctttcgat taggagataa	1088
aagatgtata taaatattat aagtagatga agaaatcgta taagtaaaaa aaaaaaaaaa	1148
aaaa	1152

<210> 28

<211> 310

<212> PRT

<213> Arabidopsis thaliana

<400> 28

Met Asp Gly Ser Ser Phe Leu Asp Ile Ser Leu Asp Leu Asn Thr Asn 1 5 10 15

Pro Phe Ser Ala Lys Leu Pro Lys Lys Glu Val Ser Val Leu Ala Ser $20 \hspace{1cm} 25 \hspace{1cm} 30 \hspace{1cm}$

Thr His Leu Lys Arg Lys Trp Leu Glu Gln Asp Glu Ser Ala Ser Glu 35 40 45

Leu Arg Glu Glu Leu Asn Arg Val Asn Ser Glu Asn Lys Lys Leu Thr 50 55 60

Glu Met Leu Ala Arg Val Cys Glu Ser Tyr Asn Glu Leu His Asn His 65 70 75 80

Leu Glu Lys Leu Gln Ser Arg Gln Ser Pro Glu Ile Glu Gln Thr Asp $85 \hspace{1cm} 90 \hspace{1cm} 95$

Ile Pro Ile Lys Lys Arg Lys Gln Asp Pro Asp Glu Phe Leu Gly Phe 100 105 110

ro	Ile	Gly 115	Leu	Ser	Ser	Gly	MBI: Lys 120	15 Se Thr	equer Glu	ce l Asn	Listi Ser	ing.S Ser 125	ST25 Ser	Asn	Glu	
	His 130	His	ніз	His	His	Gln 135	Gln	His	Glu	Gln	Lys 140	Asn	Gln	Leu	Leu	
Ser 145	Сув	Lys	Arg	Pro	Val 150	Thr	qaA	Ser	Phe	Asn 155	Lys	Ala	Ъуs	Val	Ser 160	
Thr	Val	туг	Val	Pro 165	Thr	Glu	Thr	Ser	Asp 170	Thr	Ser	Leu	Thr	Val 175	Lys	,
Asp	Gly	Phe	Gln 180	Trp	Arg	Lys	Tyr	Gly 185	Gln	Lys	Val	Thr	Arg 190	Asp	Asn	
Pro	Ser	Pro 195		Ala	Tyr	Phe	Arg 200	Суз	Ser	Phe	Ala	Pro 205	Ser	Сув	Pro	
Val	Lys 210		Lys	Val	Gln	Arg 215	Ser	Ala	Glu	Asp	Pro 220	Ser	Leu	Leu	Val	
Ala 225	Thr	Tyr	Glu	Gly	Thr 230	His	Asn	His	Leu	Gly 235	Pro	Asn	Ala	Ser	Glu 240	
				245					250					233		
			260)				265	i				270		Asn	
		275	;				280)				285			. FAs	
Asp	Ser 290		Ph∈	Thr	: Ala	Ala 295		ı Ala	a Ala	Ala	11€ 300	Ser	Gly	Arg	, Leu	
Met 305		Gl:	ı Sei	r Arg	Thr 310	<u>.</u>										
<21 <21 <21 <21	.1> .2>	29 1270 DNA Aral		psis	thal	Liana	ı									
<22 <22 <22 <22	21>	CDS (47 G89		1150)		,									
<40 taa	00> atcc	29 gatt	cgt	cttca	atc 1	tgati	ccc	tc c	cttc	cgag	a at	aata	atg Met 1	tac Tyr	ccg Pro	55
CC: Pro	a cc o Pr 5	t cc o Pr	c tc o Se	a ag r Se	c at	c ta e Ty 10	r Al	t cc a Pr	t cc	g at o Me	g ct t Le 15	u va	g aat 1 Ast	t tg n Cy	c tcc s Ser	103
99 G1: 20	у Су	s Ar	g ac g Th	g cc r Pr	t ct o Le 25	n GI	g ct n Le	c cc u Pr	a to o Se	30	y AI	c cg a Ar	a tc g Se	t at r Il	t cgc e Arg 35	151
										Page	38					

									-4			9.				
					gct Ala											199
					tcc Ser											247
					ctg Leu											295
					tat Tyr											343
					tgc Cys 105											391
					att Ile											439
					aag Lys											487
gta Val	cag Gln	gga Gly 150	tgc Cys	aca Thr	gca Ala	ggc Gly	gac Asp 155	tca Ser	ctt Leu	gtc Val	ttc Phe	cac His 160	tac Tyr	tct Ser	ggt Gly	535
					aga Arg											583
					cct Pro 185											631
gac Asp	gat Asp	gag Glu	atc Ile	aac Asn 200	gca Ala	acc Thr	att Ile	gta Val	cgc Arg 205	cct Pro	ctt Leu	cca Pro	cat His	ggt Gly 210	gtc Val	679
aag Lys	ctc Leu	cat His	tca Ser 215	att Ile	atc	gat Asp	gct Ala	tgc Cys 220	cat His	agt Ser	ggt Gly	acc Thr	gtt Val 225	ctg Leu	gat. Asp	727
					aga Arg											775
					tca Ser											823
gcc Ala 260	att Ile	tca Ser	att Ile	agt Ser	gga Gly 265	tgt Cys	gat Asp	gat Asp	gat Asp	cag Gln 270	act Thr	tcg Ser	gcc Ala	gac Asp	aca Thr 275	871
tca Ser	gcg Ala	ctg Leu	tcg Ser	aag Lys 280	atc Ile	acg Thr	tct Ser	acg Thr	ggt Gly 285	gct Ala	atg Met	act Thr	ttc Phe	tgt Cys 290	ttt Phe	919
att Ile	caa Gln	gca Ala	att Ile 295	gaa Glu	cgc Arg	agc Ser	gca Ala	caa Gln 300	ggc Gly	aca Thr	acc Thr	tat Tyr	gga Gly 305	agc Ser	ctt Leu	967
					acc Thr											1015
					gtg Val				Leu		Met				999 Gly	1063

	325				;	330	MBI 1	.5 Se	quen		isti 335	ng.S	T25		
gga Gly 340	agt Ser	gcg Ala	att (Gly (gga Gly 345	tta . Leu .	aga Arg	cag Gln	GIU	cct Pro 350	caa Gln	ctg Leu	act of	ura .	tgc Cys 355
caa Gln	aca Thr	ttc Phe	gat Asp	gtc Val 360	tat Tyr	gca Ala	aag Lys	Pro	ttc Phe 365	act Thr	ctc Leu	tag	taaa	ggaca	aa
gtca	acttt	tt a	tgta	tagc	g ag	tgtg	attt	gag	aatc	cgt	ccat	ataa	сс а	cctt	ttgtt
tct	attt	tt a	tttt	tctt	t ca	aaag	aata	aag	gaaa	aca	ttga	tttg	gt g	atto	9
<21 <21 <21 <21	l> 3 2> I	00 867 PRT Arabi	.dops	is t	hali	.ana									
<40		30												_	
Met 1	Tyr	Pro	Pro	Pro 5	Pro	Ser	Ser	Ile	Tyr 10	Ala	Pro	Pro	Met	Leu 15	vai
Asn	Cys	Ser	Gly 20	Сув	Arg	Thr	Pro	Leu 25	Gln	Leu	Pro	Ser	Gly 30	Ala	Arg
Ser	Ile	Arg 35	Суз	Ala	Leu	Сув	Gln 40	Ala	Val	Thr	His	Ile 45	Ala	Asp	Pro
Arg	Thr 50	Ala	Pro	Pro	Pro	Gln 55	Pro	Ser	Ser	Ala	Pro 60	Ser	Pro	Pro	Pro
Gln 65	Ile	His	Ala	Pro	Pro 70	Gly	Gln	Leu	Pro	His 75	Pro	His	Gly	Arg	Lys 80
Arg	Ala	Val	Ile	Cys 85	Gly	Ile	Ser	Tyr	Arg 90	Phe	Ser	Arg	His	Glu 95	Leu
Lys	Gly	Cys	Ile 100	Asn	Asp	Ala	Lys	Суs 105	Met	Arg	Нів	Leu	Leu 110	Ile	Asn
Lys	Phe	Lys 115	Phe	Ser	Pro	Asp	Ser 120	Ile	Leu	Met	Leu	Thr 125	Glu	Glu	Glu
Thi	Asp 130	Pro	Tyr	Arg	Ile	Pro 135	Thr	Lys	Gln	Asn	Met 140	Arg	Met	Ala	Leu
Ty:		Leu	Val	Gln	Gly 150	Сув	Thr	Ala	Gly	Asp 155	Ser	Leu	Val	Phe	His 160
Ту	r Sez	: Gly	His	Gly 165	Ser	Arg	Gln	Arg	Asn 170	Tyr	Asn	Gly	Asp	Glu 175	Val
As	p Gly	у Туг	Asp 180	Glu	Thr	Leu	Сує	Pro 185	Leu	Авр	Phe	Glu	Thr 190	Gln	Gly
Ме	t Ile	e Val		Asp	Glu	ılle	200	n Ala	Thr	: Ile	val	Arg 205	Pro	Leu	Pro
ні	s Gl	y, Val	L Lys	Lev	Hia	Ser	: 11	e Ile		Ala Page		B His	Ser	Gly	Thr

Val Leu Asp Leu Pro Phe Leu Cys Arg Met Asn Arg Ala Gly Gln Tyr 230 235

Val Trp Glu Asp His Arg Pro Arg Ser Gly Leu Trp Lys Gly Thr Ala

Gly Gly Glu Ala Ile Ser Ile Ser Gly Cys Asp Asp Asp Gln Thr Ser 260 265 270

Ala Asp Thr Ser Ala Leu Ser Lys Ile Thr Ser Thr Gly Ala Met Thr

Phe Cys Phe Ile Gln Ala Ile Glu Arg Ser Ala Gln Gly Thr Thr Tyr

Gly Ser Leu Leu Asn Ser Met Arg Thr Thr Ile Arg Asn Thr Gly Asn

Asp Gly Gly Ser Gly Gly Val Val Thr Thr Val Leu Ser Met Leu

Leu Thr Gly Gly Ser Ala Ile Gly Gly Leu Arg Gln Glu Pro Gln Leu 340 345 350

Thr Ala Cys Gln Thr Phe Asp Val Tyr Ala Lys Pro Phe Thr Leu 355 360 365

<210> 31 <211> 726

<212> DNA

Arabidopsis thaliana <213>

<220>

<221>

<222> (1)..(726)

<400> 31

atg gcc tcg tca tca tca tca tct tat aga ttc caa tct ggg tct tac Met Ala Ser Ser Ser Ser Ser Tyr Arg Phe Gln Ser Gly Ser Tyr

cct ctt tcg tca agt cct tct ctt ggg aat ttc gtc gaa cgc att aaa Pro Leu Ser Ser Pro Ser Leu Gly Asn Phe Val Glu Arg Ile Lys 20 25 30

gac gct tgt cat ttc ctt gtc tct gct gtt ttg ggt acc att atc tcc Asp Ala Cys His Phe Leu Val Ser Ala Val Leu Gly Thr Ile Ile Ser 144

gcg atc ttg acc ttc ttc ttc gca cta gtg ggc aca ttg cta ggg gca Ala Ile Leu Thr Phe Phe Phe Ala Leu Val Gly Thr Leu Leu Gly Ala 192 55

ctt aca gga gct ttg ata ggt caa gaa act gag agt ggt ttc att aga Leu Thr Gly Ala Leu Ile Gly Gln Glu Thr Glu Ser Gly Phe Ile Arg 240

gga gca gca att gga gcc att tcg gga gct gtt ttc tct atc gag gtc Gly Ala Ala Ile Gly Ala Ile Ser Gly Ala Val Phe Ser Ile Glu Val 288

														_			
tt he	gaa Glu	tca Ser	tct Ser 100	ctg Leu	gat Asp	ctc Leu	tgg Trp	aaa	equer tcc Ser	qat	qaq	tca	qqt	ttc Phe	gga Gly	336	5
gt Cys	ttt Phe	ctc Leu 115	tac Tyr	ttg Leu	att Ile	gat Asp	gtc Val 120	att Ile	gtt Val	agt Ser	ctt Leu	cta Leu 125	agc Ser	999 Gly	aga Arg	384	1
ctt Leu	gta Val 130	cga Arg	gag Glu	cgc Arg	att Ile	ggt Gly 135	cct Pro	gca Ala	atg Met	cta Leu	agt Ser 140	gca Ala	gtg Val	caa Gln	agt Ser	43:	2
caa 31n 145	atg Met	gga Gly	gct Ala	gtg Val	gat Asp 150	aca Thr	gct Ala	ttt Phe	gat Asp	gat Asp 155	cac His	aca Thr	agc Ser	ctt Leu	ttt Phe 160	48	D
gat Asp	aca Thr	gga Gly	ggc Gly	tca Ser 165	aaa Lys	gga Gly	ttg Leu	aca Thr	gga Gly 170	gac Asp	ctt Leu	gtt Val	gag Glu	aaa Lys 175	atc Ile	52	В
cca Pro	aag Lys	atg Met	aca Thr 180	atc Ile	act Thr	ggc Gly	aac Asn	aat Asn 185	aac Asn	act Thr	gat Asp	gct Ala	tct Ser 190	gag Glu	aac Asn	57	6
Thr	Āsp	Ser 195	tgt Cys	Ser	Val	Сув	Leu 200	Gln	Asp	Phe	GIn	Leu 205	GIÀ	GIU	THE	62	
Val	Arg 210	Ser	ttg Leu	Pro	His	Cys 215	His	His	Met	Phe	11S 220	rea	PTO	cys	He	67	2
gac Asp 225	aat Asn	tgg Trp	ctc Leu	ctt Leu	aga Arg 230	cac His	ggt Gly	tct Ser	tgc Cys	ccg Pro 235	atg Met	tgt Cys	aga Arg	cgt Arg	gat Asp 240	72	
att Ile	taa		ſ													72	6
<21 <21 <21 <21	1 > 2 >	32 241 PRT Arab	idop	sis	thal	iana											
<40	0>	32										•					
Met 1	Ala	Ser	Ser	Ser 5	Ser	Ser	Ser	Tyr	Arg 10	Phe	Gln	Ser	Gly	Ser 15	Tyr		
Pro	Leu	Ser	Ser 20	Ser	Pro	Ser	Leu	Gly 25	Asn	Phe	Val	Glu	Arg 30	Ile	Lys		
Asp	Ala	Сув 35	His	Phe	Leu	Val	Ser 40	Ala	Val	Leu	Gly	Thr 45	Ile	Ile	Ser		
Ala	Ile 50	Leu	Thr	Phe	Phe	Phe 55	Ala	Leu	Val	Gly	Thr 60	Leu	Leu	Gly	Ala		
Leu 65	Thr	Gly	Ala	Leu	Ile 70	Gly	Gln	Glu	Thr	Glu 75	Ser	Gly	Phe	Ile	Arg 80		
Gly	Ala	Ala	Ile	Gly 85	Ala	Ile	. Ser	Gly	Ala 90	Val	Phe	Ser	: Ile	95	val		
Phe	Glu	Ser	Ser 100		Asp	Leu	Trp	Lys 105	Ser	Asp	Glu	. Ser	Gly	Phe	Gly		

MBI15 Sequence Listing.ST25

Cys Phe Leu Tyr Leu Ile Asp Val Ile Val Ser Leu Leu Ser Gly Arg

Leu Val Arg Glu Arg Ile Gly Pro Ala Met Leu Ser Ala Val Gln Ser 130 135 140

Gln Met Gly Ala Val Asp Thr Ala Phe Asp Asp His Thr Ser Leu Phe 145 150 155 160

Asp Thr Gly Gly Ser Lys Gly Leu Thr Gly Asp Leu Val Glu Lys Ile 165 170 175

Pro Lys Met Thr Ile Thr Gly Asn Asn Asn Thr Asp Ala Ser Glu Asn 180 185 190

Thr Asp Ser Cys Ser Val Cys Leu Gln Asp Phe Gln Leu Gly Glu Thr
195 200 205

Val Arg Ser Leu Pro His Cys His His Met Phe His Leu Pro Cys Ile 210 215 220

Asp Asn Trp Leu Leu Arg His Gly Ser Cys Pro Met Cys Arg Arg Asp 225 230 235 240

Ile

<210> 33

<211> 1370

<212> DNA <213> Arabidopsis thaliana

<220>

<221> CDS

<222> (184)..(969)

<223> G569

<400> 33

gtcgacccac gcgtccgggt ttttctttta tcctcttatc gctaatctgg agctctatat 60 120 agactataaa gggtttttga ttgattcggg agctcgagat ttgacttctt ttagctgatt cggcaagttt gtatctagaa aggatcgatt ggtgaggtca atagtggttg gtgggtttta 180 gta atg gaa gac ggt gag ctt gat ttc tcc aat cag gaa gtg ttt tcg Met Glu Asp Gly Glu Leu Asp Phe Ser Asn Gln Glu Val Phe Ser 228 agt tcg gag atg ggt gaa tta cca cct agc aat tgt tcg atg gat agt Ser Ser Glu Met Gly Glu Leu Pro Pro Ser Asn Cys Ser Met Asp Ser 276 ttc ttt gat ggg ctt tta atg gat act aat gct gct tgt acc cac act Phe Phe Asp Gly Leu Leu Met Asp Thr Asn Ala Ala Cys Thr His Thr 324 cac acc tgt aac ccc act gga cca gag aac act cat act cac acg tgc His Thr Cys Asn Pro Thr Gly Pro Glu Asn Thr His Thr His Thr Cys 372 ttc cat gtc cac acc aag att ctc ccg gat gag agc gat gaa aaa gtt Phe His Val His Thr Lys Ile Leu Pro Asp Glu Ser Asp Glu Lys Val 420

MBI15 Sequence Listing.ST25	
tct act gat gat aca gct gag tct tgt ggg aag aag ggt gaa aag ag Ser Thr Asp Asp Thr Ala Glu Ser Cys Gly Lys Lys Gly Glu Lys Ax 80 85 90 95	:g
cct ttg gga aac cgg gaa gcg gtt aga aag tat aga gag aag aag aa Pro Leu Gly Asn Arg Glu Ala Val Arg Lys Tyr Arg Glu Lys Lys Ly 100 105 110	ng 516 /s
gct aaa gct gct tct ttg gag gat gag gtt gca agg ctt agg gcg gt Ala Lys Ala Ala Ser Leu Glu Asp Glu Val Ala Arg Leu Arg Ala Va 115 120 125	g 564 al
aat cag cag ctg gtg aag agg ttg caa aat cag gct acc ttg gaa gc Asn Gln Gln Leu Val Lys Arg Leu Gln Asn Gln Ala Thr Leu Glu Al 130 135 140	et 612 la
gag gtt tcg agg ctt aag tgt ttg ctt gtg gat ttg aga gga aga at Glu Val Ser Arg Leu Lys Cys Leu Leu Val Asp Leu Arg Gly Arg II 145 150 155	ca 660 Le
gat gga gag att gga tct ttt cct tat cag aaa cct atg gct gca aa Asp Gly Glu Ile Gly Ser Phe Pro Tyr Gln Lys Pro Met Ala Ala As 160 165 170 170	an .
att cct tct tcc tcg cac atg atg aat cct tgt aat gta caa tgt ga Ile Pro Ser Phe Ser His Met Met Asn Pro Cys Asn Val Gln Cys As 180 185 190	at 756 sp
gat gaa gtt tat tgc cct cag aat gtg ttt gga gtg aat agc caa ga Asp Glu Val Tyr Cys Pro Gln Asn Val Phe Gly Val Asn Ser Gln Gl 195 200 205	aa 804 [°] lu
ggt gcc tcg atc aat gac caa ggg tta agt ggt tgt gat ttt gat ca Gly Ala Ser Ile Asn Asp Gln Gly Leu Ser Gly Cys Asp Phe Asp Gl 210 215 220	ag 852 ln
cta caa tgc atg gct aat cag aac tta aat gga aat gga aac gga tc Leu Gln Cys Met Ala Asn Gln Asn Leu Asn Gly Asn Gly Asn Gly Sc 225 230 235	ca 900 er
ttc agc aac gtc aat aca tct gtc tcg aat aag aga aaa ggt ggg c Phe Ser Asn Val Asn Thr Ser Val Ser Asn Lys Arg Lys Gly Gly H 240 245 250 250	at 948 is 55
cgt gca tca aga gca gtt tga agcatcatca agcttgtact atctatttcc Arg Ala Ser Arg Ala Val 260	999
accagcatag atattgtatt ccaaataagt tgtagagttc agctgcagga tcagct	tcgc 1059
tcagetttga ggggttggtg gtgtggtett tetttgtgge acgagtgaga tetatg	
gaacccagat ttagtagtag tagaggcagg atttcgactt ccactaacca tcatgt	
tggtgaagaa caaggtatge ccatgaagca cactgttttg tacattgage ttgagg	
gtctctgatc tagccttact gtaacattgc aacgttctca caattgtgat cccaag	ttgc 1299
tttgttgact taaatgtgat aatatagctt aacttttact tgaaaaaaaa aaaaaa	aaaa 1359
aaaaaaaaa a	1370
<210> 34	

<210> 34 <211> 261 <212> PRT <213> Arabidopsis thaliana

<400> 34

Met Glu Asp Gly Glu Leu Asp Phe Ser Asn Gln Glu Val Phe Ser Ser 1 10 15

Ser Glu Met Gly Glu Leu Pro Pro Ser Asn Cys Ser Met Asp Ser Phe Page 44

20

Phe Asp Gly Leu Leu Met Asp Thr Asn Ala Ala Cys Thr His Thr His 35 40 45

Thr Cys Asn Pro Thr Gly Pro Glu Asn Thr His Thr His Thr Cys Phe 50 60

His Val His Thr Lys Ile Leu Pro Asp Glu Ser Asp Glu Lys Val Ser 65 70 75 80

Thr Asp Asp Thr Ala Glu Ser Cys Gly Lys Lys Gly Glu Lys Arg Pro

Leu Gly Asn Arg Glu Ala Val Arg Lys Tyr Arg Glu Lys Lys Lys Ala

Lys Ala Ala Ser Leu Glu Asp Glu Val Ala Arg Leu Arg Ala Val Asn 115 120 125

Gln Gln Leu Val Lys Arg Leu Gln Asn Gln Ala Thr Leu Glu Ala Glu 130 135 140

Val Ser Arg Leu Lys Cys Leu Leu Val Asp Leu Arg Gly Arg Ile Asp 145 150 150 160

Gly Glu Ile Gly Ser Phe Pro Tyr Gln Lys Pro Met Ala Ala Asn Ile 165 170 175

Pro Ser Phe Ser His Met Met Asn Pro Cys Asn Val Gln Cys Asp Asp 180 185 190

.Glu Val Tyr Cys Pro Gln Asn Val Phe Gly Val Asn Ser Gln Glu Gly 195 200 205

Ala Ser Ile Asn Asp Gln Gly Leu Ser Gly Cys Asp Phe Asp Gln Leu 210 215 220

Gln Cys Met Ala Asn Gln Asn Leu Asn Gly Asn Gly Asn Gly Ser Phe 225 230 235 240

Ser Asn Val Asn Thr Ser Val Ser Asn Lys Arg Lys Gly Gly His Arg 245 250 255

Ala Ser Arg Ala Val

<210> 35

<211> 1638

<212> DNA <213> Arabidopsis thaliana

<220>

221> CDS

<222> (267)..(1259)

223> G558

<400> 35

MBI15 Sequence Listing.ST25	
ggaatttcgg atcgtgtctc tctctgtttc tttgtttcaa tccgatttcg aatcaagccc	60
tttacttgtg caccttcaag atttcgtttt ttccagcgcc cagaatgctc cgggtgacca	120
acatttgttc ctgattcatt tcctattggt tcgtattgtc tgtgcacaca agagaaattt	180
caagaagttg ttactaaaag agaggccaca agtggatatt gtctttgtta tcaagtgtta	240
gtacagaaaa gtggtgagaa agtaat atg gct gat acc agt ccg aga act gat Met Ala Asp Thr Ser Pro Arg Thr Asp 1 5	293
gtc tca aca gat gac gac aca gat cat cct gat ctt ggg tcg gag gga Val Ser Thr Asp Asp Asp Thr Asp His Pro Asp Leu Gly Ser Glu Gly 10 15 20 25	341
gca cta gtg aat act gct gct tct gat tcg agt gac cga tcg aag gga Ala Leu Val Asn Thr Ala Ala Ser Asp Ser Ser Asp Arg Ser Lys Gly 30 35 40	389
aag atg gat caa aag act ctt cgt agg ctt gct caa aac cgt gag gca Lys Met Asp Gln Lys Thr Leu Arg Arg Leu Ala Gln Asn Arg Glu Ala 45 50 55	437
gca agg aaa agc aga ttg agg aag aag gct tat gtt cag cag cta gag Ala Arg Lys Ser Arg Leu Arg Lys Lys Ala Tyr Val Gln Gln Leu Glu 60 65 70	485
aac agc cgc ttg aaa cta acc cag ctt gag cag gag ctg caa aga gca Asn Ser Arg Leu Lys Leu Thr Gln Leu Glu Gln Glu Leu Gln Arg Ala 75 80 85	533
aga cag cag ggc gtc ttc att tca ggc aca gga gac cag gcc cat tct Arg Gln Gln Gly Val Phe Ile Ser Gly Thr Gly Asp Gln Ala His Ser 90 95 100 105	581
act ggt gga aat ggt gct ttg gcg ttt gat gct gaa cat tca cgg tgg Thr Gly Gly Asn Gly Ala Leu Ala Phe Asp Ala Glu His Ser Arg Trp 110 115 120	629
ttg gaa gaa aag aac aag caa atg aac gag ctg agg tct gct ctg aat Leu Glu Glu Lys Asn Lys Gln Met Asn Glu Leu Arg Ser Ala Leu Asn 125 130 135	677
gcg cat gca ggt gat tct gag ctt cga ata ata gtc gat ggt gtg atg Ala His Ala Gly Asp Ser Glu Leu Arg Ile Ile Val Asp Gly Val Met 140 145 150	725
gct cac tat gag gag ctt ttc agg ata aag agc aat gca gct aag aat Ala His Tyr Glu Glu Leu Phe Arg Ile Lys Ser Asn Ala Ala Lys Asn 155 160 165	773
gat gtc ttt cac ttg cta tct ggc atg tgg aaa aca cca gct gag aga Asp Val Phe His Leu Leu Ser Gly Met Trp Lys Thr Pro Ala Glu Arg 170 175 180 185	821
tgt ttc ttg tgg ctc ggt gga ttt cgt tca tcc gaa ctt cta aag ctt Cys Phe Leu Trp Leu Gly Gly Phe Arg Ser Ser Glu Leu Leu Lys Leu 190 195 200	869
ctg gcg aat cag ttg gag cca atg aca gag aga cag ttg atg ggc ata Leu Ala Asn Gln Leu Glu Pro Met Thr Glu Arg Gln Leu Met Gly Ile 205 210 215	917
aat aac ctg caa cag aca tcg cag cag gct gaa gat gct ttg tct caa Asn Asn Leu Gln Gln Thr Ser Gln Gln Ala Glu Asp Ala Leu Ser Gln 220 225 230	965
ggg atg gag agc tta caa cag tca cta gct gat act tta tcg agc ggg Gly Met Glu Ser Leu Gln Gln Ser Leu Ala Asp Thr Leu Ser Ser Gly 235 240 245	1013
act ctt ggt tca agt tca tca ggg aat gtc gca agc tac atg ggt cag Thr Leu Gly Ser Ser Ser Gly Asn Val Ala Ser Tyr Met Gly Gln 250 265	1061

MBI15 Sequence Listing.ST25

atg gcc atg gca atg gga aag tta ggt aca ctc gaa gga ttt atc cgc Met Ala Met Ala Met Gly Lys Leu Gly Thr Leu Glu Gly Phe Ile Arg 270 275 280	1109
cag gct gat aat ttg aga cta caa aca ttg caa cag atg ata aga gta Gln Ala Asp Asn Leu Arg Leu Gln Thr Leu Gln Gln Met Ile Arg Val 285 290 295	1157
tta aca acg aga cag tca gca cgt gct cta ctt gca ata cac gat tac Leu Thr Thr Arg Gln Ser Ala Arg Ala Leu Leu Ala Ile His Asp Tyr 300 305 310	1205
ttc tca cgg cta cga gct cta agc tcc tta tgg ctt gct cga ccc aga Phe Ser Arg Leu Arg Ala Leu Ser Ser Leu Trp Leu Ala Arg Pro Arg 315 320 325	1253
gag tga aactgtattt tggtcacatg tcagetgtac aaaatccata tggacacaaa Glu 330	1309
accaggagag actattaatc aacacttgtc agattcttct taccaaatcc atcaacaaat	1369
aagcaaattt ctgggaaaca aaagactctt tgtatgtagg tttcttctac atggttgtgg	1429
taattcatgt tgttttagtt gtagtcatca gtttttaatt tagcatttga aaagttcaat	1489
gttgtttata tagcatotto gattatotta gaaaggttat tgaattttgt tttttttgt	1549
tacttttgtg tgtggtaaag gtgttttaac cttgcaactt ctgtactgta	1609
aatattaaga tgttctattt gagttttgt	1638

<210> 36

<211> 330

<213> Arabidopsis thaliana

<400> 36

Met Ala Asp Thr Ser Pro Arg Thr Asp Val Ser Thr Asp Asp Asp Thr 1 10 15

Asp His Pro Asp Leu Gly Ser Glu Gly Ala Leu Val Asn Thr Ala Ala 20 30

Ser Asp Ser Ser Asp Arg Ser Lys Gly Lys Met Asp Gln Lys Thr Leu 35 40 45

Lys Lys Ala Tyr Val Gln Gln Leu Glu Asn Ser Arg Leu Lys Leu Thr 65 70 80

Gln Leu Glu Gln Glu Leu Gln Arg Ala Arg Gln Gln Gly Val Phe Ile 90 95

Ser Gly Thr Gly Asp Gln Ala His Ser Thr Gly Gly Asn Gly Ala Leu 100 105 110 .

Ala Phe Asp Ala Glu His Ser Arg Trp Leu Glu Glu Lys Asn Lys Gln 115 120 125

Met Asn Glu Leu Arg Ser Ala Leu Asn Ala His Ala Gly Asp Ser Glu 130 135 140

Leu 145	Arg	Ile	Ile	Val	Asp 150	Gly	Val	Met	Ala	His 155	Tyr	Glu	Glu	Leu	Phe 160	
Arg	Ile	Lys	Ser	Asn 165	Ala	Ala	Lys	Asn	Asp 170	Val	Phe	His	Leu	Leu 175	Ser	
Gly	Met	Trp	Lys 180	Thr	Pro	Ala	Glu	Arg 185	Cys	Phe	Leu	Trp	Leu 190	Gly	Gly	
Phe	Arg	Ser 195	Ser	Glu	Leu	Leu	Lys 200	Leu	Leu	Ala	Asn	Gln 205	Leu	Glu	Pro	
Met	Thr 210	Glu	Arg	Gln	Leu	Met 215	Gly	Ile	Asn	Asn	Leu 220	Gln	Gln	Thr	Ser	
Gln 225	Gln	Ala	Glu	Asp	Ala 230	Leu	Ser	Gln	Gly	Met 235	Glu	Ser	Leu	Gln	Gln 240	
Ser	Leu	Ala	Asp	Thr 245	Leu	Ser	Ser	Gly	Thr 250	Leu	Gly	Ser	Ser	Ser 255	Ser	
Gly	Asn	Val	Ala 260	Ser	Tyr	Met	Gly	Gln 265	Met	Ala	Met	Ala	Met 270	Gly	Lys	
Leu	Gly	Thr 275		Glu	Gly	Phe	Ile 280	Arg	Gln	Ala	Asp	Asn 285	Leu	Arg	Leu	
Gln	Thr 290		Gln	Gln	Met	Ile 295	Arg	Val	Leu	Thr	Thr 300	Arg	Gln	Ser	Ala	
Arg 305		Leu	Leu	Ala	Ile 310		Asp	Tyr	Phe	Ser 315	.Arg	Leu	Arg	Ala	Leu 320	
Ser	Ser	Leu	Trp	Leu 325		Arg	Pro	Arg	Glu 330			·			. •	
<21 <21 <21 <21	1>	37 436 DNA Arab	oidop	sis	thal	iana	L									
<22 <22 <22 <22	1> !2>	CDS (83) G139	(3)6	13)												
tc															gatete	60
acg	gtata	ttt	tgga	tcgt	aa t	c at Me 1	g ga	ac go sp Gl	gc ga ly Gl	a ga lu As 5	it ti sp Pl	t go ne Al	c gg a Gl	ga aa Ly Ly	ng gcg ys Ala 10	112
gct Ala	gct Ala	gaa Glu	a gco ı Ala	aaq Lyi	g gga Gly	ttg / Lei	g aad ı Ası	e ccg	g gga 5 Gly 20	a tta / Lei	a ato	gte Val	cto Lev	ctt Let 25	gtt val	160
gt! Va:	t gga l Gly	a ggt y Gly	y Pro	cti Le	t ctt	gto ı Va	g tto 1 Pho	c cta e Lei 35	a ato u Ilo	gce Ala	aa a As	tao n Ty	gtq Va 40	g cti Lei	tac Tyr	208

00/31418

WO 01/35726	PCT/US0
MBI15 Sequence Listing.ST25	
gtt tat gct cag aag aac cta cct cca agg aag aag aag ccc gtt tcc Val Tyr Ala Gln Lys Asn Leu Pro Pro Arg Lys Lys Pro Val Ser 45 50 55	256
aaa aag aag ctc aag cgg gag aag cta aag caa gga gtc cct gtc cct Lys Lys Lys Leu Lys Arg Glu Lys Leu Lys Gln Gly Val Pro Val Pro 60 65 70	304
gga gaa taa aagccagctt aagctteett eacttgtgee teetteaaag Gly Glu 75	353
cggtttttgt tcggttacca aatttcaccc ttgcgggttt ttttcttcct ttacttctgt	413
catgaggatt atctttgagg cct	436
<210> 38 <211> 76 <212> PRT <213> Arabidopsis thaliana	
<400> 38	
Met Asp Gly Glu Asp Phe Ala Gly Lys Ala Ala Ala Glu Ala Lys Gly 1 10 15	
Leu Asn Pro Gly Leu Ile Val Leu Leu Val Val Gly Gly Pro Leu Leu 20 25 30	
Val Phe Leu Ile Ala Asn Tyr Val Leu Tyr Val Tyr Ala Gln Lys Asn 35 40 45	
Leu Pro Pro Arg Lys Lys Pro Val Ser Lys Lys Lys Leu Lys Arg	
Glu Lys Leu Lys Gln Gly Val Pro Val Pro Gly Glu 65 70 75	
<210> 39 <211> 1470 <212> DNA <213> Arabidopsis thaliana	
<220> <221> CDS <222> (280)(1317) <223> G265	

ctttggtctt ggaagccaaa tcaaaccttt ccttcaatcc tcaaattttc gaaaattttc tcttttgctt tacgttctct caattcttat ttgtaagaaa gtttgttcct ttaatcaatc 120 180 aaatcaaaga gacttttgaa gattgtttcc caatttgcgt caatcgggat cgagtcaaat ctgaaatctt ctccactcat catctgacta taagacttaa tcaagggact ttttgttcgg 240 gtttggtttt aaacgtcttg gattcgaagt ggttaaggt atg gat gaa aat aat Met Asp Glu Asn Asn 1 294 342 gtt gat gat tet tet tet gae teg gte g
t get tgg age gaa aac aac Val Asp Asp Ser Ser Ser Asp Ser Val Val A
la Trp Ser Glu Asn Asn 390 Page 49

			25				MBI	15 Se 30	equer	ce I	isti	ing.S	T25 35			
aaa Lys	Ser	ttc Phe 40	atc Ile	gtc Val	aag Lys	aat Asn	cca Pro 45	gca Ala	gag Glu	ttt Phe	tca Ser	aga Arg 50	gac Asp	ctt Leu	ctt Leu	438
ccg Pro	aga Arg 55	ttc Phe	ttc Phe	aag Lys	cat His	aag Lys 60	aat Asn	ttc Phe	tca Ser	agt Ser	ttc Phe 65	atc Ile	cgt Arg	cag Gln	ctt Leu	486
aat Asn 70	aca Thr	tat Tyr	ggt Gly	ttt Phe	cga Arg 75	aaa Lys	gta Val	gat Asp	cct Pro	gag Glu 80	aaa Lys	tgg Trp	gaa Glu	ttc Phe	ttg Leu 85	534
aat Asn	gat Asp	gat Asp	ttt Phe	gtt Val 90	aga Arg	ggt Gly	cga Arg	cct Pro	tac Tyr 95	ctt Leu	atg Met	aag Lys	aac Asn	att Ile 100	cat His	582
aga Arg	cga Arg	aaa Lys	ccg Pro 105	gtt Val	cat His	agc Ser	cac His	tcg Ser 110	tta Leu	gtg Val	aat Asn	cta Leu	caa Gln 115	gcg Ala	caa Gln	630
aat Asn	cct Pro	ttg Leu 120	acg Thr	gaa Glu	tca Ser	gaa Glu	aga Arg 125	cgg Arg	agc Ser	atg Met	gag Glu	gat Asp 130	cag Gln	ata Ile	gaa Glu	678
aga Arg	ctg Leu 135	aaa Lys	aat Asn	gag Glu	aaa Lys	gaa Glu 140	ggc Gly	ctt Leu	ctt Leu	gcg Ala	gag Glu 145	tta Leu	cag Gln	aac Asn	caa Gln	726
gag Glu 150	caa Gln	gaa Glu	cgg Arg	aaa Lys	gag Glu 155	ttt Phe	gag Glu	ctg Leu	caa Gln	gta Val 160	acg Thr	aca Thr	ttg Leu	aaa Lys	gat Asp 165	774
cgg Arg	tta Leu	caa Gln	cat His	atg Met 170	gaa Glu	caa Gln	cat His	cag Gln	aaa Lys 175	tca Ser	ata Ile	gtg Val	gca Ala	tat Tyr 180	gtt Val	822
tca Ser	cag Gln	gtt Val	ttg Leu 185	Gly	aaa Lys	cca Pro	gga Gly	Ctt Leu 190	ser	cta Leu	aac Asn	ctc Leu	gaa Glu 195	aac Asn	cat His	870
Ğlü	Arg	Arg 200	Lys	Arg	aga Arg	Phe	G1n 205	Glu	Asn	ser	ren	210	PLO	261	261	918
tca Ser	cac His 215	Ile	gaa Glu	cag Gln	gtc Val	gaa Glu 220	гув	tta Leu	gaa Glu	tct Ser	Ser 225	neu	acg Thr	ttt Phe	tgg Trp	966
gag Glu 230	Asn	ctt Leu	gta Val	tcg Ser	gaa Glu 235	tca Ser	tgc Cys	gag Glu	aag Lys	agc Ser 240	GIA	ttg Leu	cag Gln	tca Ser	Ser 245	1014
Ser	Met	Asp	His	250) Ala	Ala	Glu	ı Ser	255	Leu	Sei	TIE	: СІУ	260		1062
cga	ccc Pro	aaa Lys	tca Ser 265	: Ser	aag Lys	att Ile	gat Asp	atg Met 270	. ASI	tca Ser	gaç Gli	ccg Pro	Pro 275	, vai	acc Thr	1110
Va]	Thr	280	Pro) Ala	a Pro	Lys	285	r Gly	y val	. AST	ı AS	290)	: III	ggaa Glu	1158
Glı	295	s Lev	ı Thi	r Glu	ı Asn	300) G1	y Sei	r Tni	c GII	30	5	ı GIC	ı va	cag Gln	1206
310	r Glu O	ı Ar	g Arg	g Asj	315	GI	y AB	n As	р жы	320))	y Asi	r mys		gga Gly 325	1254
aa	t ca	a ag	g ac	g ta	t tgg	g tg	g aa	t tc		g aa Page		a aat	t aad	c at	t aca	1302

MBI15 Sequence Listing.ST25

Asn Gln Arg Thr Tyr Trp Trp Asn Ser Gly Asn Val Asn Asn Ile Thr 330 335 340

gag aaa gct tct tga catgaatgag gtttttgtaa aatagttttc ttttggttcc 1357 Glu Lys Ala Ser

-

actgagatta ttgtatgtgt tcattattta ttactctgtt tctgtaaaaa caaatctctc 1417

tattgtttga ggcaggagtg acataaatgc atatgcagaa ttggtttcaa aaa

1470

<210> 40

<211> 345

<212> PRT

<213> Arabidopsis thaliana

<400> 40

Lys Thr Tyr Glu Met Val Asp Asp Ser Ser Ser Asp Ser Val Val Ala
20 25 30

Trp Ser Glu Asn Asn Lys Ser Phe Ile Val Lys Asn Pro Ala Glu Phe 35 40 45

Ser Arg Asp Leu Leu Pro Arg Phe Phe Lys His Lys Asn Phe Ser Ser 50 55 60

Phe Ile Arg Gln Leu Asn Thr Tyr Gly Phe Arg Lys Val Asp Pro Glu 65 70 75 80

Lys Trp Glu Phe Leu Asn Asp Asp Phe Val Arg Gly Arg Pro Tyr Leu 85 90 95

Met Lys Asn Ile His Arg Arg Lys Pro Val His Ser His Ser Leu Val

Asn Leu Gln Ala Gln Asn Pro Leu Thr Glu Ser Glu Arg Arg Ser Met 115 120 125 $_{\perp}$

Glu Asp Gln Ile Glu Arg Leu Lys Asn Glu Lys Glu Gly Leu Leu Ala 130 135 140

Glu Leu Gln Asn Gln Glu Gln Glu Arg Lys Glu Phe Glu Leu Gln Val 145 150 155 160

Thr Thr Leu Lys Asp Arg Leu Gln His Met Glu Gln His Gln Lys Ser 165 170 175

Ile Val Ala Tyr Val Ser Gln Val Leu Gly Lys Pro Gly Leu Ser Leu 180 185 190

Asn Leu Glu Asn His Glu Arg Arg Lys Arg Arg Phe Gln Glu Asn Ser 195 200 205

Leu Pro Pro Ser Ser Ser His Ile Glu Gln Val Glu Lys Leu Glu Ser 210 215 220

Ser	Leu	Thr	Phe	Trp	Glu	Asn	MBI: Leu	l5 Se Val	equer Ser	Glu	ist: Ser	ing.S Cys	T25 Glu	Lys	Ser	
225					230					235					240	
Gly	Leu	Gln	Ser	Ser 245	Ser	Met	Asp	His	Asp 250	Ala	Ala	Glu	Ser	Ser 255	Leu	
Ser	Ile	Gly	Asp 260	Thr	Arg	Pro	Lys	Ser 265	Ser	Lys	Ile	Asp	Met 270	Asn	Ser	
Glu	Pro	Pro 275	Val	Thr	Val	Thr	Ala 280	Pro	Ala	Pro	Lys	Thr 285	Gly	Val	Asn	
Asp	Asp 290	Phe	Trp	Glu	Gln	Cys 295	Leu	Thr	Glu	Asn	Pro 300	Gly	Ser	Thr	Glu	
Gln 305	Gln	Glu	Val	Gln	Ser 310	Glu	Arg	Arg	Asp	Val 315	Gly	Asn	Asp	Asn	Asn 320	
Gly	Asn	Lys	Ile	Gly 325	Asn	Gln	Arg	Thr	Tyr 330	Trp	Trp	Asn	Ser	Gly 335	Asn	
Val	Asn	Asn	Ile 340	Thr	Glu	Lys	Ala	Ser 345								
<21 <21 <21 <21	1> : 2> :	41 913 DNA Arab	idopa	sis :	thal:	iana										
<22 <22 <22 <22	1> 2>	CDS (52) G100	(7! 6	83)										٠		
<22 <22 <22	1>	(52) G100	6		ac a	aaaa	aaac	t ct	atag	ttag	ttt	ctct	gaa	a. at Me	g tac t Tyr	57
<22 <22 <22 <40 gat	1>	(52) G100 41 caa	tcaa	caaa	gaa	tcc	gac	tac	act	tta	ttq	qaq	tcg	ne 1 ata	g tac t Tyr aca Thr	57 105
<22 <22 <22 <40 gat	1> 2> 3> 0> aaat cag	(52) G100 41 caa tgc Cys	aat Asn	caaa ata Ile	gaa Glu	tcc Ser	gac Asp 10	tac Tyr	gct Ala	ttg Leu gag Glu	ttg Leu	gag Glu 15 cga Arg	tcg Ser	ata I ata	aca	
<22 <22 <22 <40 gat gga Gly	1> 2> 3> 0> aaat cag Gln cac His	(52) G100 41 caa tgc Cys 5 ttg	aat Asn Cta	ata Ile gga Gly	gaa Glu gga Gly	tcc Ser gga Gly 25	gac Asp 10 gga Gly	tac Tyr gag Glu	gct Ala aac Asn	ttg Leu gag Glu	ttg Leu ctg Leu 30	gag Glu 15 cga Arg	tcg Ser ctc Leu	ata Ile	aca Thr	105
<222 <222 <222 <40 gat gga Gly cgt Arg	1> 2> 3> 0> aaaat caggin cac His 20 acac Thr	(52) G100 41 caa tgc Cys 5 ttg Leu	aat Asn cta Leu	ata Ile gga Gly tcg	gaa Glu gga Gly tgt Cys 40	tcc Ser gga Gly 25 ttc Phe	gac Asp 10 gga Gly aca Thr	tac Tyr gag Glu gag Glu	gct Ala aac Asn agt	ttg Leu gag Glu tgg Trp 45	ttg Leu ctg Leu 30 gga Gly	gag Glu 15 cga Arg ggt Gly	tcg Ser ctc Leu	ata ata Ile aat Asr	aca Thr gag Glu	105
<222 <222 <422 <40 gat ggaaggly cgt Arg tca ser 35 aaa	1> 2> 3> 0> aaaat caggGln cacsHis 20 acac Thr	(52) G100 41 caa tgc Cys 5 ttgg Ettge Pro	aaat Asn cta Leu agt Ser	caaaa ataa Ile gga Gly tcg Ser tca	gaa Glu gga Gly tgt Cys 40 gag Glu	gga Gly 25 ttc Phe	gac Asp 10 gga Gly aca Thr	gag Glu gag Glu ttg Leu	gct Ala aac Asn agt Ser Val 60	ttg Leu gag Glu tgg Trp 45 tac	ctg Leu 30 gga Gly	gag Glu 15 cga Arg ggt Gly	tcg Ser Ctc Lev	ata lata lata lata lata lata lata lata	aca Thr gag Glu ttg Leu 50	105 153 201
<222 <222 <420 gat gga Gly cgt Arg tca Ser 35 aaa Lys	1> 22> 3> 0> aaaat caggGln cacaGln cacaGln gagGln gagGlu cttc	(52) G100 41 caa tgc Cys 5 ttgg Cys 5 ttgg Pro	aaat Asn cta Leu agt Ser gat Asp 70	ata ata Ile gga Gly tcg Ser tca Ser 55	gaaa Glu gga tgt Cys 40 gag Glu acg	tcc Ser gga Gly 25 ttc Phe	gac Asp 10 gga Gly aca Thr	tac Tyr gag Glu gagg Glu ttg Leu	gct Alaaac Asn agt Ser Val 60 gac	ttgg Glu tgg Glu tgg Trp 45 tac Tyr	ctg Leu 30 gga Gly	gag Glu 15 cga Arg ggt Gly	tcg Ser ctc Leu ttg Leu ctc Leu	ata ata lata lata lata lata lata lata l	aca Thr gag Glu ttg Leu 50	105 153 201 249

									•				0123			
	His													gcg Ala		441
gag Glu	ata Ile	cgt Arg	gat Asp	ccg Pro 135	gcg Ala	aag Lys	aat Asn	gga Gly	gct Ala 140	agg Arg	gtt Val	tgg Trp	tta Leu	999 Gly 145	acg Thr	489
														gct Ala		537
														gtt Val		585
														tct Ser		633
tcg Ser 195	tcg Ser	tcg Ser	tcg Ser	tcg Ser	tcc Ser 200	tct Ser	tct Ser	acg Thr	tcg Ser	tcg Ser 205	tct Ser	gaa Glu	aac Asn	ggg Gly	aag Lys 210	681
ttg Leu	aaa Lys	cga Arg	agg Arg	aga Arg 215	ʻaaa Lys	gca Ala	gag Glu	aat Asn	ctg Leu 220	acg Thr	tcg Ser	gag Glu	gtg Val	gtg Val 225	cag Gln	729
														ttg Leu		777
	taa	gtt	gato	ett g	gtgtg	gttt	g ta	gttg	gaata	gtt	ttg	ctat	aaat	gttg	gag	833
Ser																
	ccaaç	gta a	aagt	gtto	ec cg	gtgat	gtaa	a att	agtt	act	aaad	cagag	gee a	atata	atcttc	893
gca	ccaaç	_	• -	_		gtgat	gtaa	a att	agtt	act	aaad	cagag	gee a	atata	atcttc	893 913
gca	0> 4 1> 2 2> 1	aaa a 42 243 PRT	aaaa	aaaa	aa		gtaa	att	cagtt		aaad	cagaç	gcc a	atata	atcttc	
gca aat <21 <21 <21	0> 4 1> 2 2> 1	aaa a 42 243 PRT	aaaa	aaaa			gtaa	a att	cagtt	act :	aaad	cagag	gcc a	atata	atcttc	
gca aat <21 <21 <21: <40	0> 4 1> 2 2> 1 3> 7	aaa a 12 243 PRT Arabi	iaaaa idops	aaaaa sis t	na :hali	iana				ž.				atata Glu 15	·	
gca aat <21 <21 <21 <40 Met	0> 4 1> 2 2> 1 3> 7 0> 4	42 243 PRT Arabi	idops Gln	cys	hali Asn	iana	Glu	Ser	Asp 10	: Tyr	Ala	Leu	Leu	Glu	Ser	
gca aat <211 <211 <211 <400 Met 1	0> 41> 22> 13> 70> 4	aaa a 42 243 PRT Arabi	idops Gln His 20	Cys 5	hali Asn Leu	iana Ile Gly	Glu	Ser Gly 25	Asp 10	: Tyr Glu	Ala Asn	Leu	Leu Leu 30	Glu 15	Ser Leu	
gca aat <211 <211 <211 <400 Met 1	00> 4 1> 2 2> 1 3> 7 Tyr Thr	42 2243 PRT Arabi 42 Gly Arg	dops Gln His 20	Cys 5 Leu	Asn Leu Ser	iana Ile Gly Ser	Glu Gly Cys 40	Ser Gly 25	Asp 10 Gly	Tyr Glu Glu	Ala Asn Ser	Leu Glu Trp 45	Leu Leu 30	Glu 15 Arg	Ser Leu Leu	
gca aat <211 <211 <211 <400 Met 1	Caaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa	Arg Ser 35	dops Gln His 20 Thr	Cys 5 Leu Pro	Asn Leu Ser	Ile Gly Ser Ser 55	Glu Gly Cys 40	Ser Gly 25 Phe	Asp 10 Gly Thr	Tyr Glu Glu Leu	Ala Asn Ser Val	Leu Glu Trp 45	Leu Leu 30 Gly	Glu 15 Arg Gly	Ser Leu Leu Leu	

Page 53

Met Glu Glu Lys Pro Lys Lys Ala Ile Pro Val Thr Glu Thr Ala Val 100 $\,$ 105 $\,$ 110 $\,$,

Lys	Ala	Lys 115	His	Tyr	Arg	Gly	Val 120	Arg	Gln	Arg	Pro	Trp 125	Gly	Lys	Phe	
Ala	Ala 130	Glu	Ile	Arg	Asp	Pro 135	Ala	Lys	Asn	Gly	Ala 140	Arg	Val	Trp	Leu	
Gly 145	Thr	Phe	Glu	Thr	Ala 150	Glu	Asp	Ala	Ala	Leu 155	Ala	Tyr	qaA	Ile	Ala 160	
Ala	Phe	Arg	Met	Arg 165	Gly	Ser	Arg	Ala	Leu 170	Leu	Asn	Phe	Pro	Leu 175	Arg	
Val	Asn	Ser	Gly 180	Glu	Pro	Asp	Pro	Val 185	Arg	Ile	Thr	Ser	Lys 190	Arg	Ser	
Ser	Ser	Ser 195	Ser	Ser	Ser	Ser	Ser 200	Ser	Ser	Thr	Ser	Ser 205	Ser	Glu	Asn	
Gly	Lув 210	Leu	Lys	Arg	Arg	Arg 215	Lys	Ala	Glu	Asn	Leu 220	Thr	Ser	Glu	Val	
Val 225		Val	Lys	Сув	Glu 230	Val	Gly	Asp	Glu	Thr 235	Arg	Val	Asp	Glu	Leu 240	
Leu	Val	Ser														
<21 <21 <21 <21	1> 2>	43 912 DNA Arab	idop	sis :	thal:	iana										
<22 <22 <22 <22	1>		(8 9	59)									•			
<40 cgt	0> cgac	43 ctc	ttaa	ttaa	ga c	gact	tgag	a ga	gaaa	gaaa	gat	acgt	gga	ag a M	tg acc et Thr	58
aaa Lys	tct Ser	gga Gly 5	gag	aga Arg	cca Pro	Lys	cag Gln 10	aga Arg	cag Gln	agg Arg	Lys	999 Gly 15	tta Leu	tgg Trp	tca Ser	106
cct	gaa Glu 20	gaa Glu	gac Asp	cag Gln	aag Lys	ctc Leu 25	aag Lys	agt Ser	ttc Phe	atc Ile	ctc Leu 30	tct Ser	cgt	ggc	cat	154
gct Ala 35	tgc Cys	tgg Trp	acc Thr	act Thr	gtt Val 40	ccc Pro	ato	cta Leu	gct Ala	gga Gly 45	ttg Leu	caa Gln	agg Arg	aat Asn	999 Gly 50	202
aaa Lys	ago Ser	tgo Cys	aga Arg	tta Leu 55	agg Arg	tgg Trp	att Ile	aat Asn	tac Tyr 60	cta Leu	aga Arg	cca Pro	gga Gly	Leu 65	aag	250
agg	999 999 999	tcg Ser	ttt Phe 70	agt Ser	gaa Glu	gaa Glu	gaa Glu	gaa Glu 75	gag Glu	acc Thr	ato	ttg Leu	act Thr 80	tta Leu	cat His	298
tct	tec	: ttg	ggt	aac	aag	tgg	tct	. cgg		gca Page		tat	: tta	ccg	gga	346

															•	
Ser S		Leu 85	Gly	Asn	Lys	Trp					List Lys			Pro	Gly	
aga a Arg T																394
aga t Arg T 115																442
aca g Thr G																490
acc g Thr G																538
cca a Pro T	hr															586
aac a Asn S																634
tca a Ser A 195						Tyr										682
att a Ile A																730
aat a Asn A																778
ttt t Phe L	eu															826
Phe P		Ile								taa	gaag	gagte	gaa t	atga	tcgta	879
agagg	aac	at a	agct	agtt	a ct	tgtg	jttac	ago	2							912
<210><211><211><212><213>	2 P	68 RT	.dops	is t	:hali	lana									٠	
<400>	4	4														
Met T 1	hr i	Lys	Ser	Gly 5	Glu	Arg	Pro	Lys	Gln 10	Arg	Gln	Arg	Lys	Gly 15	Leu	
Trp S	er	Pro	Glu 20	Glu	Asp	Gln	Lys	Leu 25	Lys	Ser	Phe	Ile	Leu 30	Ser	Arg	
Gly H		Ala 35	Cys	Trp	Thr	Thr	Val 40	Pro	Ile	Leu	Ala	Gly 45	Leu	Gln	Arg	
Asn G 5	ly 0	Lys	Ser	Сув	Arg	Leu 55	Arg	Trp	Ile	Asn	Tyr 60	Leu	Arg	Pro	Gly	
Leu L 65	ys .	Arg	Gly	Ser	Phe 70	Ser	Glu	Glu	Glu	Glu 75	Glu	Thr	Ile	Leu	Thr 80	

MBI15 Sequence Listing.ST25

							MBI1	.5 Se	equer	ice I	isti	ng.S	T25				
Leu	His	Ser	Ser	Leu 85	Gly	Asn	Lya	Trp	Ser 90	Arg	Ile	Ala	Lys	Tyr 95	Leu		
Pro	Gly	Arg	Thr 100	Asp	Asn	Glu	Ile	Lys 105	Asn	Tyr	Trp	His	Ser 110	Tyr	Leu		
Lys	Lys	Arg 115	Trp	Leu	Lys	Ser	Gln 120	Pro	Gln	Leu	Lys	Ser 125	Gln	Ile	Ser		
Asp	Leu 130	Thr	Glu	Ser	Pro	Ser 135	Ser	Leu	Leu	Ser	Cys 140	Gly	Lys	Arg	Asn		
Leu 145		Thr	Glu	Thr	Leu 150	Asp	His	Val	Ile	Ser 155	Phe	Gln	Lys	Phe	Ser 160		
Glu	Asn	Pro	Thr	Ser 165	Ser	Pro	Ser	Lys	Glu 170	Ser	Asn	Asn	Asn	Met 175	Ile		
			180	Asn				185					190				
		195		Pro			200					205					
	210			Glu		215					220						
225	•			Asn	230					235					240		
		•		Gln 245					250			Tyr	Tyr	Ser 255	Ser		
Gly	Asp	Phe	260	Ile	Asn	Ser	Asp	Gln 265	Asn	Tyr	Val						
<23	1> 12>	45 1575 DNA Arab		sis	thal	iana											
<22 <22	20> 21> 22> 23>		. (15 60	75)													
200	00> g gct t Ala	. ata	tat Tyr	tac Tyr 5	cct Pro	aat Asn	agt Ser	gtc Val	ggc Gly	atg Met	caa Gln	tct Ser	ctt Leu	tac Tyr 15	caa Gln	48	
ga: Gl:	a tco u Sei	att Ile	tac Tyr 20	cto Leu	aac Asn	gaa Glu	caa Gln	caa Glr 25	caa Gln	caa Gln	caa Glm	caa Glm	caa Gln 30	gct	tct Ser	96	
tc Se	t tco	tct Sei 35	gct Ala	gca Ala	tct Ser	tto Phe	tcc Ser 40	gag Glu	att Ile	gtt Val	tco Ser	ggt Gly 45	gat Asp	gtt Val	cga Arg	144	
aa	c aa	c gag	gate	gta	ttt	ato	cca	CC	a aca	ago	gac	gta	gco	gto	aac	192	

_													ST25			
Asn	Asn 50	Glu	Met	Val	Phe :	Ile 55	Pro	Pro	Thr	Ser	Asp 60	Val	Ala	Val	Asn	
													ggt Gly			240
													tct Ser			288
													agt Ser 110			336
aat Asn	ctt Leu	aat Asn 115	cct Pro	tct Ser	act Thr	atg Met	tct Ser 120	gat Asp	gag Glu	aat Asn	999 Gly	aag Lys 125	agc Ser	ttg Leu	agt Ser	384
													gtt Val			432
													cgt Arg			480
													ctt Leu			528
													gat Asp 190			576
													ttt Phe			624
													tcg Ser			. 672
													agc Ser			720
tta Leu	aca Thr	atg Met	gtg Val	gat Asp 245	gag Glu	gta Val	gat Asp	aaa Lys	agg Arg 250	tat Tyr	aac Asn	caa Gln	tac Tyr	cat His 255	cat His	768
					Ala		Ser	Phe					ggt Gly 270			816
gca Ala	gct Ala	aag Lys 275	cct Pro	tac Tyr	aca Thr	tcc Ser	gta Val 280	gct Ala	ctg Leu	aat Asn	aga Arg	atc Ile 285	tct Ser	cgc Arg	cat His	864
													gtg Val			912
													gag Glu			960
													aga Arg			1008
													caa Gln 350			1056

Page 57

tta Leu	cct Pro	gaa Glu 355	aac Asn	tct Ser	gtc Val	tct Ser	ata	ctt	cqa	qct	tqq	ing.S ctc Leu 365	ttt	gag Glu	cat His	1104
ttc Phe	ctt Leu 370	cat His	cca Pro	tat Tyr	cct Pro	aaa Lys 375	gaa Glu	tca Ser	gag Glu	aaa Lys	atc Ile 380	atg Met	ctt Leu	tca Ser	aag Lys	1152
cag Gln 385	aca Thr	gga Gly	cta Leu	tcg Ser	aaa Lys 390	aac Asn	cag Gln	gtt Val	gca Ala	aat Asn 395	tgg Trp	ttt Phe	att Ile	aac Asn	gcg Ala 400	1200
aga Arg	gtt Val	cga Arg	cta Leu	tgg Trp 405	aaa Lys	cca Pro	atg Met	att Ile	gaa Glu 410	gag Glu	atg Met	tat Tyr	aaa Lys	gaa Glu 415	gag Glu	1248
ttt Phe	gga Gly	gaa Glu	tca Ser 420	gca Ala	gag Glu	tta Leu	ctc Leu	tct Ser 425	aac Asn	tct Ser	aat Asn	caa Gln	gac Asp 430	acc Thr	aaa Lys	1296
aaa Lys	atg Met	cag Gln 435	gaa Glu	aca Thr	tct Ser	cag Gln	ctc Leu 440	aaa Lys	cac His	gaa Glu	gac Asp	tct Ser 445	tcg Ser	tct Ser	tcg Ser	1344
caa Gln	caa Gln 450	cag Gln	aat Asn	cag Gln	gga Gly	aac Asn 455	aac Asn	aac Asn	aac Asn	aac Asn	atc Ile 460	cca Pro	tat Tyr	aca Thr	tct Ser	1392
gat Asp 465	gca Ala	gaa Glu	caa Gln	aac Asn	cta Leu 470	gtc Val	ttt Phe	gca Ala	gat Asp	cct Pro 475	aaa Lys	cca Pro	gac Asp	cgt Arg	gct Ala 480	1440
act Thr	act Thr	gga Gly	gat Asp	tac Tyr 485	gac Asp	agc Ser	ttg Leu	atg Met	aac Asn 490	tat Tyr	cat His	999 999	ttt Phe	ggt Gly 495	att Ile	1488
gat Asp	gat Asp	tac Tyr	aat Asn 500	Arg	tac Tyr	gtt Val	Gly	ctt Leu 505	gga Gly	aac Asn	caa Gln	caa Gln	gat Asp 510	ggc Gly	aga Arg	1536
tat Tyr	tct Ser	aat Asn 515	Pro	cat His	caa Gln	tta Leu	cac His 520	gac	ttt Phe	gtt Val	gtc Val	taa				1575
<21 <21 <21 <21	1> 2>	46 524 PRT Arab	idop	sis	thal	iana	•								-	
<40	0>	46														
Met 1	Ala	Val	Tyr	Tyr 5	Pro	Asn	Ser	Val	Gly 10	Met	Gln	Ser	Leu	Tyr 15	Gln	
Glu	Ser	Ile	Tyr 20	Leu	Asn	Glu	Gln	Gln 25	Gln	Gln	Gln	Gln	Gln 30	Ala	Ser	

Ser Ser Ser Ala Ala Ser Phe Ser Glu Ile Val Ser Gly Asp Val Arg 35 40 45

Asn Asn Glu Met Val Phe Ile Pro Pro Thr Ser Asp Val Ala Val Asn 50 55

Gly Asn Val Thr Val Ser Ser Asn Asp Leu Ser Phe His Gly Gly Gly 65 70 75 80

Leu Ser Leu Ser Leu Gly Asn Gln Ile Gln Ser Ala Val Ser Val Ser 85 90 95

MBI15 Sequence Listing.ST25

Pro Phe Gln Tyr His Tyr Gln Asn Leu Ser Asn Gln Leu Ser Tyr Asn 100 105 110

Asn Leu Asn Pro Ser Thr Met Ser Asp Glu Asn Gly Lys Ser Leu Ser 115 120 125

Val His Gln His His Ser Asp Gln Ile Leu Pro Ser Ser Val Tyr Asn 130 135 140

Asn Asn Gly Asn Asn Gly Val Gly Phe Tyr Asn Asn Tyr Arg Tyr Glu 145 150 155 160

Thr Ser Gly Phe Val Ser Ser Val Leu Arg Ser Arg Tyr Leu Lys Pro 165 170 175

Thr Gln Gln Leu Leu Asp Glu Val Val Ser Val Arg Lys Asp Leu Lys 180 185 190

Leu Gly Asn Lys Lys Met Lys Asn Asp Lys Gly Gln Asp Phe His Asn 195 200 205

Gly Ser Ser Asp Asn Ile Thr Glu Asp Asp Lys Ser Gln Ser Gln Glu 210 215 220

Leu Ser Pro Ser Glu Arg Gln Glu Leu Gln Ser Lys Lys Ser Lys Leu 225 230 235 240

Leu Thr Met Val Asp Glu Val Asp Lys Arg Tyr Asn Gln Tyr His His 245 250 255

Gln Met Glu Ala Leu Ala Ser Ser Phe Glu Met Val Thr Gly Leu Gly 260 265 270

Ala Ala Lys Pro Tyr Thr Ser Val Ala Leu Asn Arg Ile Ser Arg His 275 280 285

Phe Arg Cys Leu Arg Asp Ala Ile Lys Glu Gln Ile Gln Val Ile Arg 290 295 300

Gly Lys Leu Gly Glu Arg Glu Thr Ser Asp Glu Gln Gly Glu Arg Ile 305 310 315 320

Pro Arg Leu Arg Tyr Leu Asp Gln Arg Leu Arg Gln Gln Arg Ala Leu 325 330 335

His Gln Gln Leu Gly Met Val Arg Pro Ala Trp Arg Pro Gln Arg Gly 340 345 350

Leu Pro Glu Asn Ser Val Ser Ile Leu Arg Ala Trp Leu Phe Glu His 355 360 365

Phe Leu His Pro Tyr Pro Lys Glu Ser Glu Lys Ile Met Leu Ser Lys 370 375 380

Gln Thr Gly Leu Ser Lys Asn Gln Val Ala Asn Trp Phe Ile Asn Ala 385 390 395 400

MBI15 Sequence Listing.ST25

Phe Gly Glu Ser Ala Glu Leu Leu Ser Asn Ser Asn Gln Asp Thr Lys 420 425 430	
Lys Met Gln Glu Thr Ser Gln Leu Lys His Glu Asp Ser Ser Ser Ser 445	
Gln Gln Gln Asn Gln Gly Asn Asn Asn Asn Ile Pro Tyr Thr Ser 450 455 460	
Asp Ala Glu Gln Asn Leu Val Phe Ala Asp Pro Lys Pro Asp Arg Ala 465 470 475 480	
Thr Thr Gly Asp Tyr Asp Ser Leu Met Asn Tyr His Gly Phe Gly Ile 485 490 495	
Asp Asp Tyr Asn Arg Tyr Val Gly Leu Gly Asn Gln Gln Asp Gly Arg 500 505 510	
Tyr Ser Asn Pro His Gln Leu His Asp Phe Val Val 515 520	
<210> 47 <211> 1983 <212> DNA <213> Arabidopsis thaliana	
<220> <221> CDS	
<222> (73)(1956) <223> G965	
<223> G965	60
<223> G965	60 111
<223> G965 <400> 47 gattctctgt gtatgtctga atccttacag gatccaagag ctttggaaaa aagatataat gaataacaag at atg ggt tta gct act aca act tct tct atg tca caa gat Met Gly Leu Ala Thr Thr Thr Ser Ser Met Ser Gln Asp	
<pre><223> G965 <400> 47 gattctctgt gtatgtctga atccttacag gatccaagag ctttggaaaa aagatataat gaataacaag at atg ggt tta gct act aca act tct tct atg tca caa gat</pre>	111
<pre><223> G965 <400> 47 gattctctgt gtatgtctga atccttacag gatccaagag ctttggaaaa aagatataat gaataacaag at atg ggt tta gct act aca act tct tct atg tca caa gat</pre>	111
<pre><223> G965 <400> 47 gattctctgt gtatgtctga atccttacag gatccaagag ctttggaaaa aagatataat gaataacaag at atg ggt tta gct act aca act tct tct atg tca caa gat</pre>	111 159 207
<pre><223> G965 <400> 47 gattctctgt gtatgtctga atccttacag gatccaagag ctttggaaaa aagatataat gaataacaag at atg ggt tta gct act aca act tct tct atg tca caa gat</pre>	111 159 207 255
<pre><223> G965 <400> 47 gattctctgt gtatgtctga atccttacag gatccaagag ctttggaaaa aagatataat gaataacaag at atg ggt tta gct act aca act tct tct atg tca caa gat</pre>	111 159 207 255 303

MBI15 Sequence Listing.ST25

					gac Asp 115											447
					tct Ser											495
atg Met	atc Ile	gga Gly	acc Thr 145	gtc Val	cac His	gtg Val	gaa Glu	gga Gly 150	gga Gly	aag Lys	ggt Gly	ttg Leu	tct Ser 155	tta Leu	tct Ser	543
					gcc Ala											591
tat Tyr	tgt Cys 175	gca Ala	gcc Ala	gtt Val	gat Asp	gga Gly 180	act Thr	tct Ser	tct Ser	tct Ser	tct Ser 185	aac Asn	gca Ala	tcc Ser	gct Ala	639
					aat Asn 195											687
					cac His											735
					gcg Ala											783
					tat Tyr											831
					aga Arg											879
				Pro	aat Asn 275											927
tcg Ser	tca Ser	tcg Ser	gcc Ala	gga Gly 290	aca Thr	gct Ala	aat Asn	gat Asp	agt Ser 295	cct Pro	cct Pro	ttg Leu	tct Ser	ccg Pro 300	gct Ala	975
					caa Gln											1023
gaa Glu	gag Glu	gtg Val 320	gac Asp	cga Arg	cgg Arg	Tyr	aac Asn 325	cac His	tac Tyr	tgc Cys	gaa Glu	caa Gln 330	atg Met	caa Gln	atg Met	1071
					gac Asp											1119
					caa Gln 355											1167
aaa Lys	gac Asp	gcg Ala	gta Val	gcg Ala 370	gtt Val	cag Gln	ctt Leu	aaa Lys	cgc Arg 375	agc Ser	tgt Cys	gag Glu	ctt Leu	cta Leu 380	999 Gly	1215
gat Asp	aaa Lys	gag Glu	gcg Ala 385	gca Ala	gj gag	gct Ala	gca Ala	tcc Ser 390	tcg Ser	999 Gly	tta Leu	acc Thr	aaa Lys 395	999 Gly	gaa Glu	1263
					t tg Leu											1311

		400					MBI:	L5 Se	equer	ice 1	List	ing.9 410	T25			
ttt Phe	cat His 415	cat His	atg Met	ggt Gly	atg Met	atg Met 420	gag Glu	caa Gln	gag Glu	gca Ala	tgg Trp 425	aga Arg	ccg Pro	caa Gln	cgt Arg	1359
99t Gly 430	ttg Leu	cct Pro	gaa Glu	cgc Arg	tcc Ser 435	gtt Val	aat Asn	atc Ile	ctt Leu	aga Arg 440	gct Ala	tgg Trp	cta Leu	ttc Phe	gag Glu 445	1407
cat His	ttt Phe	ctt Leu	aat Asn	ccg Pro 450	tac Tyr	cca Pro	agc Ser	gat Asp	gct Ala 455	gat Asp	aag Lys	cac His	ctc Leu	tta Leu 460	gca Ala	1455
cga Arg	cag Gln	act Thr	ggt Gly 465	tta Leu	tcc Ser	aga Arg	aat Asn	cag Gln 470	gtg Val	tca Ser	aat Asn	tgg Trp	ttc Phe 475	ata Ile	aat Asn	1503
gct Ala	agg Arg	gtt Val 480	cgc Arg	cta Leu	tgg Trp	aaa Lys	cca Pro 485	atg Met	gtg Val	gaa Glu	gag Glu	atg Met 490	tat Tyr	caa Gln	caa Gln	1551
gaa Glu	gca Ala 495	aaa Lys	gaa Glu	aga Arg	gaa Glu	gaa Glu 500	gca Ala	gaa Glu	gaa Glu	gaa Glu	aat Asn 505	gaa Glu	aat Asn	caa Gln	caa Gln	1599
caa Gln 510	caa Gln	aga Arg	aga Arg	cag Gln	caa Gln 515	caa Gln	aca Thr	aac Asn	aac Asn	aac Asn 520	gac Asp	acg Thr	aaa Lys	ccc Pro	aac Asn 525	1647
aac Asn	aat Asn	gaa Glu	aac Asn	aac Asn 530	ttc Phe	act Thr	gtc Val	ata Ile	acc Thr 535	gca Ala	caa Gln	act Thr	cca Pro	acg Thr 540	acg Thr	1695
atg Met	aca Thr	tcg Ser	aca Thr 545	cat His	cac His	gaa Glu	aac Asn	gac Asp 550	tct Ser	tca Ser	ttc Phe	ctc Leu	tct Ser 555	tcc Ser	gtc Val	1743
gcc Ala	gcc Ala	gct Ala 560	tct Ser	cac His	ggc Gly	ggt Gly	tca Ser 565	gac Asp	gcg Ala	ttc Phe	acc Thr	gtc Val 570	gcc Ala	acg Thr	tgt Cys	1791
cag Gln	caa Gln 575	gac Asp	gtc Val	agt Ser	gac Asp	ttc Phe 580	His	gtc Val	gac Asp	gga Gly	gat Asp 585	ggt Gly	gtg Val	aac Asn	gtc Val	1839
ata Ile 590	Arg	ttc Phe	ggg ggg	acc Thr	aaa Lys 595	cag Gln	act Thr	ggt Gly	gac Asp	gtg Val 600	Ser	ctt Leu	acg Thr	ctt Leu	ggt Gly 605	1887
cta Leu	cgc Arg	cac His	tct Ser	ggc Gly 610	Asn	att	cct Pro	gat Asp	aag Lys 615	Asn	act Thr	tct Ser	ttc Phe	ser 620	gtt Val	1935
aga Arg	gac	ttt Phe	gga Gly 625	Asp	ttt Phe	tag	tct	tctt	tgt	ttct	caat	tt a	ttca	tc		1983
<21 <21 <21 <21	.1> .2>	48 627 PRT Arab	oidop	sis	thal	iana	ı					•				
<40	O->	48														
Met 1	: Gly	, Leu	ı Ala	Thr 5	Thr	Thr	Ser	Ser	Met 10	Ser	Glr	Asp	Туг	His 15	His	
His	s Glr	ı Gly	7 Ile 20	e Phe	e Ser	Phe	e Ser	Asr 25	ı Gly	Phe	His	a Arg	Ser 30	: Sei	Ser	

Thr Thr His Gln Glu Glu Val Asp Glu Ser Ala Val Val Ser Gly Ala Page 62 35

MBI15 Sequence Listing.ST25

Gln Ile Pro Val Tyr Glu Thr Ala Gly Met Leu Ser Glu Met Phe Ala 50 $$ 55 $$ 60

Tyr Pro Gly Gly Gly Gly Gly Gly Ser Gly Gly Glu Ile Leu Asp Gln 65 70 75 80

Ser Thr Lys Gln Leu Leu Glu Gln Gln Asn Arg His Asn Asn Asn Asn 90 95

Asn Ser Thr Leu His Met Leu Leu Pro Asn His His Gln Gly Phe Ala

Phe Thr Asp Glu Asn Thr Met Gln Pro Gln Gln Gln His Phe Thr 115 120 125

Trp Pro Ser Ser Ser Asp His His Gln Asn Arg Asp Met Ile Gly 130 135 140

Thr Val His Val Glu Gly Gly Lys Gly Leu Ser Leu Ser Leu Ser Ser 145 150 150 160

Ser Leu Ala Ala Ala Lys Ala Glu Glu Tyr Arg Ser Ile Tyr Cys Ala 165 170 175

Ala Val Asp Gly Thr Ser Ser Ser Ser Asn Ala Ser Ala His His His 180 180 190

Gln Phe Asn Gln Phe Lys Asn Leu Leu Glu Asn Ser Ser Gln
195 200 205

His His His Gln Val Val Gly His Phe Gly Ser Ser Ser Ser Ser 210 220

Pro Met Ala Ala Ser Ser Ser Ile Gly Gly Ile Tyr Thr`Leu Arg Asn 225 230 230 235

Ser Lys Tyr Thr Lys Pro Ala Gln Glu Leu Leu Glu Glu Phe Cys Ser 245 250 255

Val Gly Arg Gly His Phe Lys Lys Asn Lys Leu Ser Arg Asn Asn Ser 260 265 270

Asn Pro Asn Thr Thr Gly Gly Gly Gly Gly Gly Ser Ser Ser Ser 275 280 285

Ala Gly Thr Ala Asn Asp Ser Pro Pro Leu Ser Pro Ala Asp Arg Ile 290 295 295

Glu His Gln Arg Arg Lys Val Lys Leu Leu Ser Met Leu Glu Glu Val 305 310 315 320

Asp Arg Arg Tyr Asn His Tyr Cys Glu Gln Met Gln Met Val Val Asn 325 330 335

- MBI15 Sequence Listing.ST25
 Ser Phe Asp Gln Val Met Gly Tyr Gly Ala Ala Val Pro Tyr Thr Thr
 340 345 350
- Leu Ala Gln Lys Ala Met Ser Arg His Phe Arg Cys Leu Lys Asp Ala 355 360 365
- Val Ala Val Gln Leu Lys Arg Ser Cys Glu Leu Leu Gly Asp Lys Glu 370 375 380
- Ala Ala Gly Ala Ala Ser Ser Gly Leu Thr Lys Gly Glu Thr Pro Arg 385 390 395 400
- Leu Arg Leu Leu Glu Gln Ser Leu Arg Gln Gln Arg Ala Phe His His 405 410 415
- Met Gly Met Met Glu Gln Glu Ala Trp Arg Pro Gln Arg Gly Leu Pro 420 425 430
- Glu Arg Ser Val Asn Ile Leu Arg Ala Trp Leu Phe Glu His Phe Leu 435 440 445
- Asn Pro Tyr Pro Ser Asp Ala Asp Lys His Leu Leu Ala Arg Gln Thr 450 455 460
- Gly Leu Ser Arg Asn Gln Val Ser Asn Trp Phe Ile Asn Ala Arg Val 465 470 475 480
- Arg Leu Trp Lys Pro Met Val Glu Glu Met Tyr Gln Gln Glu Ala Lys 485 490 495
- Glu Arg Glu Glu Ala Glu Glu Glu Asn Glu Asn Gln Gln Gln Arg 500 505 510
- Arg Gln Gln Gln Thr Asn Asn Asn Asp Thr Lys Pro Asn Asn Asn Glu 515 520 525
- Asn Asn Phe Thr Val Ile Thr Ala Gln Thr Pro Thr Thr Met Thr Ser 530 535 540
- Thr His His Glu Asn Asp Ser Ser Phe Leu Ser Ser Val Ala Ala Ala 545 550 560
- Ser His Gly Gly Ser Asp Ala Phe Thr Val Ala Thr Cys Gln Gln Asp 565 570 575
- Val Ser Asp Phe His Val Asp Gly Asp Gly Val Asn Val Ile Arg Phe 580 585 595
- Gly Thr Lys Gln Thr Gly Asp Val Ser Leu Thr Leu Gly Leu Arg His 595 600 605
- Ser Gly Asn Ile Pro Asp Lys Asn Thr Ser Phe Ser Val Arg Asp Phe 610 620

Gly Asp Phe

MBI15 Sequence Listing.ST25

<210><211><211><212><213>	49 1420 DNA Arabid	lopsis (halia	ana									
<220> <221> <222> <223>	CDS (138). G793	(1046))										
<400>		ctaacaa	et cca	acacaaq	a tto	ette	cat	ggaa	aacti	at t	ctto	cgactt	60
		tegetal		_					_	_		_	120
ctttac	tcgt tt			ct aat la Asn						lis /			170
	r Āsp P	ca tct Pro Ser 15											218
		tc tcc he Ser											266
		cca cct Pro Pro	Pro M										314
ggg aa Gly As 60	t cat a n His A	at cat Asn His	atg g Met 6 65	ggt gcc Bly Ala	att Ile	gga Gly	gga Gly 70	ggt Gly	gga Gly	cct Pro	gta Val	999 Gly 75	362
		ag atg 31n Met 80											410
	в Gly Р	tt ctt Phe Leu 95											458
		gat aat Asp Asn			Ser								506
	o Met S	ca cag Ser Gln	Pro A										554
att cgg Ile Arg 140	g cct a g Pro A	aga gtt Arg Val	agg g Arg A 145	gct agg Ala Arg	cga Arg	Gly	caa Gln 150	Ala	acc Thr	gat Asp	cca Pro	cat His 155	602
		gag agg Blu Arg 160			Glu								650
	ı Gln G	gaa ctt Slu Leu 175											698
		gag att Slu Ile			Val								746
aag gte Lys Val 20	l Leu S	agc atg Ser Met	Ser A	egt ctt Arg Leu 210	ggt Gly	gga Gly	gcc Ala	ggt Gly 215	gct Ala	gtc Val	gca Ala	cca Pro	794
		gaa atg Glu Met				Ser		Glu					842

	MBI15 Seque	nce Listing.ST25	
220 225		230	235
gcc gtg tgg gag aaa tgg Ala Val Trp Glu Lys Trp 240	tca aac gat ggg Ser Asn Asp Gly 245	aca gag agg caa gtg g Thr Glu Arg Gln Val 2 250	gct 890 Ala
aag ctg atg gaa gaa aac Lys Leu Met Glu Glu Asn 255	gtt gga gca gcg Val Gly Ala Ala 260	atg caa ctt ttg caa (Met Gln Leu Leu Gln (265	ca 938 Ser
aag gct ctt tgc ata atg Lys Ala Leu Cys Ile Met 270	ccg atc tca ttg Pro Ile Ser Leu 275	gca atg gcg att tac a Ala Met Ala Ile Tyr 1 280	cat 986 His
tct cag cca cca gac aca Ser Gln Pro Pro Asp Thr 285	tct tct tca atc Ser Ser Ser Ile 290	gtc aaa cca gag atg Val Lys Pro Glu Met 295	aat 1034 Asn
cct cca ccg tag atttttg Pro Pro Pro 300	ttc atccaacggt c	cccagctga tgattgacat	1086
tttgctctgt ttcccactac t	agacttttg tgactc	atga aaggtaagta aaaag	gcatt 1146
ggagatggaa tctaagtagg a			
aggaaaaagc tctcgcttgc t	tggctagta tttatc	attt tgatgaaagt aactc	ttttt 1266
tgttcaaaga ctttagtgtg a	ttttcagga ccaagg	gctt tgagggtagt gctag	ctgta 1326
gtaatagtaa tgaaggtgtg g	gatcgtgtt tttgaa	ttat gtaaaaaagg aagaa	aaaac 1386
aaatgttggt attatattat g	gttttgcct gaaa		1420
<210> 50 <211> 302 <212> PRT <213> Arabidopsis thal	iana		
<400> 50			
Met Ala Asn Asn Asn Asr 1 . 5	Ile Pro His Asp 10	Ser Ile Ser Asp Pro 15	Ser
	·		
Pro Thr Asp Asp Phe Phe	e Glu Gln Ile Let 25	Gly Leu Ser Asn Phe 30	Ser
Pro Thr Asp Asp Phe Phe 20 Gly Ser Ser Gly Ser Gly 35	25	30	
20 Gly Ser Ser Gly Ser Gly	Leu Ser Gly Ild 40	e Gly Gly Val Gly Pro 45	Pro
Gly Ser Ser Gly Ser Gly 35 Pro Met Met Leu Gln Leu	Leu Ser Gly Ile 40 1 Gly Ser Gly Ass	e Gly Gly Val Gly Pro 45 n Glu Gly Asn His Asn 60	Pro His
Gly Ser Ser Gly Ser Gly 35 Pro Met Met Leu Gln Let 50 Met Gly Ala Ile Gly Gl	Leu Ser Gly Ile 40 1 Gly Ser Gly Ass 55 7 Gly Gly Pro Va	Gly Gly Val Gly Pro 45 Glu Gly Asn His Asn 60 Gly Phe His Asn Gln 75 y Lys Gly His Gly Phe	Pro His Met 80
Gly Ser Ser Gly Ser Gly 35 Pro Met Met Leu Gln Leu 50 Met Gly Ala Ile Gly Gl; 65 Phe Pro Leu Gly Leu Se	Leu Ser Gly Ile 40 Gly Ser Gly Ass 55 Gly Gly Pro Val Leu Asp Gln Gl 90	e Gly Gly Val Gly Pro 45 Glu Gly Asn His Asn 60 Gly Phe His Asn Gln 75 y Lys Gly His Gly Phe 95	Pro His Met 80
Gly Ser Ser Gly Ser Gly 35 Pro Met Met Leu Gln Leu 50 Met Gly Ala Ile Gly Gl 65 Phe Pro Leu Gly Leu Se 85 Lys Pro Asp Glu Thr Gl	Leu Ser Gly Ile 40 Gly Ser Gly Ass 7 Gly Gly Pro Val 8 Leu Asp Gln Gl 90 y Lys Arg Phe Gl 105	e Gly Gly Val Gly Pro 45 n Glu Gly Asn His Asn 60 l Gly Phe His Asn Gln 75 y Lys Gly His Gly Phe 95 n Asp Asp Val Leu Asp	Pro His Met 80 Leu Asn

MBI15 Sequence Listing.ST25
130
135
140

Arg Ala Arg Arg Gly Gln Ala Thr Asp Pro His Ser Ile Ala Glu Arg
145
150
150
160

Leu Arg Arg Glu Arg Ile Ala Glu Arg Ile Arg Ser Leu Gln Glu Leu

Val Pro Thr Val Asn Lys Thr Asp Arg Ala Ala Met Ile Asp Glu Ile 180 185 190

Val Asp Tyr Val Lys Phe Leu Arg Leu Gln Val Lys Val Leu Ser Met 195 200 205

Ser Arg Leu Gly Gly Ala Gly Ala Val Ala Pro Leu Val Thr Glu Met 210 215 220

Pro Leu Ser Ser Ser Val Glu Asp Glu Thr Gln Ala Val Trp Glu Lys 225 230 235 240

Trp Ser Asn Asp Gly Thr Glu Arg Gln Val Ala Lys Leu Met Glu Glu 245 250 255

Asn Val Gly Ala Ala Met Gln Leu Leu Gln Ser Lys Ala Leu Cys Ile 260 265 270

Met Pro Ile Ser Leu Ala Met Ala Ile Tyr His Ser Gln Pro Pro Asp 275 280 285

Thr Ser Ser Ser Ile Val Lys Pro Glu Met Asn Pro Pro Pro 290 295 300

<210> 51

<211> 1198 <212> DNA

<213> Arabidopsis thaliana

<220>

<221> CDS

<222> (96)..(1052)

<223> G764

55	60	BI15 Seque	nce Listing.S7 65	70 70
tgg aag gct aag ctt Trp Lys Ala Lys Leu 75	ggg gaa aa Gly Glu Ly	aa gag tgg ys Glu Trp 80	tac ttc ttt t Tyr Phe Phe C	gc gta aga 353 ys Val Arg 85
gac cga aaa tac ccg Asp Arg Lys Tyr Pro 90	act ggt tt Thr Gly Le	ta aga acg eu Arg Thr 95	Asn Arg Ala T	ct aaa gcc 401 Chr Lys Ala .00
ggt tat tgg aaa gct Gly Tyr Trp Lys Ala 105	Thr Gly Ly	aa gat aaa ys Asp Lys 10	gag atc ttc a Glu Ile Phe I 115	aaa ggg aaa 449 Lys Gly Lys
tct ctt gtt ggt atg Ser Leu Val Gly Met 120	aag aaa ac Lys Lys Th 125	ca ttg gtt hr Leu Val	Phe Tyr Lys 0	gga aga gct 497 Sly Arg Ala
cct aaa gga gta aaa Pro Lys Gly Val Lys 135	aca aat to Thr Asn Tr 140	gg gtc atg rp Val Met	cat gag tat of His Glu Tyr / 145	ga tta gaa 545 Arg Leu Glu 150
ggc aaa ttc gct atc Gly Lys Phe Ala Ile 155	gat aat ct Asp Asn Le	tc tct aaa eu Ser Lys 160	acc gct aag a Thr Ala Lys A	aac gaa tgt 593 Asn Glu Cys 165
gtt att agt cgt gtt Val Ile Ser Arg Val 170	ttt cat ac Phe His Th	ca cgg act hr Arg Thr 175	Asp Gly Thr 1	aag gag cat 641 Lys Glu His L80
atg tcc gtt ggt tta Met Ser Val Gly Leu 185	Pro Pro Le	tg atg gat eu Met Asp 90	tct tct cca ! Ser Ser Pro ! 195	tat cta aag 689 Tyr Leu Lys
agt aga gga caa gac Ser Arg Gly Gln Asp 200	tct tta go Ser Leu Al 205	cc ggg acc la Gly Thr	acc ctt ggt g Thr Leu Gly G 210	ggg ttg ttg 737 Gly Leu Leu
tct cac gtt acc tac Ser His Val Thr Tyr 215	ttc tcc ga Phe Ser As 220	ac caa aca sp Gln Thr	acc gat gac a Thr Asp Asp 1 225	aag agt ctt 785 Lys Ser Leu 230
gtg gcc gat ttt aaa Val Ala Asp Phe Lys 235	Thr Thr M	tg ttt ggt let Phe Gly 240	tcc gga tcg Ser Gly Ser	act aac ttt 833 Thr Asn Phe 245
tta cca aac ata ggt Leu Pro Asn Ile Gly 250	tct cta c Ser Leu L	ta gac ttc eu Asp Phe 255	Asp Pro Leu	ttt cta caa 881 Phe Leu Gln 260
aac aat tot toa gta Asn Asn Ser Ser Val 265	Leu Lys M	itg ttg ctt Met Leu Leu 170	gac aat gaa Asp Asn Glu 275	gaa acc caa 929 Glu Thr Gln
ttt aag aag aat ctt Phe Lys Lys Asn Leu 280	cac aat t His Asn S 285	ca ggt tca Ser Gly Ser	tca gag agt Ser Glu Ser 290	gaa cta aca 977 Glu Leu Thr
gcg agt tct tgg caa Ala Ser Ser Trp Gln 295	ggt cac a Gly His A 300	aat tot tat Asn Ser Tyr	ggt tcc act Gly Ser Thr 305	ggt cca gtg 1025 Gly Pro Val 310
aat ctt gat tgc gtt Asn Leu Asp Cys Val 315	. Trp Lys P	tc tga att Phe	tggaaaa tcgaa	aattt 1072
ggatgttaac tagggggt	at atagggt	ttt taaaaa	cagt gtatatat	
agctttagat tctaggat	at acaaaga	atga cactaa	taga ttcttata	
aaaaaa				1198

<210> 52 <211> 318

MBI15 Sequence Listing.ST25

<212> PRT

<213> Arabidopsis thaliana

<400> 52

Met Asp Tyr Lys Val Ser Arg Ser Gly Glu Ile Val Glu Gly Glu Val

Glu Asp Ser Glu Lys Ile Asp Leu Pro Pro Gly Phe Arg Phe His Pro 20 25 30

Thr Asp Glu Glu Leu Ile Thr His Tyr Leu Arg Pro Lys Val Val Asn 35 40 45

Ser Phe Phe Ser Ala Ile Ala Ile Gly Glu Val Asp Leu Asn Lys Val

Glu Pro Trp Asp Leu Pro Trp Lys Ala Lys Leu Gly Glu Lys Glu Trp 65 70 75 80

Tyr Phe Phe Cys Val Arg Asp Arg Lys Tyr Pro Thr Gly Leu Arg Thr 85 90 95

Asn Arg Ala Thr Lys Ala Gly Tyr Trp Lys Ala Thr Gly Lys Asp Lys

Glu Ile Phe Lys Gly Lys Ser Leu Val Gly Met Lys Lys Thr Leu Val 115 120 125

Phe Tyr Lys Gly Arg Ala Pro Lys Gly Val Lys Thr Asn Trp Val Met 130 135 140

His Glu Tyr Arg Leu Glu Gly Lys Phe Ala Ile Asp Asn Leu Ser Lys 145 150 155 160

Thr Ala Lys Asn Glu Cys Val Ile Ser Arg Val Phe His Thr Arg Thr 165 170 175

Asp Gly Thr Lys Glu His Met Ser Val Gly Leu Pro Pro Leu Met Asp 180 180 190

Ser Ser Pro Tyr Leu Lys Ser Arg Gly Gln Asp Ser Leu Ala Gly Thr 195 200 205

Thr Leu Gly Gly Leu Leu Ser His Val Thr Tyr Phe Ser Asp Gln Thr 210 215 220

Thr Asp Asp Lys Ser Leu Val Ala Asp Phe Lys Thr Thr Met Phe Gly 225 230 240

Ser Gly Ser Thr Asn Phe Leu Pro Asn Ile Gly Ser Leu Leu Asp Phe 245 250 255

Asp Pro Leu Phe Leu Gln Asn Asn Ser Ser Val Leu Lys Met Leu Leu 260 265 270

Asp Asn Glu Glu Thr Gln Phe Lys Lys Asn Leu His Asn Ser Gly Ser 275 280 285

MBI15 Sequence Listing.ST25

Ser Glu Ser Glu Leu Thr Ala Ser Ser Trp Gln Gly His Asn Ser Tyr 290 295 300

Gly Ser Thr Gly Pro Val Asn Leu Asp Cys Val Trp Lys Phe 305 310

<210: <211: <212: <213:	> 9: > Di	32 NA	dops	is t	hali	ana										
<220 <221 <222 <223	> C	DS 43). 350	. (75	9)												
<400 cttt	> 5 cttc	3 tc a	attt	agaa	ç tt	agta	gcta	gtc	ttca	aga	ta a M 1	ec A	ca c la L	tt g eu G	aa lu	54
act Thr 5	ctt Leu	act Thr	tct Ser	cca Pro	aga Arg 10	tta Leu	tct Ser	tct Ser	ccg Pro	atg Met 15	ccg Pro	act Thr	ctg Leu	ttt Phe	caa Gln 20	102
gat Asp	tca Ser	gca Ala	cta Leu	999 Gly 25	ttt Phe	cat His	gga Gly	agc Ser	aaa Lys 30	ggc Gly	aaa Lys	cga Arg	tct Ser	aag Lys 35	cga Arg	150
tca Ser	aga Arg	tct Ser	gaa Glu 40	ttc Phe	gac Asp	cgt Arg	cag Gln	agt Ser 45	ctc Leu	acg Thr	gag Glu	gat Asp	gaa' Glu 50	tat Tyr	atc Ile	198
gct Ala	tta Leu	tgt Cys 55	ctc Leu	atg Met	ctt Leu	ctt Leu	gct Ala 60	cgc Arg	gac Asp	gga Gly	gat Asp	aga Arg 65	aac Asn	cgt Arg	gac Asp	246
ctt Leu	gac Asp 70	ctg Leu	cct Pro	tct Ser	tct Ser	tcg Ser 75	tct Ser	tca Ser	cct Pro	cct Pro	ctg Leu 80	ctt Leu	cct Pro	cct Pro	ctt Leu	294
cct Pro 85	act Thr	ccg Pro	atc Ile	tac Tyr	aag Lys 90	tgt Cys	agc Ser	gtc Val	tgt Cys	gac Asp 95	aag Lys	gcg Ala	ttt Phe	tcg Ser	tct Ser 100	342
tac Tyr	cag Gln	gct Ala	ctt Leu	ggt Gly 105	gga Gly	cac His	aag Lys	gca Ala	agt Ser 110	cac His	cgg Arg	aaa Lys	agc Ser	ttt Phe 115	tcg Ser	390
ctt Leu	act Thr	caa Gln	tct Ser 120	gcc Ala	gga Gly	gga Gly	gat Asp	gag Glu 125	ctg Leu	tcg Ser	aca Thr	tcg Ser	tcg Ser 130	gcg Ala	ata Ile	438
acc Thr	acg Thr	tct Ser 135	Gly	ata Ile	tcc Ser	ggt Gly	ggc Gly 140	Gly 999	gga Gly	gga Gly	agt Ser	gtg Val 145	aag Lys	tcg Ser	cac His	486
Val	Cys 150	Ser	Ile	Суѕ	His	Lys 155	Ser	Pne	Ala	Thr	ggt Gly 160	GIN	Ата	Den	GIY	534
ggc Gly 165	His	aaa Lys	cgg Arg	tgc Cys	cac His 170	Tyr	gaa Glu	gga Gly	aag Lys	aac Asn 175	gga Gly	ggc Gly	ggt Gly	gtg Val	agt Ser 180	582
Ser	Ser	Val	Ser	185	Ser	Glu	Asp	val	190	ser	aca Thr	Ser	uis	195	361	630
agt	ggc	cac	: cgt	999	ttt	gac	ctc	aac		ccg Page		ata	ccg	gaa	ttc	678

							MBII	.5 Se	equer	ice I	isti	ng.s	T25			
Ser (Gly	His	Arg 200	Gly	Phe	Asp	Leu	Asn 205	Ile	Pro	Pro	Ile	Pro 210	Glu	Phe	
tcg a	Met	gtc Val 215	aac Asn	gga Gly	gac Asp	gaa Glu	gag Glu 220	gtg Val	atg Met	agt Ser	Pro	atg Met 225	ccg Pro	gcg Ala	aag Lys	726
Lys :	ctc Leu 230	cgg Arg	ttt Phe	gac Asp	ttc Phe	ccg Pro 235	gag Glu	aaa Lys	ccc Pro	taa	acat	aaac	ct a	ggaa	aaact	779
ttac	agaa	tt c	attt	tata	g ga	aatt	gttt	tac	tgta	tat	acaa	atat	.cg a	tttt	gattg	839
atgt	tctt	ct t	cact	gaaa	a at	tate	atto	ttt	gttg	tat	aatt	gatg	itt t	ctga	aaaag	899
atat	aact	tt t	tatt	aaaa	a aa	aaaa	aaaa	aaa	l							932
<210 <211 <212 <213	> 2 > F	4 38 RT rabi	dops	sis t	hali	iana									•	
<400	> 5	4														
Met 1	Ala	Leu	Glu	Thr 5	Leu	Thr	Ser	Pro	Arg 10	Leu	Ser	Ser	Pro	Met 15	Pro	
Thr	Leu	Phe	Gln 20	Asp	Ser	Ala	Leu	Gly 25	Phe	His	Gly	Ser	Lys 30	Gly	Lys	
Arg	Ser	Lys 35	Arg	Ser	Arg	Ser	Glu 40	Phe	Asp	Arg	Gln	Ser 45	Leu	Thr	Glu	
Asp	Glu 50	Tyr	Ile	Ala	Leu	Сув 55	Leu	Met	Leu	Leu	Ala 60	Arg	Авр	Gly	Авр	
Arg 65	Asn	Arg	Asp	Leu	Asp 70	Leu	Pro	Ser	Ser	Ser 75	Ser	Ser	Pro	Pro	Leu 80	
Leu	Pro	Pro	Leu	Pro 85	Thr	Pro	Ile	Tyr	Lys 90	Суз	Ser	Val	Сув	Asp 95	Lys	
Ala	Phe	Ser	Ser 100	туг	Gln	Ala	Leu	Gly 105	Gly	His	Lys	Ala	Ser 110	His	Arg	
ГÀЗ	Ser	Phe 115	Ser	Leu	Thr	Gln	Ser 120	Ala	Gly	Gly	Asp	Glu 125	Leu	Ser	Thr	
Ser	Ser 130	Ala	Ile	Thr	Thr	Ser 135		Ile	Ser	Gly	Gly 140	Gly	Gly	Gly	Ser	
Val 145	Lys	Ser	His	Val	Cys 150		Ile	Cys	His	Lys 155	Ser	Phe	Ala	Thr	Gly 160	
Gln	Ala	Leu	Gly	Gly 165		Lys	Arg	Cys	His 170	Tyr	Glu	Gly	Lys	Asn 175	Gly	
Gly	Gly	Val	Ser 180		Ser	Val	Ser	Asn 185	Ser	Glu	Asp	Val	Gly 190	Ser	Thr	
Ser	His	Val 195		Ser	Gly	His	Arg 200	Gly		Asp age		Asn 205	Ile	Pro	Pro	

MBI15 Sequence Listing.ST25

Ile	Pro (Glu 1	Phe s	Ser N	1et \	/al / 215	Asn (3ly /	Asp (3lu (31u \ 220	/al N	let s	Ser I	Pro	
Met 225	Pro .	Ala :	Lys 1	Lys I	Leu <i>l</i> 230	Arg 1	Phe I	Asp 1	Phe I	Pro (235	Glu 1	Lys I	Pro			
<210 <211 <212 <213	> 1 ?> D	5 022 NA rabi	dops	is t	hali	ana										
<220 <220 <220 <220	L> C 2> (DS 31). 986	. (84	6)												
<400	0> 5 taaat	is itg g	ctcc	tgtg	a ac	ctaa	attt	atg Met 1	gac Asp	tat Tyr	gat Asp	ccc Pro 5	aac Asn	acc Thr	aat Asn	54
ccg Pro	ttc Phe 10	gac Asp	ctt Leu	cat His	Phe	tcc Ser 15	ggt Gly	aaa Lys	ctt Leu	ccg Pro	aaa Lys 20	aga Arg	gaa Glu	gtc Val	tcg Ser	102
gct Ala 25	tca Ser	gct Ala	tct Ser	aaa Lys	gtt Val 30	gta Val	gag Glu	aag Lys	aaa Lys	tgg Trp 35	tta Leu	gtg Val	aaa Lys	gat Asp	gag Glu 40	
aag Lys	aga Arg	aat Asn	atg Met	cta Leu 45	caa Gln	gat Asp	gaa Glu	ata Ile	aac Asn 50	cgg Arg	gtt Val	aat Asn	tcg Ser	gag Glu 55	aac Asn	198
aag Lys	aag Lys	cta Leu	acc Thr 60	gaa Glu	atg Met	tta Leu	gca Ala	aga Arg 65	gtc Val	tgt Cys	gag Glu	aag Lys	tac Tyr 70	tat Tyr	gct Ala	246
ctt Lev	aat Asn	aat Asn 75	ctt Leu	atg Met	gag Glu	gag Glu	ttg Leu 80	cag Gln	agt Ser	cga Arg	aag Lys	agt Ser 85	cct Pro	gaa Glu	agt Ser	294
gtt Val	aac Asn 90	ttt Phe	cag Gln	aac Asn	aaa Lys	cag Gln 95	cta Leu	acg Thr	999 Gly	aaa Lys	cga Arg 100	aaa Lys	caa Gln	gaa Glu	ctt Leu	342
gat Asp 105	gag Glu	ttt Phe	gtt Val	agc Ser	tcc Ser 110	cca Pro	att Ile	gga Gly	ctc Leu	agt Ser 115	ctc Leu	gga Gly	cca Pro	atc Ile	gag Glu 120	390
aac Asi	atc lle	acc Thr	aac Asn	gat Asp 125	aaa Lys	gcg Ala	inr	vai	tca Ser 130	1111	gct Ala	tac Tyr	ttt Phe	gct Ala 135	gct Ala	438
gag	aag Lys	tct Ser	gac Asp 140	Thr	agc Ser	ttg Leu	act Thr	gtg Val 145	гÀа	gat Asp	gga Gly	tat Tyr	caa Gln 150	tgg Trp	agg Arg	486
aaa Ly	a tac s Tyr	999 Gly 155	Gln	aag Lys	att Ile	acg Thr	aga Arg 160	Asp	aat Asn	cca Pro	tct Ser	cct Pro 165	aga Arg	gct Ala	tac Tyr	534
tt. Ph	c aga e Arg	у Сув	tcg Ser	ttt Phe	tca Ser	ccg Pro 175	Ser	tgt Cys	cta Leu	gtc Val	aag Lys 180	пур	aag Lys	gtg Val	caa Gln	582
cg Ar 18	a agt g Sei 5	gca Ala	gaa Glu	gat Asp	cca Pro 190	Ser	ttc Phe	ttg Leu	gta Val	gcc Ala 195	THE	tac Tyr	gaa Glu	ggg Gly	Thr 200	630

cat aac cac acc gga cca cat gca agt gtg tcc agg aca gtg aaa ctt

His	Asn	His	Thr	Gl <u>y</u> 205	Pro	His	MBI Ala	15 S Ser	eque Val 210	nce Ser	List Arg	ing. Thr	ST25 Val	Lys 215	Leu	
						ctt Leu									aga Arg	726
						ttg Leu										774
						gca Ala 255										822
		gag Glu					tga	aagi	ttct	cta g	gaaca	atgta	at · a	tttci	tgttt	876
tgt	cta	ttt (gtt	gctca	at to	ctag	gtaaa	a aag	ggtaa	aaga	ttt	gttt	gat (ettga	attagg	936
agg	cata	gat g	gtcaa	attt	a at	gtgt	gtgi	ata	ataai	tac	atca	aato	cta a	agtai	tccaaa	996
aag	ggtca	acc o	ccai	ttta	at c	tate	3									1022
<210 <210 <210 <210	l> 2 2> 1	56 271 PRT Arab:	idopa	₃is t	hal:	iana										
<40	0> !	56														
Met 1	Asp	Tyr	Asp	Pro 5	Asn	Thr	Asn	Pro	Phe 10	Asp	Leu	His	Phe	Ser 15	Gly	
Lys	Leu	Pro	Lys 20	Arg	Glu	Val	Ser	Ala 25	Ser	Ala	Ser	Lys	Val 30	Val	Glu	
ГÀЗ	Lys	Trp 35	Leu	Val	Lys	Asp	Glu 40	Lys	Arg	Asn	Met	Leu 45	Gln	Asp	Glu	
Ile	Asn 50	Arg	Val	Asn	Ser	Glu 55	Asn	Lys	Ĺув		Thr 60	Glu	Met	Leu	Ala	
Arg 65	Val	Сув	Glu	Lys	Туг 70	Tyr	Ala	Leu	Asn	Asn 75	Leu	Met	Glu	Glu	Leu 80	
Gln	Ser	Arg	Lys	Ser 85	Pro	Glu	Ser	Val	Asn 90	Phe	Gln	Asn	Lys	Gln 95	Leu	
Thr	Gly	Lys	Arg 100	Lys	Gln	Glu	Leu	Asp 105	Glu	Phe	Val	Ser	Ser 110	Pro	Ile	
Gly	Leu	Ser 115	Leu	Gly	Pro	Ile	Glu 120	Asn	Ile	Thr	Asn	Asp 125	Lys	Ala	Thr	
Val	Ser 130	Thr	Ala	Tyr	Phe	Ala 135	Ala	Glu	Lys	Ser	Asp 140	Thr	Ser	Leu	Thr	
Val 145	Lys	Asp	Gly	Tyr	Gln 150	Trp	Arg	Lys	Туг	Gly 155	Gln	Lув	Ile	Thr	Arg 160	
Asp	Asn	Pro	Ser	Pro 165	Arg	Ala	Tyr	Phe	170	_		Phe	Ser	Pro 175	Ser	
										age						

MBI15 Sequence Listing.ST25

Суз	Leu	Val	Lys 180	Lys	Lys	Val	Gln	Arg 185	Ser	Ala	Glu	Asp	Pro 190	Ser	Phe	
Leu	Val	Ala 195	Thr	Tyr	Glu	Gly	Thr 200	His	Asn	His	Thr	Gly 205	Pro	His	Ala	
Ser	Val 210	Ser	Arg	Thr	Val	Lув 215	Leu	Asp	Leu	Val	Gln 220	Gly	Gly	Leu	Glu	
Pro 225	Val	Glu	Glu	Lys	Lys 230	Glu	Arg	Gly	Thr	Ile 235	Gln	Glu	Val	Leu	Val 240	
Gln	Gln	Met	Ala	Ser 245	Ser	Leu	Thr	Lys	Asp 250	Pro	Lys	Phe	Thr	Ala 255	Ala	
Leu	Ala	Thr	Ala 260	Ile	Ser	Gly	Arg	Leu 265	Ile	Glu	His	Ser	Arg 270	Thr		
<210 <210 <210 <210	1> 2>	57 1230 DNA Arab		sis	thal:	iana										
	1 > 2 >	CDS (1). G134	. (10 9	89)												
	0> gct Ala		cgg Arg	aga Arg 5	gaa Glu	gta Val	cgg Arg	tgc Cys	cgg Arg 10	tgc Cys	ggc	aga Arg	cgg Arg	atg Met 15	tgg Trp	48
gtt Val	caa Glr	cca Pro	gac Asp 20	gcc	cgt Arg	acc Thr	gto Val	caa Gln 25	. tgc . Cys	tca Ser	acc Thr	tgc Cys	cac His 30	acc Thr	gtc Val	96
acg Thr	Cag Glr	cto Lev 35	tac Tyr	tcg Ser	cta Leu	gtg Val	gac Asp 40	ata Ile	gct Ala	cgc Arg	ggt Gly	gca Ala 45	aac Asn	cgc Arg	ata Ile	144
att Ile	cat His	: ggg : Gly	y ttt / Phe	caa Glr	cag Gln	cta Leu 55	ctt Let	aga Arg	caa Glr	cac His	caa Glr 60	a ccg	caa Gln	cat His	cat His	192
gaa Glu 65	caa Gl:	a caa	a caa n Glr	caa Glr	caa Glm 70	atg Met	atg Met	g gct E Ala	caa Glr	e ccg Pro 75	g cca Pro	a cca o Pro	cgg Arg	ctg Lev	ctt Leu 80	240
gag Glu	g cci	t cti	r cco	tco Sei 85	g ccg	ttt Phe	999 Gl	g aag y Lys	aag Lys 90	g aga	g gca	a gtt a Val	tta Lev	tgo Cys 95	ggc Gly	288
gto Va	aa L As	c ta n Ty	t aag r Lys 100	s Gly	a aaa y Lys	agt Sei	tai Ty:	t ago r Sei 109	r Lei	g aaa u Ly	a ggi	t tgo y Cyi	ato Ile 110	3 261	gat Asp	336
gc: Ala	t aa a Ly	g to s Se 11	r Me	g aga	a tct g Sei	tta Lei	tte Le 12	u va.	t car	a caa n Gl	a ate	g gg(t Gl; 12	A Litte	e Pro	t att	384
ga As	c tc p Se 13	r Il	t ct	c ate	g cto	aca Th:	r Gl	a gal u Asj	t ga p Gl	a gc	c ag a Se 14	r PI	g cag o Gli	g aga	a ata g Ile	432
CC	g ac	g aa	g ag	a aa	c at	t ag	g aa	g gc	g at	g ag	a tg	g tt	a gt	t ga	a ggg	480

PCT/US00/31418 WO 01/35726

		MBI1	5 Sequence I	Listing.ST25	
Pro Thr Lys A	Arg Asn Ile 150	Arg Lys A	Ala Met Arg 155	Trp Leu Val	Glu Gly 160
aac aga gca a Asn Arg Ala A	agg gac tca Arg Asp Ser 165	cta gtg t Leu Val F	ttc cat ttc Phe His Phe 170	tct ggt cat Ser Gly His	gga tct 528 Gly Ser 175
cag cag aat g Gln Gln Asn A	gac tac aac Asp Tyr Asn 180	Gly Asp G	gag atc gat Glu Ile Asp 185	ggt caa gat Gly Gln Asp 190	gaa gcc 576 Glu Ala
ttg tgc cct t Leu Cys Pro I 195	tta gac cat Leu Asp His	gaa aca g Glu Thr G 200	gaa gga aaa Glu Gly Lys	atc att gat Ile Ile Asp 205	gac gag 624 Asp Glu
att aac cgg a Ile Asn Arg I 210	ata ctc gtg Ile Leu Val	agg cct c Arg Pro I 215	ctc gtc cat Leu Val His	gga gct aag Gly Ala Lys 220	ctt cac 672 Leu His
gct gtc atc g Ala Val Ile A 225	gac gcc tgt Asp Ala Cys 230	Asn Ser C	ggg act gtc Gly Thr Val 235	ctt gat tta Leu Asp Leu	ccc ttc 720 Pro Phe 240
att tgc agg a Ile Cys Arg N	atg gag agg Met Glu Arg 245	aat ggt t Asn Gly S	tct tat gaa Ser Tyr Glu 250	tgg gaa gac Trp Glu Asp	cat aga 768 His Arg 255
tca gtc aga g Ser Val Arg 7	gct tac aaa Ala Tyr Lys 260	Gly Thr A	gat ggt gga Asp Gly Gly 265	gca gct ttc Ala Ala Phe 270	tgt ttc 816 Cys Phe
agt gct tgt g Ser Ala Cys 2 275	gac gat gat Asp Asp Asp	gaa tcc a Glu Ser S 280	agt ggt tac Ser Gly Tyr	act cct gtg Thr Pro Val 285	ttc acg 864 Phe Thr
ggg aag aac a Gly Lys Asn 1 290	aca gga gcc Thr Gly Ala	atg act t Met Thr 1 295	tat agc ttc Tyr Ser Phe	ata aag gcg Ile Lys Ala 300	gtg aag 912 Val Lys
aca gct gga o Thr Ala Gly I 305	cca gca ccc Pro Ala Pro 310	Thr Tyr (ggc cac ctg Gly His Leu 315	ctt aac ctt Leu Asn Leu	atg tgt 960 Met Cys 320
tct gca ata o Ser Ala Ile A	cga gag gcc Arg Glu Ala 325	cag tct o	cgc ctc gcc Arg Leu Ala 330	ttt aac ggg Phe Asn Gly	gac tac 1008 Asp Tyr 335
aca agc tct of Thr Ser Ser A	gat gca tcc Asp Ala Ser 340	Ala Glu E	cca ctg cta Pro Leu Leu 345	aca tca tct Thr Ser Ser 350	gag gaa 1056 Glu Glu
ttt gac gtg t Phe Asp Val 1 355	tac gcg aca Tyr Ala Thr	aag ttt g Lys Phe \ 360	gta ctc tga Val Leu	atgctgtaca (tatgatgctg 1109
caaatagete g	gaaacgttt c	tatgtgtat	gtatcatgta	atgattatgt (gcatagcct 1169
ctctcttctt ac	cgagcaata a	gctatgaaa	taattgattc	gctaagaaat	taaaatgaa 1229
a					1230

<400> 58

Met Ala Ser Arg Arg Glu Val Arg Cys Arg Cys Gly Arg Arg Met Trp 1 5 10 15

Val Gln Pro Asp Ala Arg Thr Val Gln Cys Ser Thr Cys His Thr Val 20 25 30

<210> 58 <211> 362 <212> PRT <213> Arabidopsis thaliana

MBI15 Sequence Listing.ST25

- Thr Gln Leu Tyr Ser Leu Val Asp Ile Ala Arg Gly Ala Asn Arg Ile 35 40 45
- Ile His Gly Phe Gln Gln Leu Leu Arg Gln His Gln Pro Gln His His 50 55
- Glu Gln Gln Gln Gln Met Met Ala Gln Pro Pro Pro Arg Leu Leu 65 70 75 80
- Glu Pro Leu Pro Ser Pro Phe Gly Lys Lys Arg Ala Val Leu Cys Gly 85 90 95
- Val Asn Tyr Lys Gly Lys Ser Tyr Ser Leu Lys Gly Cys Ile Ser Asp 100 105 110
- Ala Lys Ser Met Arg Ser Leu Leu Val Gln Gln Met Gly Phe Pro Ile 115 120 125
- Asp Ser Ile Leu Met Leu Thr Glu Asp Glu Ala Ser Pro Gln Arg Ile 130 135 140
- Pro Thr Lys Arg Asn Ile Arg Lys Ala Met Arg Trp Leu Val Glu Gly 145 150 155 160
- Asn Arg Ala Arg Asp Ser Leu Val Phe His Phe Ser Gly His Gly Ser 165 170 175
- Gln Gln Asn Asp Tyr Asn Gly Asp Glu Ile Asp Gly Gln Asp Glu Ala 180 185 190
- Leu Cys Pro Leu Asp His Glu Thr Glu Gly Lys Ile Ile Asp Asp Glu 195 200 205
- Ile Asn Arg Ile Leu Val Arg Pro Leu Val His Gly Ala Lys Leu His 210 215 220
- Ala Val Ile Asp Ala Cys Asn Ser Gly Thr Val Leu Asp Leu Pro Phe 225 230 240
- Ile Cys Arg Met Glu Arg Asn Gly Ser Tyr Glu Trp Glu Asp His Arg 245 250 255
- Ser Val Arg Ala Tyr Lys Gly Thr Asp Gly Gly Ala Ala Phe Cys Phe 260 265 270
- Ser Ala Cys Asp Asp Asp Glu Ser Ser Gly Tyr Thr Pro Val Phe Thr 275 280 285
- Gly Lys Asn Thr Gly Ala Met Thr Tyr Ser Phe Ile Lys Ala Val Lys 290 295 300
- Thr Ala Gly Pro Ala Pro Thr Tyr Gly His Leu Leu Asn Leu Met Cys 305 310 315 320
- Ser Ala Ile Arg Glu Ala Gln Ser Arg Leu Ala Phe Asn Gly Asp Tyr
 Page 76

MBI15 Sequence Listing.ST25 330 335

Phe Asp Val Tyr Ala Thr Lys Phe Val Leu 355

325

INTERNATIONAL SEARCH REPORT

Interna al application No.

PCT/US00/31418

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A01H 1/00, 5/00; C12N 5/14, 15/82 US CL : 435/320.1, 419, 468; 800/278, 279, 287, 301, 305-310, 312, 314, 317, 320, 322 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S.: 435/320.1, 419, 468; 800/278, 279, 287, 301, 305-310, 312, 314, 317, 320, 322								
Documentation	Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched							
Electronic da EAST, USPA	Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EAST, USPAT, STN, Agricola, CaPlus, Biosis, Embase							
C DOC	UMENTS CONSIDERED TO BE RELEVANT							
C. DOC	Citation of document, with indication, where app	propriate, of the relevant passages Relevant to claim No.						
X	WO 97/47183 A1 (PURDUE RESEARCH FOUNDA	ATION) 18 December 1997 1-9, 12, 13, 25						
	(18.12.1997), entire reference.							
Y		10, 11, 26, 27						
x	US 5,939,601 (KLESSIG et al) 17 August 1999 (17.0	08.1999), entire reference. 1-9, 12, 13, 25						
 Y		10, 11, 26, 27						
A	Database Genbank on NCBI, US National Library o No. AB009055, SATO, S. et al 'Strucural analysis o IV. Sequence features of the regions of 1,456,315 bp assigned P1 and TAC clones. 27 December 2000, D 41-54, see bases 16,003-16,490, 16,571-16,683 and	p covered by nineteen physically NA RES. 1998, Vol. 5, No. 1, pages						
,,		. *						
Further	er documents are listed in the continuation of Box C.	See patent family annex.						
, —	Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the						
1	nt defining the general state of the art which is not considered to be	principle or theory underlying the invention						
•	rular relevance application or patent published on or after the international filing date	"X" document of particular relevance; the chained investion cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone						
establisi specifie		"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art						
	nt referring to an oral disclosure, use, exhibition or other means							
"P" docume priority	on published prior to the international filing date but later than the date claimed	"&" document member of the same patent family						
	actual completion of the international search	Date of mailing of the international search report						
23 Februar	y 2001 (23.02.2001)	Authorized officer						
C B W	mailing address of the ISA/US commissioner of Patents and Trademarks ox PCT //ashington, D.C. 20231 No. (703)305-3230	David Kruse PARALEGAL SPECIALIST Telephone No. 703-308-TECHNOLOGY CENTER 1600						

Facsimile No. (703)305-3230
Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

Internal application No.

PCT/US00/31418

	Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)						
This i	nternat	ional report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:					
1.		Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:					
2.		Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:					
3.	6.4(a).	Claim Nos.: 14 because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule					
Box I	I Ob	servations where unity of invention is lacking (Continuation of Item 2 of first sheet)					
		ional Searching Authority found multiple inventions in this international application, as follows: ontinuation Sheet					
1.		As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.					
2.	Ш	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.					
3.		As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:					
4.	\boxtimes	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-13 & 25-27 and SEQ ID NOs 1&2					
Rema	rk on l	·					

INTERNATIONAL SEARCH REPORT

Inte......nal application No.

PCT/US00/31418

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Groups I-XXIX, claim(s) 1-14 and 25-27, drawn to a transgenic plant having modified seed characteristics, polynucleotides and vectors for producing said transgenic plant and a method of making said transgenic plant. Applicant must elect one pair of sequences (one nucleic acid and the corresponding amino acid translation) to be examined, i.e. SEQ ID NO: 1 and 2 in Group I, SEQ ID NO: 3 and 4 in Group II, SEQ ID NO: 5 and 6 in Group III, etc.

Group XXX, claim(s) 15-17, drawn to a method of identifying a factor that is modulated.

Group XXXI, claims(s) 18, drawn to a method of identifying a molecule that modulates activity or expression of a polynucleotide or polypeptide.

Group XXXII, claims(s) 19 and 20, drawn to an integrated computer system.

Group XXXIII, claim(s) 21-24, drawn to a method for identifying a polynucleotide sequence comprising selecting a nucleic acid sequence from a database that meets a selected sequence criteria.

The inventions listed as Groups I-XXXIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions listed as Groups I-XXXIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Groups I-XXIX are drawn to a transgenic plant and a method of producing said plant with a nucleic acid sequence. The methods of Groups I-XXIX differ from each other in that they are directed to a plant transformation method and transgenic plant with a structurally and functionally distinct nucleic acid sequence which encodes a structurally and functionally distinct amino acid sequence. In addition, Groups XXX, XXXI and XXXIII are different methods from any of Groups I-XXIX in that they have different method steps and different end products, and Group XXXII requires a computer system. Thus, there is no single special technical feature, which links the inventions of Groups I-XXXIII under PCT Rule 13.2.